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 Résumé 
 Le développement depuis les années 1980 de la chimie supramoléculaire a permis la 
synthèse d’objets discrets toujours plus complexes. Le rôle des métaux a été prépondérant, 
grâce notamment à leur mode de coordination qui permet d’orienter de façon rationnelle 
l’organisation moléculaire au sein même de l’architecture supramoléculaire. Ainsi, les 
métalla-cages ont été au centre de l’attention des chimistes, de par leur facilité d’accès au 
niveau synthétique mais aussi de par leur large spectre d’utilisation.  
Depuis la mise sur le marché et le succès clinique du cisplatine comme agent 
antitumoral, les métaux de transition sont également particulièrement étudiés dans une telle 
optique d’application. Parmi les plus prometteurs, les complexes mononucléaires arène-
ruthénium ont démontré un fort potentiel antiprolifératif tout en étant moins toxiques que les 
complexes de platine.  
 Le but de cette thèse de doctorat était de combiner les propriétés d’assemblage  des 
complexes arène-ruthénium en chimie supramoléculaire avec leurs propriétés 
antiprolifératives. Pour cela, plusieurs métalla-cages ont été construites ; leurs habilités à 
encapsuler de façon permanente ou réversible des molécules invitées ont été étudiées par 
différentes méthodes spectroscopiques, et les comportements antiprolifératifs des systèmes 
ainsi obtenus ont été établis in vitro envers différentes lignées de cellules cancéreuses.  
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Complexes organométalliques, complexes arène-ruthénium, chimie supramoléculaire, auto-
assemblage, métalla-cycles, complexes dinucléaires, complexes tétranucléaires, complexes 
hexanucléaires, complexes octanucléaires, carceplex, host-guest, activité anti-cancéreuse, G-
quadruplexe,  
 
 
 
 Summary 
 Since the development of supramolecular chemistry in the 1980s more and more 
discrete molecular objects have been synthesised. In this research area metals play a key role. 
Indeed, the coordination-driven self-assembly allows a directional-bonding approach that 
organises the different building blocks into supramolecular objects according to the 
coordination modes of the transition metal. Therefore, the versatility of metalla-cages and 
their application potential raised an increasing interest for this chemistry.     
On the other hand, ever since the clinical success of cisplatin as an antitumour drug, 
transition metals have raised considerable expectations for the treatment of cancer. So far, 
mononuclear arene ruthenium complexes are of central interest due to established cytotoxicity 
towards cancer cells and low general toxicity. 
The aim of this thesis was to combine the assembling properties of arene ruthenium 
complexes in supramolecular chemistry with their antiproliferative activity. Thus, different 
metalla-cages were synthesised, the permanent or reversible hosting ability of which was 
studied by various spectroscopic methods with different guest molecules. The antiproliferative 
behaviour of the resulting systems was established in vitro towards different cancer cell lines.  
 
Keywords 
Organometallic complexes, arene ruthenium complexes, supramolecular chemistry, self-
assembly, metalla-cycles, dinuclear complexes, tetranuclear complexes, hexanuclear 
complexes, octanuclear complexes, carceplex, host-guest, anticancer activity, G-quadruplex. 
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Chapter 1: Introduction  
1.1 Arene Ruthenium Complexes 
1.1.1 Ruthenium: The Element 44 
Ruthenium is one of the six elements, Ru, Os; Rh, Ir; Pd, and Pt – commonly called 
“platinum metals” – which together with the lighter homologues Fe, Co, Ni form Group VIII 
of the periodic table. Karl Karlovitch Klaus discovered this transition metal in 1844 in ores 
from the Urals and named “the new body, in honor of [his] motherland” ruthenia, the latinised 
name for Russia.
1
 Ruthenium is a rare element with a terrestrial abundance in the earth’s 
crustal rocks estimated at around 0.0001 ppm, and was the last element of the platinum metals 
to be discovered. Ruthenium is found in the metallic state along with the other metals of 
Group VIII, in particular in the nickel-copper sulphide ores found in South Africa, Canada 
(Grand Sudbury) and in the river sands of the Urals. These ores are purified by treatment with 
aqua regia, in order to remove Pt, Pd and Au, and by treatment with hot nitric acid to remove 
Ag as its soluble nitrate. Fusing with NaHSO4, and then with Na2O2, to eliminate Rh and Ir, 
finally leads to the extraction of ruthenium as a lustrous and silvery metal that crystallises in a 
hexagonal close-packed (hcp) structure.
2
 Ruthenium is the element 44 of Mendeleev’s 
periodic table, its molecular weight is 101.07 g∙mol-1, its density is 12.41 g∙cm-3 at 20°C, and 
seven isotopes are naturally occurring. The electronic configuration of ruthenium is Kr [4d
7
] 
[5s
1
]. The organometallic chemistry of ruthenium mainly revolves around the oxidation states 
(0), (II) and (IV), the latter being more stable in the presence of strongly donating ligands, 
such as cyclopentadienyl (Cp) or pentamethylcyclopentadienyl (Cp*).
3
 Other formal 
oxidation states are known such as (I) in [Ru(CO)2Cp]2 or (III) in [RuCl2Cp*]n.
4
 In 
mononuclear complexes the ligands usually contribute 10 electrons to give the metal an 18-
electron configuration, although sterically demanding ligands may stabilize electronically 
unsaturated derivatives, as in the triisopropylphosphine complex [RuCl(PPr
i
3)Cp] (16 
electrons).
5
 Other complexes of ruthenium have a square-planar stereochemistry with a 16-
electron configuration, due to the high level of energy of the orbital pz that cannot be filled in 
this square-planar geometry. This type of complexes can react to give an 18-electron 
intermediate before eliminating a ligand, thus coming back to the stable 16-electron 
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configuration. This reactivity provides to these complexes remarkable catalytic properties.
6
 
The wide range of oxidation states, the different geometries associated along with an 
important variety of coordination numbers as well as the possible tuning of the complex by 
ligands are the basis of the rich chemistry of ruthenium and more generally of the transition 
metals. However, these are also limitations and drawbacks in this chemistry and for this 
reason chemists need to control the reactivity of the metal centre. In particular, the control of 
the metal oxidation state is crucial. 
1.1.2 The Arene Ligand 
Arenes or aromatic hydrocarbons are defined by the International Union of Pure and 
Applied Chemistry (IUPAC) as hydrocarbons with a conjugated cyclic molecular structure 
that is much more stable than the hypothetical localized structure.
7
 Arenes are nowadays some 
of the most popular ligands in ruthenium(II) chemistry. This popularity is particularly due to 
its strong π-acceptor behaviour that enhances the stability of the transition metal’s d orbitals. 
This stabilisation of the orbitals of the ruthenium leads to a great stability against oxidation, in 
particular from Ru(II) to Ru(III). Another consequence is that the metal centre shows a strong 
preference for π-donor ligands. The stabilisation of the transition metal’s d orbitals can be 
explained by the theory of the molecular orbitals.
8
 An arene is a L3 ligand and consequently 
gives 3 electron pairs to the metal in a coaxial way from p orbitals to vacant d orbitals of the 
metal, but also receives lateral bonding in return from filled d orbitals of the metal to π* 
antibonding p orbitals of the ligand. This bonding mode is called back π-bonding (see Figure 
1). 
 
Figure 1. Bonding modes between transition metal and π-acceptor ligand 
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This high stabilisation of the transition metal’s d orbitals by arene ligand via back π-
bonding is described by molecular orbital diagrams. In the case of an octahedral or pseudo-
octahedral complex ML6, the simplified molecular orbital diagram – established without back 
π-bonding – (see Figure 2, A) shows that 3 d orbitals of the metal are nonbonding, molecular 
orbitals called t2g. However, if the ligand L is a π-acceptor, like in the case of the arene ligand, 
these nonbonding d orbitals will be involved in the back π-bonding with the π* antibonding 
orbitals of L (see Figure 2, B). Therefore, these d orbitals will become bonding orbitals, and 
the 18-electron complex will be stabilised.
9
  
 
Figure 2. Molecular orbital diagram of an octahedral complex ML6 
In addition to this electronic protection of the oxidation state of the ruthenium centre, 
the arene ligands present other advantages. They are widely available and readily derivatised 
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by attaching different substituents on the benzene ring through electrophilic substitution.
10
 
Moreover, the structural occupation of three coordinating sites forces the arene ruthenium 
complex to adopt a pseudo-octahedral geometry. Finally, from a chemical reactivity point of 
view, the arene ligands are quite inert towards substitution reactions. It means that arene 
ruthenium units are relatively stable against a large variety of chemical reagents and reaction 
conditions.
11
  
1.1.3 Dimeric Arene Ruthenium Chloro Complexes 
The first arene ruthenium complex was prepared by Winkhaus and Singer in 1967 by 
reduction in ethanol of ruthenium tri-chloride hydrate (RuCl3 ∙ x H2O) in the presence of 1,3-
cyclohexadiene (C6H8). This neutral diamagnetic complex was obtained as a brown 
precipitate, for which a polymeric structure with the formula [RuCl2(C6H6)]n was proposed.
12
 
 
In 1972 Baird showed this polymeric formula to be erroneous and suggested a dimeric 
structure
13
 by analogy with the complexes [(η5-C5H5)M(μ2-Cl)Cl]2 (M = Ir, Rh) published by 
Maitlis in 1969.
14
 Eventually, in 1974, Bennett confirmed this dimeric structure [(η6-
C6H6)Ru(μ2-Cl)Cl]2 in which each ruthenium atom is at the oxidation state II, and where the 
hapticity (η) of the arene is equal to 6. The two ruthenium centres are linked by two chloro 
bridges.
15
  
 
The recognition of the dimeric nature of these arene ruthenium complexes had marked 
the beginning of 40 years of arene-ruthenium-based chemistry. Thus, many different arene 
ruthenium dimers were synthesised and the method developed by Winkhaus and Singer is still 
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employed nowadays with electronically poor dienes. For instance, the dehydrogenation of (-)-
(α)-phellandrene by ruthenium tri-chloride hydrate in ethanol leads to the formation of the 
well-used para-cymene (p-cym) dimer [(η6-p-cym)Ru(μ2-Cl)Cl]2.
13
  
 
However, this method cannot be employed with the electronically rich arenes, such as 
hexamethylbenzene (hmb). In this case, the arene exchange method at elevated temperature 
can lead to the desired dimer. In 1982, following this method, Bennett succeeded in 
synthesising the hmb ruthenium dimer by exchange of the para-cymene ligand with the 
hexamethylbenzene arene at around 180°C.
16
  
 
The enthusiasm for arene ruthenium dimers did not wane during the 1990s and found a 
revival with the emergence of functionalised arenes. These functionalisations are of interest 
because they are expected to combine the properties of the arene ruthenium unit with the 
properties of the grafted functions.
17
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Figure 3. Examples of functionalised arenes in arene ruthenium dimers 
A convenient method to introduce these functions is the preliminary functionalisation 
of an arene, followed by a Birch-type reduction
18
 that converts the aromatic ring into a diene, 
which is then used as reagent for Winkhaus and Singer’s method. For example, the dinuclear 
complexes [(η6-C6H5(CH2)3OCO-p-C6H4-OC8H17)Ru(μ2-Cl)Cl]2 (A) and [(η
6
-p-
C6H4(CH2COOCH2CH3)2)Ru(μ2-Cl)Cl]2 (B) were obtained in 2006 (see Figure 3).
19
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1.2 Supramolecular Chemistry of Host-Guest Systems 
1.2.1 Coordination-Driven Self-Assembly and Molecular Recognition 
Supramolecular chemistry has been defined by Jean-Marie Lehn as “the chemistry 
beyond the molecule”.20 This means that supramolecular chemistry is not focused on the 
synthesis of a single molecule constructed gradually via the formation of direct covalent 
linkages but deals with the assembly of a molecular object constituted by several single 
molecules held together by a variety of weak interactions, such as hydrogen bonds, 
hydrophobic and π-π interactions, and electrostatic effects.21 These weak interactions are used 
by Nature to construct large and ordered molecular arrays with precise functions at the sub-
cellular and cellular levels.
22
 The most famous and telling example of supramolecular 
assembly created by Nature is the double helical structure of deoxyribonucleic acid (DNA), 
elucidated by Watson and Crick in 1953, in which two separate strands of nucleotides are 
connected through hydrogen bonds.
23
 If the weak interactions have a predominant position in 
natural supramolecular assemblies, a considerable number of systems were however 
synthesised by chemists via metal-donor bonds – strictly covalent bonds – in order to 
assemble organic building blocks into molecular objects. Thus, supramolecular chemistry can 
be seen as an interface of organic chemistry – with the synthesis of the different building 
blocks – and inorganic chemistry – with the coordination of these organic building blocks to a 
transition metal. Furthermore, this meeting point also gathers physical chemistry – with the 
experimental and theoretical studies of interactions – and biochemistry – with the biological 
processes that start with substrate binding and recognition – together.24 
The concept of supramolecular chemistry described by Lehn as “the designed 
chemistry of the intermolecular bond”25 is based on a process by which a supramolecular 
species forms spontaneously from its components.
26
 This process, called “self-assembly” is a 
simple convergent path giving rise to the assembled target in a straightforward manner, and 
this, for the majority of the synthetic systems.
27
 However, it is important to notice that self-
assembly is not confined to supramolecular systems, but on the contrary is ubiquitous 
throughout life chemistry. The growth of crystals,
28
 the formation of liquid crystals,
29
 the 
spontaneous generation of synthetic lipid bilayers,
30
 and the alignment of molecules on 
existing surfaces
31
 are some examples of self-assembly in chemical systems.  
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A very interesting subset of self-assembly, is the coordination-driven self-assembly,
32
 
which allows a directional-bonding approach that organises the different building blocks 
following the coordination modes of the transition metal.
33
 Indeed, whereas many of the 
weaker noncovalent interactions are nondirectional – for example, hydrogen bonds, van der 
Waals, and hydrophobic interactions – covalent metal-ligand bonds, also called dative bonds, 
are highly directional and relatively strong. Consequently, coordination-driven self-assembly 
leads to the straightforward construction of large and rigid supramolecular objects with well-
defined shapes, sizes, and geometries.
34
 Over the last two decades, the groups of Fujita,
34
 
Stang,
35
 Raymond,
36
 Lehn,
25
 or Mirkin
37
 have pioneered the use of the directional-bonding 
coordination-driven approach to self-assembly. The idea of this approach is to combine rigid 
electron-poor metal centres and complementary, rigid electron-rich organic donors to provide 
a wide variety of discrete two dimensional (2D) and three dimensional (3D) polygonal and 
polyhedral coordination assemblies. It is important to notice that metal-ligand coordination 
bonds are kinetically labile, also being strong as compared to most other noncovalent 
interactions.  
This lability is crucial since one important feature of supramolecular chemistry is that 
molecular assemblies are normally reversible. Therefore, the final product is in 
thermodynamic equilibrium with its components. In particular, this notion of reversibility is 
fundamental in the case of the systems assembled by molecular recognition. Like self-
assembly, molecular recognition is a process that is widely found throughout both natural and 
synthetic systems. Molecular recognition is essential in a range of biological areas – for 
instance substrates-enzymes or proteins-DNA interactions – and is also of central importance 
in a number of chemical fields – sensors, separation science or catalysis for example –. In 
particular, molecular recognition is closely linked with host-guest chemistry.
38
 
1.2.2 Host-Guest Systems and Carceplexes 
Host-guest chemistry is a subset of supramolecular chemistry based on molecular 
recognition.
39
 For many biological systems, as for substrate-enzyme systems, host-guest 
chemistry is the link between the nature of these biological systems and their functions. In 
other words, the structural adaptations of both enzyme and substrate in order to accommodate 
their shapes and to allow interactions and catalytic processes are the visible expressions of the 
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host-guest phenomenon. In that precise system, the enzyme can be seen as a host and the 
substrate as a guest of the host-guest system.  
The place where the guest is accommodated by the host is called binding site. 
Furthermore, in a given supramolecular system the degree of electronic and steric 
complementary between host and guest dictates the magnitude of the molecular recognition 
occurring. In particular, the stoichiometry of a host-guest system is defined by the number of 
guest molecules that one molecule of host is able to accommodate. 
It should be noted that host-guest chemistry is not only a natural and biological 
phenomenon, but is also widely used by chemists. Indeed, since D. J. Cram baptised this field 
of supramolecular chemistry in 1974,
40
 many efforts have been invested on the design of 
numerous host-guest systems. In particular, a large array of synthetic hosts, capable of 
binding guest ions or molecules, has been developed. The field began with ionophores such as 
crown ethers
41
 and cryptands,
25
 (see Figure 4).  
 
Figure 4. Some common host molecules 
In the 1970s Cram began to develop cavitands,
42
 and in the 1980s the first calixarenes 
were synthesised.
43
 Cavitands have enforced cavities, and therefore they cannot collapse upon 
themselves. Such preorganisation optimises the van der Waals contacts between host and 
guest. Later, Cram synthesised a spheroid compound constituted by two hemispherical 
cavitands link together and able to entrap guests in such manner that the loss of the guest 
molecule is only possible via rupture of a covalent bond. Then, in 1983 Cram proposed the 
name of carceplex to define these host molecules that permanently incarcerate their guests.
44
 
Since this beginning of synthetic host-guest chemistry, host-guest systems and the limit case 
crown ether cryptand cyclodextrin calixarene 
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of the carceplex molecules have been widely studied, with many different types of host and 
guest molecules. 
1.2.3 Pyrene, the Guest of Honour 
Among all the different guest molecules that have been encapsulated via host-guest 
chemistry since the 1970’s, pyrene is one of the best studied. The success of pyrene as a guest 
molecule can be partially explained by the chemical nature of its structure. Pyrene is a highly 
symmetrical molecule (point group D2h), and is the smallest peri-fused polycyclic aromatic 
hydrocarbon (PAHs) compound.
45
 This planar structure confers to pyrene a very interesting 
sterical environment, which gives it the opportunity to fit into small host’s cavity. This 
suggests that the design of host’s small pockets can be ideal for pyrene. 
 
Moreover, despite having 16 π electrons and consequently not following the Hückel’s 
4n + 2 π electrons rule, which states that cyclic planar molecules in which each atom has a p 
orbital are aromatic if they contain 4n + 2 π electrons, pyrene is an aromatic molecule, based 
on Clar sextet theory,
46
 Platt’s ring perimeter,47 and the Randić-Herndon conjugated circuit 
models
48
 commonly employed for qualitative characterisation of the aromaticity of polycyclic 
aromatic compounds.
49
 This aromaticity is crucial for the use of pyrene as guest molecule. 
Indeed, as described in section 1.2.1, supramolecular chemistry in general, and host-guest 
chemistry in particular are mainly based on weak interactions such as hydrophobic or π - π 
stacking interactions. The presence of a rich π electronic environment is consequently 
susceptible to give strong intermolecular interactions, via π - π stacking, between an aromatic 
constituent of the host molecule and pyrene. This parallel π - π stacking can also be reinforced 
by T-shape interactions.
50
  
pyrene 
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Furthermore, the rich photochemistry and predictable substitution reactions of pyrene 
have important applications in organic chemistry, biochemistry, and materials science. For 
example, pyrene has been commonly used as a fluorescent probe because of its intense 
fluorescence,
51
 its fluorescence lifetime reported to be very long (1.4 μs),52 its excimeric 
formation,
53
 and its fluorescence anisotropy.
54
 In particular, fluorescence quenching of pyrene 
is routinely employed
55
 for oxygen measurements in solution,
56
 tissues,
57
 and in living cells.
58
 
This wealth of potential applications of the pyrene properties is also an advantage for the use 
of pyrene as guest molecule in host-guest systems. 
1.2.4 Metalla-Assemblies, Versatile Host Systems 
If pyrene is a popular guest, metalla-assemblies are equally used as host molecules or 
carceplexes. This currency can be explained by the numerous advantages of the directional-
bonding approach provided by coordination-driven self-assembly, see section 1.2.1. Indeed, 
the wide variety of possible structures that can be constructed via the use of either different 
building blocks or different metals affords a large array for the architectures of the cavities 
where the guest molecules will be encapsulated.  
Concerning the different building blocks, the shapes of these building blocks are 
dominated by their turning angles. This type of angle is defined as the angle formed between 
the two coordinating sites of a ditopic ligand. For example, a linear ditopic ligand, such as 
4,4’-bipyridine (bpy), will have its two sites of coordination oriented at 180° from each other 
while a ditopic building block such as 3,5-bis(pyridin-4-yl)-benzene (bpb) has a turning angle 
of 120° between its two pyridyl donor sites. By extension of this directional-bonding 
approach, the design of building blocks with more than two coordination sites allows the 
design of many possible angles, and consequently many possible geometries. For instance, the 
2,4,6-tri(pyridin-4-yl)-1,3,5-triazine (tpt) ligand or the 5,10,15,20-tetra(pyridin-4-yl)porphyrin 
(tpp-2H) have an angle of respectively 120° and 90° between two neighbours pyridyl donor 
sites, (see Figure 5). 
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Figure 5. Representations of some ligands and their geometries 
Concerning the different transition metals, the shapes of the final structure is dictated 
by the stereochemistry of the metal. This stereochemistry depends of the oxidation state, of 
the coordination number, of the ligands coordinated and of the metal itself. All these factors 
drastically influence the shapes of the metalla-assemblies and their hosting abilities and 
numerous examples can be found in the literature. 
 
Figure 6. Examples of metalla-assemblies as host systems 
A Cu(II)-linked macrocyclic receptor reported by Maverick ables to encapsulate guest 
molecule such as 1,4-diazabicyclo[2.2.2]octane (see Figure 6),
59
 square planar and prismatic 
ethylenediamine Pd complexes of Fujita able to encapsulate guest molecules (1,3,5-
trimethoxybenzene in solution in the square,
60
 adamantane among others in the prism
61
) (see 
Figure 6), Fe- and Ga-containing M4L6 anionic cages reported by Raymond able to trap and 
Maverick’s receptor Fujita’s square 
180° 120° 120° 90° 
bpy bpb tpt tpp 
Chapter 1: Introduction 
 
 
  13 
  
 
stabilize cation guests,
62
 Re-containing squares reported by Hupp,
63
 and of course all the host 
cages designed by Peter Stang, who is one of the first pioneers of the field together with 
Makoto Fujita.
32, 35, 64 
1.2.5 Arene Ruthenium Metalla-Assemblies as Host Systems  
In the field of coordination-driven self-assembly, platinum, palladium and rhenium 
have been of central interest, but arene ruthenium complexes have also received considerable 
attention, in particular because they show a number of interesting characteristics.
65
 First, the 
starting material is the easily accessible arene ruthenium dimer [(η6-arene)Ru(μ2-Cl)Cl]2. 
Second, arene ruthenium complexes are robust and can be stored without a protecting inert 
atmosphere. These dimers are generally well soluble in standard organic solvents such as 
chloroform and interestingly, they are also soluble in water, monomeric aqua complexes 
being formed.
66
 Finally, after abstraction of the halide ligands, three facial coordination sites 
are available for the coordination of neutral or anionic ligands (X, Y, Z). The corresponding 
complex has a so-called half-sandwich structure presenting a piano-stool geometry, (see 
Figure 7). 
 
Figure 7. Typical piano-stool shape of half-sandwich arene ruthenium complexes 
The three available coordination sites of arene ruthenium complexes can be used to 
construct metalla-macrocyclic complexes as well as coordination cages. One possibility to 
obtain those constructions is to combine the half-sandwich complexes with linear ligands such 
as bpy, or with trifunctional ligands, such as adenine-derivatives. Thus, over the last two 
decades, many metalla-cycles have been synthesised using half-sandwich arene ruthenium 
complexes with different ligands and used as host systems. Among them, we can quote for 
instance the metalla-macrocyclic complexes synthesised by the groups of Sheldrick
67
 or 
Severin.
66, 68
 The same strategy has been applied by Fish,
69
 Rauchfuss,
70
 and Yamanari
71
 with 
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half-sandwich complexes of rhodium and iridium to construct metalla-cages able to 
encapsulate guest molecules.  
Another method to synthesise arene ruthenium cages capable to host guest molecules 
is to use dinuclear metalla-clips. This strategy has been developed by our group and is based 
on the synthesis of an arene ruthenium dinuclear complex designed from arene ruthenium 
dimers and tetradentate ligand precursors such as 1,4-dihydroxy-benzoquinone derivatives. 
The synthesis is straightforward, since reaction of [(η6-arene)Ru(μ2-Cl)Cl]2 with 1,4-
benzoquinone derivatives (2,5-dihydroxy-1,4-benzoquinone (dhbq-H2); 2,5-dichloro-1,4-
benzoquinone (dClbq- H2)) affords the corresponding dinuclear arene ruthenium metalla-clips 
[(η6-arene)2Ru2(OO∩OO)Cl2] (OO∩OO = 2,5-dioxydo-1,4-benzoquinonato (dobq), 2,5-
dichlorido-1,4-benzoquinonato (dClobq)) with a metal–metal distance of 7.9 Å, (see Figure 8 
for the examples of two dinuclear clips C1,
72
 and C2
73
 with para-cymene as arene). 
 
Figure 8. Dinuclear arene ruthenium metalla-clips C1 and C2 
These metalla-clips can then be used as building blocks to assemble cationic arene 
ruthenium metalla-prisms.
65
 These hexanuclear cations consist of three dinuclear metalla-clips 
and two trigonal tpt panels. The synthesis is straightforward, since addition of a halide 
scavenger to the metalla-clip in the presence of tpt leads to the connection of the two panels 
by self-assembly (see Scheme 1 for a representation of the synthesis of arene ruthenium 
metalla-prisms and the example of [Ru6(p-cym)6(tpt)2(dobq)3]
6+
 ([P1]
6+
) synthesis). The 
metalla-prisms are usually isolated as trifluoromethanesulfonate salts.
72
 
C1 C2 
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Scheme 1. Synthesis of arene ruthenium metalla-prisms 
As shown in Scheme 1, those metalla-prisms contain a cavity and can permanently 
encapsulate a flat molecule such as pyrene (C16H10), fluoranthene (C16H10), triphenylene 
(C18H12), benzo[e]pyrene (C20H12), and coronene (C24H12). In this particular case, if the 
synthesis of the metalla-prism is carried out in the presence of such a flat aromatic molecule, a 
carceplex is found.
73
 Permanent encapsulation of square-planar complexes Pd(acac)2 and 
Pt(acac)2 (acac = acetylacetonato) was also been observed giving the “complex-in-a-complex” 
cations [Pd(acac)2prism]
6+
 and [Pt(acac)2prism]
6+
, (see Figure 9).
72
 
 
Figure 9. Structure of [Pd(acac)2P1]
6+
, hydrogen atoms being omitted for clarity 
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1.3 Mononuclear Arene Ruthenium Complexes for Anticancer Treatment 
1.3.1 Metals in Medicine 
The beginnings of the use of metals in medicine were empiric. Gold was used to treat 
ulcers in ancient China more than four thousand years ago, and silver coins were added to 
containers for water storage in order to prevent intoxications due to silver’s anti-bacterial 
property in ancient Rome, but the use of these metals was not based on real scientific 
knowledge.
74
 Thus, in France during the 16
th
 and 17
th
 century, some physicians published 
several recipes of so-called “drinkable gold” made by distilling alcohol solutions with 
sulphuric acid and gold chloride. During this process diethyl ether is synthesised in situ and 
dissolves gold chloride, which forms a yellow coloured phase, l’or potable.75 This solution 
was used as an elixir de beauté by Diane de Poitiers, who was a favourite of King Henri II, 
and recent findings suggest that this drinkable gold was the cause of a chronic intoxication 
leading to the death of Diane de Poitiers.
76
 Nevertheless, disasters like this one did not 
discourage the cosmetic industry of the 21
th
 century to use gold nanoparticles and other 
expensive and precious metals for modern elixirs de beauté.  
More recently, in the early years of the 20th century, Paul Ehrlich discovered an 
arsenic drug against syphilis by screening a library of compounds and baptised it Salvarsan. 
Then, Ehrlich's laboratory developed a more water-soluble arsenical compound, called 
Neosalvarsan, which was easier to prepare and became available in 1912.
77
 However, these 
arsenical compounds presented considerable side effects, and they were supplanted as 
treatments for syphilis in the 1940s by penicillin. After these only partial successes for metal-
containing drugs, the pharmaceutical industry focused on the design of purely organic drugs 
and natural products, until the discovery by Barnett Rosenberg of the antiproliferative activity 
of the platinum complex cisplatin.
78
 
The different geometries of the complexes, as well as the important variety of ligands 
that it is possible to coordinate onto different transition metals, allowed the syntheses of many 
kinds of molecules impossible to obtain via organic synthesis. However, despite the clinical 
success of cisplatin, this pool of complexes has only partially been explored by the 
pharmaceutical industry. 
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1.3.2 Cisplatin and other Platinum-Containing Anticancer Drugs 
Cisplatin, or cis-diamminedichloroplatinum(II), is a square-planar Pt(II) complex (see 
Figure 12) and was the first metal-based drug to enter into worldwide clinical use for the 
treatment of cancer in 1978. Currently, cisplatin is used either by itself or in combination with 
other drugs for treating ovarian, lung, testicular, bladder, oesophageal, colon and prostate 
cancers. Moreover, this molecule is used as a benchmark for research in this area. For 
instance, the activities of platinum and non-platinum potential drugs are usually compared to 
cisplatin in most publications. More information concerning the chemical and physical 
properties of cisplatin, its biological mechanism of action or its clinical applications as well as 
many other topics can be found in the numerous articles, reviews and books of Rosenberg,
79
 
Lippard,
80
 Reedijk,
81
 Farrell,
82
 Lippert,
83
 Sadler,
84
 or Schellens.
85
 
Nevertheless, cisplatin presents major limitations, for example a strong nephrotoxicity, 
a phenomenon of resistance acquired by tumour cells, and other side effects such as bone 
marrow suppression.
86
 Thus, in order to decrease these side effects, more than 4000 platinum 
compounds have been tested as potential anticancer drugs. Among them, about 1% has 
entered clinical trials, and the Food and Drug Administration (FDA) have approved only two 
complexes: carboplatin and oxaliplatin, (see Figure 10). 
 
Figure 10. Structures of cisplatin, carboplatin and oxaliplatin 
These new platinum anticancer drugs exhibit a better selectivity against cancer cells 
than cisplatin, but some of the limitations precisely due to the presence of platinum still 
reside. This is the reason why many researches are now focusing on metalla-drugs containing 
other metals as potential anticancer agents. Among them, ruthenium based-drugs are the most 
promising ones. 
cisplatin carboplatin oxaliplatin 
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1.3.3 Ruthenium versus Platinum 
Ruthenium complexes have raised considerable expectations for the treatment of 
cancer since the beginning of the 1990s.
87
 Some of these molecules directly attack and kill 
cancer cells, while others present antimetastatic properties, preventing the tumour from 
releasing cancer cells that spread to other parts of the body. The structures and properties of 
these complexes range from traditional coordination compounds that lose their ligands by 
direct interaction with the biological targets, to organometallic compounds, which in addition 
to interact with the biological targets, can facilitate the generation of higher cytotoxic reactive 
oxygen species (ROS), such as singulet-oxygen. Finally, some ruthenium complexes are able 
to act as enzyme inhibitors which question the survival of the cell.
88
 This large array of 
possible interactions is one of the advantages that ruthenium complexes possess over platinum 
complexes.  
Another advantage for ruthenium complexes versus platinum complexes is the 
chemistry of ruthenium in the biological milieu. Among the numerous numbers of oxidation 
state of the ruthenium, only Ru(II) and Ru(III) have been incorporated into potential 
anticancer drugs. Since ruthenium is just bellow iron in the periodic table, most Ru(II) (S = 
½) and Ru(III) (S = 0) complexes are low-spin, and the water exchange rate for aquated 
Ru(II) is about one order of magnitude faster than that of Pt(II), suggesting that complexes of 
Ru(II) may be better suited for reactions with biological targets in the body. This exchange 
rate for aquated Ru(II) is also an advantage for the elimination of ruthenium by the body. 
Consequently, the accumulation effect of platinum in the body of patients treated by platinum 
drugs might be not met with ruthenium drugs. Finally, studies show that the two oxidation 
states of the ruthenium Ru(II) and Ru(III) can be interconverted by substances in the body, 
which could explain the good elimination of Ru(III) complexes, despite of a slower water 
exchange rate than Ru(II) complexes.
89
 
1.3.4 NAMI-A and KP1019: Promising Ruthenium(III) Anticancer Agents 
Imidazolium-trans-dimethylsulfoxide-imidazole-tetrachlororuthenate (NAMI-A) and 
imidazolium-trans-bis(1H-indazole)-tetrachlororuthenate (KP1019) are two ruthenium agents 
that have successfully completed phase I clinical trials.
90
 Despite their structural and chemical 
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similarities (see Figure 11), these two Ru(III) complexes show distinctly different antitumour 
behaviours. 
 
Figure 11. Structures of NAMI-A and KP1019 
In preclinical studies, NAMI-A has demonstrated inhibitory effects against the 
formation of cancer metastases in a variety of tumour animal models, but appears to have no 
direct cytotoxic effects on primary tumours.
91
 Contemporary with the development of NAMI-
A by Sava, Keppler discovered KP1019. KP1019 is more stable toward aquation and 
hydrolysis and is more readily taken up by cells than NAMI-A.
92
 But more interestingly, 
KP1019 shows a remarkable activity against primary cisplatin-resistant colorectal tumours, 
but no pronounced anti-metastatic activities.
93
  
Eventually, since both NAMI-A and KP1019 molecules react with biological 
reductants, as for example ascorbate or glutathione reductase, in protein-free model systems,
94
 
it was suggested that the reduction of Ru(III) pro-drugs to Ru(II) species may be required for 
their biological activity,
93
 suggesting that the active species are Ru(II) complexes.  
NAMI-A KP1019 
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1.3.5 Mononuclear Arene Ruthenium(II) Complexes as Potential Anticancer Agents 
The most common group of cytotoxic ruthenium compounds are arene ruthenium 
complexes where the ruthenium atom is in the oxidation state II. This type of air-stable and 
water-soluble anticancer agents was pioneered by Dyson
95
 and Sadler.
96
 In particular, Dyson’s 
RAPTA-C complex
97
 built from para-cymene ruthenium and 1,3,5-triaza-7-
phosphaadamantane (pta) and Sadler’s [(η6-biphenyl)Ru(en)Cl]+ complex98 built from 
biphenyl ruthenium and ethane-1,2-diamine (en) (see Figure 12) are two highly promising 
molecules that are currently in phase I of clinical trials. 
 
Figure 12. RAPTA-C and [(η6-biphenyl)Ru(en)Cl]+ complexes 
These arene ruthenium complexes possess chloro ligands that can dissociate as 
chloride anions, therefore theses complexes aquate and hydrolyse easily at physiological pH 
( 7.4) and low chloride concentration corresponding to intracellular conditions. However, in 
the case of a strong concentration of chloride, such as in blood plasma, this aquation 
equilibrium is decreasing and the rate of exchange is strongly inhibited.
98-99
 This difference of 
aquation equilibrium between intra and extracellular milieu is essential in term of binding 
with biomolecules, and aquation seems to be the activating step in the cytotoxicity of arene 
ruthenium complexes. However, the mechanism of these complexes is still not completely 
understood.
100
 
 
RAPTA-C [(6-biphenyl)Ru(en)Cl]+ 
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1.4 Arene Ruthenium Assemblies with Anticancer Properties 
1.4.1 Drug Delivery and Enhanced Permeability and Retention Effect 
So far only small molecules containing one metal atom, either platinum or ruthenium, 
have been discussed. This approach of small molecules as anticancer agents is the common 
strategy used by pharmaceutical industries to design new potential drugs. In 1997, to illustrate 
this widespread small molecule approach, Lipinski published five well known rules, based on 
the observation that most drugs are relatively small and lipophilic. According to these rules, 
the vast majority of the drugs approved by the FDA possess a molecular weight under 500 g ∙ 
mol
-1
 and have not more than five hydrogen bond donors and not more than ten hydrogen 
bond acceptors.
101
 
Nevertheless since the beginning of the 1980’s, basic research in biochemistry 
increasingly studied large and high molecular weight molecules, in particular in the field of 
drug delivery. The idea of drug delivery is to hide the real drug into a larger molecule, called 
drug vector, which has different properties. For instance, this drug vector can protect the drug 
against the acidic pH of the stomach or of the basic pH of the bowels, but can also protect it 
against the metabolic action of the liver, or can increase the water-solubility of the drug. In 
fact, the aim is to modify the biodistribution and the clearance of the molecule without 
changing the structure of the drug.  
Another interest of large and high molecular weight drugs is their potential selectivity 
for cancer cells. The discrimination of healthy with respect to cancer cells by a drug between 
normal and cancer cells is one of the major challenges of anticancer research. In the beginning 
of the 1980’s, Maeda discovered a possible strategy to attain this selectivity by using large 
molecules called macromolecular drugs or nanomedicines. The concept behind this approach 
is the fact that cancer cells present a very important hypervasculature and a defective vascular 
architecture of the endothelial layer of blood vessels.
102
 Moreover, in addition to this 
enhanced tumour vascular permeability, the lymphatic drainage system is substantially 
modified in cancer cells, and it appears that it does not operate efficiently.
103
 Consequently, 
macromolecular drugs and large vectors are retained in the tumour interstitium for longer 
periods than in healthy tissues. Thus, the combination of poor tissue drainage with increased 
tumour vascular permeability results in a phenomenon called the enhanced permeability and 
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retention (EPR) effect. This effect is believed to play a major role in the selectivity of 
nanomedicines towards cancer cells with an intratumour drug delivery efficacy up to 100 fold 
greater than that observed in healthy cells.
104
 Many types of nanomedicines exist, including 
antibodies and polymeric drugs, but also large drug delivery vectors such as micelles and 
nanoparticles. Indeed, an EPR effect has been observed for proteins,
105
 micelles composed of 
block copolymers,
106
 encapsulated drugs,
107
 liposomes,
108
 and even bacteria with diameters up 
to 12 μm.109 These types of nanomedicines are fabricated by organic chemistry, 
organometallic chemistry or by biological techniques. Another and very useful way to design 
macromolecular drugs is supramolecular chemistry. 
1.4.2 Arene Ruthenium Metalla-Rectangles Against Cancer 
Supramolecular chemistry, and especially coordination-driven self-assembly, is a really 
simple and straightforward method to design large molecules able to target cancer cells via 
EPR effect, but surprisingly the application of supramolecular chemistry remains extremely 
scarce. As mentioned above, arene ruthenium complexes can be used either as building blocks 
for supramolecular chemistry, or as potential anticancer agents. Thus, this double face of 
these complexes allows the possibility to combine their versatile properties in only one object, 
and consequently, it becomes possible to associate the anticancer activity of these complexes 
into large structures precisely built from these arene ruthenium compounds.  
This original approach has been developed by our group and different water-soluble arene 
ruthenium rectangles of general formula [(η6-arene)4Ru4(OO∩OO)2(N∩N)2]
4+
 (arene = p-
cym, hmb; OO∩OO = dobq, dClobq; N∩N = pyrazine (pyr), bpy, 1,2-bis(4-pyridyl)ethylene 
(bpe)) have been synthesised by our group
110
 and by Jin’s group.111 We tested all these 
metalla-rectangles against cancer cell lines, (see Figure 13 and List of Structures).
110
 The 
activities of these metalla-rectangles R1  R12 against human ovarian cancer cell lines 
(A2780) were found to be moderate to excellent, depending of the size of the linker used as 
well as the nature of the arene (para-cymene versus hexamethylbenzene). Indeed, the IC50 
values (IC50 being the drug concentration necessary for 50% inhibition of cell viability) of 
these metalla-rectangles were found in the range 4  66 μM. Later and following the same 
approach, Navarro and Barea’s group published new arene ruthenium metalla-rectangles with 
antiproliferative activities.
112
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Figure 13. Schematic representation of metalla-rectangles R1  R12 
1.4.3 Trojan Horse Concept and Arene Ruthenium Metalla-Prisms 
The molecular Trojan horse concept is based on the idea to encapsulate potential drugs 
that are not soluble in water and therefore that cannot enter the cells into the hydrophobic 
cavity of a water-soluble arene ruthenium prism. Thus, the metalla-prism becomes a drug 
vector that enhances the uptake of the hidden drug, by transporting it and releasing it into 
cancer cells, (see Figure 14). Moreover, as the prism is built by assembly of arene ruthenium 
units, it is also a potential anticancer agent. Finally, the size of the prism could allow the 
selective targeting of cancer cells via EPR effect. 
Chapter 1: Introduction 
 
 
24    
 
 
 
Figure 14. Molecular Trojan horse concept 
As described earlier, arene ruthenium metalla-prisms able to permanently encapsulate 
small molecules have been synthesised by our group. This permanent encapsulation is due to 
the carceplex behaviour of the dobq and dClobq-bridged prisms and allows the transport and 
the release of these guest molecules into cancer cells.  
The synthesis of such large and cytotoxic carceplex drug vectors is relatively new. 
Indeed, different arene ruthenium prisms have been synthesised so far by our group, but only 
the last generation has demonstrated carceplex abilities. In fact, the ability of the metalla-
prism to encapsulate guest molecules depends on the size of the cavity, and therefore on the 
length of the bridge between the ruthenium atoms. This is the reason why our group has 
always tried to increase the length of the dinuclear clips, (see Figure 15). 
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Figure 15. Length of the dinuclear clips used to synthesise metalla-prisms 
 The first metalla-prism synthesised in Neuchâtel was the para-cymene ruthenium 
chloro-bridged prism, (see Figure 16).
113
 Since the discovery of these chloro-bridged prisms, 
our group synthesised other metalla-prisms built from arene ruthenium oxalato clips, (see 
Figure 16).
114
 
 
Figure 16. Para-cymene ruthenium chloro and oxalato-bridged prisms 
In the cases of the chloro and oxalato-bridged prisms, the distance between the two 
ruthenium atoms, and thus between the two tpt panels does not allow the encapsulation of any 
molecules, and consequently these prisms cannot be used as anticancer molecular Trojan 
chloro-bridged prism oxalato-bridged prism 
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horses. But in 2008, a major breakthrough was published by our group with the syntheses of 
dobq-bridged prisms that allow the permanent encapsulation of guest molecules.
72
 Then, a 
series of different guest molecules have been encapsulated into prism P1 and the 
corresponding complexes have been tested against A2780 cancer cell lines, (see Scheme 2). 
As the metalla-prism P1 leads to a carceplex, the encapsulation of the guest molecules is 
performed during the synthesis of the prism. Moreover, once the guest is encapsulated, it 
cannot escape from the cavity of the host, unless if the cage molecule is destroyed. 
 
Scheme 2. Synthesis of trigonal-prismatic carceplexes [a-h⊂P1]
6+
 encapsulating a guest 
molecule 
  All these complexes show moderate to good cytotoxicities from 1 μM to 18 μM and 
the presence of guest molecule has either a negligible effect on the cytotoxicity (a, d, e and h) 
or significantly increases the cytotoxicity (b, c, f and g), with [b⊂P1]
6+
 (IC50(A2780) = 1 
μM),72 and [g⊂P1]
6+
 (IC50(A2780) = 2 μM)
115
 being an order of magnitude more cytotoxic 
than the empty cage [P1]
6+
 (IC50(A2780) = 23 μM). Indeed, the cytotoxicity of [b⊂P1]
6+ 
and 
[g⊂P1]
6+
 
is comparable to cisplatin. These differences could be due to the intrinsic 
cytotoxicities of the different pyrenyl derivatives, which due to the poor water solubility of 
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these compounds could not be evaluated, or to differences in the uptake and/or further 
intracellular release of these molecules. 
 Furthermore, using the highly fluorescent pyrene f as guest molecule, direct evidence 
for the efficient release of the hydrophobic guest molecule from the metalla-prism P1 into 
cancer cells has been provided.
116
 Indeed, employing this fluorescent pyrene as a cargo and 
monitoring the fluorescence of the cells, it has been possible to follow the uptake and the 
accumulation of this molecule into cancer cells via microscopy and flow cytometry. The 
mechanism of the entry of the compound into the cells has been partly elucidated as being 
dependent on an assisted diffusion pathway. This mode of uptake has been described for 
cisplatin
117
 and other platinum-based drugs,
118
 for which potential transporters have been 
identified.
119
 The existence of a facilitated mode of entry into cells implies a certain cell 
specificity, which offers a potential advantage for the use of such a delivery vehicle in 
medicinal applications.
119
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1.5 Aim of the Present Thesis  
The systematic development of arene ruthenium cages by our group has led to the 
discovery of new metalla-rectangles as well as metalla-prisms. The idea behind this global 
project has been to combine the construction of metalla-cages assembled from arene 
ruthenium building blocks with the intrinsic biological and anticancer properties of these 
arene ruthenium complexes. The results of these attempts have been the syntheses of 
cytotoxic and antiproliferative complexes with high molecular weights, potentially able to 
target cancer cells via EPR effect. 
Moreover, if we analyse the evolution of the molecules published by our group during 
the last years, we can clearly make out a trend towards the extension of the metalla-cage 
dimensions. The rise of the length of the dinuclear clips has led to the extension of the cavity 
size inside the cages. In 2008, the dimensions of the assemblies have been enough to 
permanently encapsulate some molecules, such as small PAHs or square planar complexes 
into metalla-prisms. This carceplex behaviour has allowed the use of the metalla-prisms as 
drug vectors and the transport and the release of the guest molecule into cancer cells have 
been proven. In the case of the metalla-rectangles, no encapsulation of molecules has been 
observed so far, but an important size effect for the cytotoxicity of the assemblies has been 
identified.  
This thesis is neither the beginning nor the end but part of this project initiated in 2006 
and a step forward in the evolution of the arene ruthenium assemblies as potential anticancer 
agents. In particular, during this thesis, the description of new and larger metalla-clips and the 
syntheses of the corresponding metalla-rectangles, metalla-prisms and metalla-cubes have 
been achieved. A very interesting feature of these new metalla-assemblies has been observed. 
Indeed, the rise of the metalla-clips has led to the extension of the size of the cavities of the 
corresponding metalla-assemblies to eventually allow host-guest properties between small 
aromatic molecules and metalla-prisms, but also between these guest molecules and metalla-
rectangles. The thermodynamic equilibrium between free species and host-guest complexes 
has been studied and their antiproliferative comportments have been monitored by the group 
of Professeur Dyson at the Ecole Polytechnique Fédérale de Lausanne. 
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Chapter 2: Arene Ruthenium Metalla-Rectangles 
2.1 Arene Ruthenium Metalla-Rectangles as Host Systems  
2.1.1 Overview of Arene Ruthenium Metalla-Rectangles 
The first arene ruthenium metalla-rectangle was reported in 1997.
120
 The synthesis in 
methanol of this tetranuclear complex [(η6-p-cym)4Ru4(ox)2(bpy)2]
4+
 in which two arene 
ruthenium oxalato dinuclear metalla-clips (arene = p-cym) C0 (see List of Structures) are 
bridged by two 4,4’-bipyridine linkers was straightforward and the metalla-rectangle was 
isolated as a trifluoromethanesulfonate salt in a very good yield. This first arene ruthenium 
metalla-rectangle was a key molecule for the development of the chemistry based on the use 
of arene ruthenium dinuclear metalla-clips. Despite the geometric simplicity of metalla-
rectangles, this type of structure is more difficult to obtain than symmetrical polygons. 
Indeed, addition of two different connecting ligands with metal corners does not favour the 
formation of the desired rectangle but leads to the formation of molecular squares as well as 
trinuclear species due to a strong enthalpic driving force. However, the use of arene 
ruthenium oxalato dinuclear metalla-clips allowed the exclusive synthesis of the desired 
metalla-rectangle via a pre-organisation of the different building blocks after abstraction of 
the chloride ligands by a halide scavenger, (see Scheme 3). 
 
Scheme 3. Two-step synthesis of metalla-rectangle [(η6-p-cym)4Ru4(ox)2(bpy)2]
4+
 
This metalla-rectangle was too small to accommodate guest molecules between the 
two bpy units, but the same strategy was applied to generate larger metalla-rectangles of the 
general formula [(η6-arene)4Ru4(OO∩OO)2(N∩N)2]
4+
 (arene = p-cym, hmb; OO∩OO = dobq, 
dClobq; N∩N = pyr, bpy, bpe) (R1  R12, see Table of Figures) have been synthesised in 2008 
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and 2009 by Jin’s and our group.110-111 X-ray structural analyses of R7 ([(η
6
-
hmb)4Ru4(dobq)2(bpy)2]
4+
) and R10 ([(η
6
-hmb)4Ru4(dClobq)2(bpe)2]
4+
) have been performed 
and interestingly enough, an organisation in channels has been observed in the solid state for 
the metalla-rectangle R7, (see Figure 17).
110
 This organisation in cationic nanotubes stabilised 
by trifluoromethanesulfonate anions between the rectangular channels allows the 
encapsulation of small molecules such as residual solvent molecules.  
 
Figure 17. Molecular structure of cation R7 with a view of the molecular channels along the b 
axis 
In the case of the metalla-rectangle R10, the linker being longer, the cavity is larger and 
upon crystallisation of this cation in a chloroform/diethyl ether mixture, two diethyl ether 
molecules have been encapsulated into the hydrophobic cavity of cation R10. Using the 
approach developed by our group, Jin synthesised in 2009 a new series of metalla-rectangles 
by the combination of arene ruthenium oxamide types dinuclear clips and bpy and bpe as 
linear bidentate pyridyl linkers to generate the corresponding metalla-rectangles.
121
 Jin’s 
group also proposed the construction of half-sandwich iridium metalla-rectangles via C–H 
activation to synthesize new metalla-clips.
122
 Although this strategy seems interesting, it has 
not been yet applied with arene ruthenium. Finally, Navaro and Barea’s group published in 
2009 and 2010 new arene ruthenium metalla-rectangles built with different metalla-clips and 
bpy and 4,7-phenanthroline.
112, 123
  
2.1.2 Arene Ruthenium Metalla-Rectangles and Host-Guest Chemistry 
In large supramolecular assemblies, a cavity capable of accommodating guest 
molecules does not guarantee host-guest chemistry. Indeed, in a host-guest system an 
equilibrium between the unbound and bound states exists. This thermodynamic exchange 
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between free species and bound species makes the difference between the entrapment of a 
molecule into another molecule and a host-guest system. As a consequence, in the particular 
case of metalla-rectangles, the entrapment of small molecules such as anions or solvents in the 
solid state without exchange studies cannot be considered strictly speaking as host-guest 
chemistry.
124
  
The access to the cavity is, however, essential for the host-guest process to take place. 
Therefore, in order to generate an efficient host-guest system, sufficient cavity size and portal 
size of the host are equally important, unless the cage possesses the ability to assemble-
disassemble at will in solution by self-reparation for example. As described previously, the 
size of the cavity of the metalla-rectangle depends on the length of the dinuclear metalla-clip. 
Thus, in order to design arene ruthenium metalla-rectangles able to interact in a host-guest 
fashion with small aromatic molecules, the first step is to synthesise larger dinuclear metalla-
clips.  
2.1.3 Synthesis and Characterisation of Arene Ruthenium Metalla-Clips C5  C7 
In coordination and organometallic chemistry quinones are attracting a lot of 
interest.
125
 Their numerous applications in organic chemistry,
126
 physical chemistry
127
 and 
biology
128 
are well known, and moreover, these multifunctional ligands are becoming popular 
for the synthesis of complexes with arene ruthenium units.
129
 In particular, the commercially 
available quinone derivatives, 5,8-dihydroxy-1,4-naphthoquinone (dhnq-H2), 5,8-dihydroxy-
1,4-anthraquinone (dhaq-H2), and 6,11-dihydroxy-5,12-naphthacenedione (dhtq-H2), have 
been used to form dinuclear species with ruthenium metals.
130
  
 
However, the corresponding dinuclear complexes incorporating arene ruthenium units 
remain scarce in the literature and only [(η6-p-cym)2Ru2(5,8-dioxydo-1,4-
anthraquinonato(doaq))Cl2] (C6) has been synthesized so far.
131
 Thus, using the same 
approach, we synthesised and characterised the new arene ruthenium metalla-clips [(η6-p-
dhnq-H2 dhaq-H2 dhtq-H2 
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cym)2Ru2(OO∩OO)Cl2] (OO∩OO = 5,8-dioxydo-1,4-naphthoquinonato (donq) and 6,11-
dioxydo-5,12-naphthacenedionato (dotq)) (C5 and C7), (see Figure 18). 
 
Figure 18. Dinuclear arene ruthenium metalla-clips C5, C6 and C7 
The synthesis of these metalla-clips is easy and straightforward, since two equivalents 
of anhydrous sodium acetate, one equivalent of the quinone derivatives and one equivalent of 
chloro-bridged arene ruthenium dimer react in ethanol at 90°C for 12h. After filtration and 
several washings with ethanol, acetone and pentane, the dark green solids are collected in 
high yields. The three arene ruthenium metalla-clips are soluble in chloroform. As expected, 
the 
1
H NMR spectra of C5 in CDCl3 shows one singulet at δ = 6.98 ppm corresponding to the 
protons of the 5,8-dioxydo-1,4-naphthoquinonato bridging ligand along with the signals 
associated with the p-cym ligands while the 
1
H NMR spectra of C7 in CDCl3 shows two 
doublets at δ = 8.50 and 7.72 ppm corresponding to the protons of the 6,11-dioxydo-5,12-
naphthacenedionato bridging ligand along with the signals associated with the p-cym ligands.  
2.1.4 Synthesis of a Series of Arene Ruthenium Metalla-Rectangles (R13  R21) 
The three metalla-clips C5  C7 possess a distance of 8.4 Å between the two 
ruthenium atoms, which is a significant increase of the span with respect to the arene 
ruthenium dinuclear metalla-clips previously reported. The rise of the span of these metalla-
clips allows the syntheses of larger cationic arene ruthenium metalla-rectangles R13  R21 of 
the general formula [(η6-p-cym)4Ru4(OO∩OO)2(N∩N)2]
4+
 (OO∩OO = donq (R13, R16, R19), 
C5 C6 C7 
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doaq (R14, R17, R20), dotq (R15, R18, R21); N∩N = pyr (R13, R14, R15), bpy (R16, R17, R18), bpe 
(R19, R20, R21)).  
 
Scheme 4. Syntheses of arene ruthenium metalla-rectangles R13  R21 
 The synthesis of these metalla-rectangles is straightforward. Indeed, the arene 
ruthenium dinuclear complexes (C5 – C7) react in methanol at room temperature in the 
presence of silver trifluoromethanesulfonate (halide scavenger) with different N∩N donor 
ligands (pyrazine, 4,4’-bipyridine, 1,2-bis(4-pyridyl)ethylene) to give the tetranuclear cations 
R13  R21 isolated as trifluoromethanesulfonate salts, (see Scheme 4). The 
1
H NMR spectra of 
R13  R15 display a singulet due to the pyrazine protons. Unlike free pyrazine, where the 
proton signal is found at δ = 8.57 in CD3CN, the signal in R13  R15 appears slightly shifted 
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upfield at δ = 8.46 ppm. The 1H NMR spectra of R16, R17, and R18 show two doublets due to 
the 4,4’-bipyridine protons with an upfield shift of about 0.2 ppm as compared with the free 
4,4’-bipyridine in CD3CN. The same upfield effect of about 0.2 ppm is observed with the 
protons of the 1,2-bis(4-pyridyl)ethylene linkers in complexes R19  R21. Upon formation of 
the cationic tetranuclear metalla-rectangles, the methyl and isopropyl signals of the p-cymene 
ligands in R13  R21 remain almost unchanged as compared to complexes C5 – C7, while the 
aromatic protons of the p-cymene ligands are slightly shifted downfield. Similarly, the proton 
signals of the 5,8-dioxydo-1,4-naphthoquinonato, 5,8-dioxydo-1,4-anthraquinonato and 6,11-
dioxydo-5,12-naphthacenedionato bridging ligands in all metalla-rectangles R13  R21 are 
shifted downfield as compared to their parent complexes C5 – C7.  
 
In the metalla-rectangles R14, R17, and R20 the asymmetry of the 5,8-dioxydo-1,4-
anthraquinonato bridging ligand allows the formation of two isomers. Indeed, the presence of 
two isomers is quite obvious in the case of R14 in which two distinct sets of signals for the 
5,8-dioxydo-1,4-anthraquinonato ligands are observed in the 
1
H NMR spectrum (CD3CN). 
However, the signals of the p-cym and pyrazine ligands remain equivalent despite the 
presence of these two isomers R14 and R14’, (see Figure 19). In the case of R17 and R20, in 
which the two 5,8-dioxydo-1,4-anthraquinonato bridges are far away from each other all 
signals show no sign of the presence of the two isomers and give rise to only one set of 
signals for both isomers at room temperature. 
 
Figure 19. Schematic representation of the two isomers R14 and R14' 
The infrared spectra of R13  R21 are dominated by absorptions of the coordinated 
OO∩OO and N∩N ligands, which are only slightly shifted as compared to the infrared 
R14 R14’ 
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absorptions of the free ligands. In addition to the N∩N and OO∩OO signals, strong 
absorptions due to the stretching vibrations of the trifluoromethanesulfonate anions (1260(s), 
1030(s), 638(m) cm
-1
) are also observed in the infrared spectra of the salts [R13  
R21][CF3SO3]4.  
The electronic absorption spectra of the metalla-rectangles R13  R21 are characterised 
by an intense high-energy band centered at 320 nm, which is assigned to ligand–localized or 
intra-ligand π → π* transition as well as broad low-energy bands associated to metal-to-
ligand charge transfer (MLCT) transitions. In C5 – C7, only one MLCT band is found (≈ 600 
nm), while in metalla-rectangles R13  R21 an additional band centered at around 400 nm is 
observed as well, (see Figure 20). 
 
Figure 20. UV-visible spectra of C5 – C7 and R13  R21 (10
-5
 M) in dichloromethane 
In the absence of suitable crystals for X-ray measurements, the cavity sizes of the 
different metalla-rectangles were estimated by molecular modeling and from analogous 
structures incorporating the same bridging and connecting ligands. The pyrazine series 
possess a cavity of about ≈ 8.4 x 7.0 Å2 (ruthenium-to-ruthenium edges), while the cavity 
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sizes of the 4,4’-bipyridine and 1,2-bis(4-pyridyl)ethylene series are expected to be 
approximately 8.4 x 11.2 and 8.4 x 13.6 Å
2
, respectively, (see Figure 21). 
 
 
Figure 21. Estimated cavity size of the different metalla-rectangles 
2.1.5 In- or Out-of-Cavity Interactions? 
In order to study the ability of the hydrophobic cavity of the metalla-rectangles R13  
R21 to encapsulate guest molecules in solution, we performed various NMR experiments. 
1
H 
NMR spectra of 1:1 mixtures of metalla-rectangles with planar aromatic molecules (pyrene, 
anthracene, perylene and coronene) were measured. In the case of the pyrazine-containing 
metalla-rectangles R13  R15, no chemical shift for the protons of the host and of the aromatic 
molecule was observed in CD3CN. The result is quite different with the larger metalla-
rectangles R16  R21, in which some protons of the metalla-rectangle and of the aromatic 
molecule are shifted as compared to their initial 
1
H NMR spectra, (see Figure 22).  
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Figure 22. 
1
H NMR spectra of R16 (a), pyrene + R16 (1:1 mixture) (b) and pyrene (c) (25 ºC, 
CD3CN) 
Consequently, these observations prompted us to further investigate the hosting 
potential of the metalla-rectangles R16  R21 in solution by diffusion-ordered NMR 
spectroscopy (DOSY). DOSY measurement is a powerful tool for studying host-guest 
association in solution.
132
 The diffusion coefficient depends on the shape and size of the 
molecules. Therefore, in a host-guest system in which the guest is perfectly encapsulated in 
the cavity of the host without significantly affecting the size and shape of the host, the 
diffusion coefficient of the guesthost adduct will be almost identical to the diffusion 
coefficient of the host alone. On the other hand, in a host-guest system in which the guest 
interacts with the host but not in a guesthost fashion, the host and the guest will keep their 
individual diffusion coefficients. 
Room-temperature DOSY measurements of the 4,4’-bipyridine-containing metalla-
rectangles R16  R18 in the presence of anthracene, pyrene, perylene and coronene suggest 
out-of-cavity interactions between the different rectangles and the aromatic molecules. 
However, at -40 °C, the same DOSY experiment with anthracene and metalla-rectangle R16 
clearly shows that anthracene diffuses at almost the same coefficient than the host, (see Figure 
23), thus supporting an in-cavity location of anthracene. To confirm this assumption, a 
ROESY (Rotating Frame NOE SpectroscopY) measurement at -40 °C was performed, (see 
Figure 23). The 
1
H ROESY shows that some protons of anthracene are in close proximity to 
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the protons of the 5,8-dioxydo-1,4-naphthoquinonato and 4,4’-bipyridine ligands which 
confirms together with the DOSY experiment at -40 ºC the presence of anthracene in the 
cavity of R16. All other aromatic molecules (pyrene, perylene, coronene) do not show in-
cavity interactions with metalla-rectangles R16  R18, even at low temperature, which fit with 
out-of-cavity interactions. In contrast, 1,2-bis(4-pyridyl)ethylene containing metalla-
rectangles R19  R21 show in-cavity interactions with these large planar aromatic molecules. 
 
Figure 23. DOSY (bottom) and ROESY (top) NMR spectra of R16 + 1 equivalent of 
anthracene at -40°C (CD3CN) 
DOSY experiments of anthracene with metalla-rectangles R19  R21 show both, in-
cavity and out-of-cavity interactions at room temperature, as opposed to pyrene, perylene and 
coronene for which in-cavity interaction dominates. As an example, the DOSY spectra of 
coronene, metalla-rectangle R19 and a 1:1 mixture of coronene and R19 in CD3CN at room 
temperature are presented in Figure 24. These experiments clearly show that at room 
temperature, coronene and R19 possess almost identical diffusion coefficients, which confirm 
the encapsulation of coronene in the hydrophobic cavity of R19 and the formation of a 
coroneneR19 adduct. 
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Figure 24. DOSY NMR spectra of coronene, R19 and R19 + 1 equivalent of coronene (25 ºC, 
CD3CN) 
In summary, 
1
H, DOSY and ROESY NMR studies have revealed that no meaningful 
interaction occurs between the pyrazine containing metalla-rectangles R13  R15 and planar 
aromatic molecules, while out-of-cavity interactions are prevailing in the case of the 4,4’-
bipyridine containing metalla-rectangles R16  R18, with the exception of anthracene which 
can do both, in-cavity and out-of-cavity interactions with these metalla-rectangles. On the 
other hand, in-cavity interactions take place for the 1,2-bis(4-pyridyl)ethylene containing 
metalla-rectangles R19  R21, thus giving rise to guesthost systems. Therefore, to gain 
further insight in the hosting ability of R19  R21 in solution, a series of 
1
H NMR titration in 
CD3CN solution with pyrene, perylene and coronene was performed. 
2.1.6 Host-Guest Behaviour 
The study of the host-guest properties of metalla-rectangles R19  R21 was carried out 
in acetonitrile solution by using NMR spectroscopy and fluorescence emission titration. Upon 
gradual addition of guest molecule (0.0  20.0 equivalents of pyrene, perylene or coronene) to 
an CD3CN solution of metalla-rectangles R19  R21 (4.0 mM), 
1
H NMR spectra were 
recorded. Then, the chemical shift changes (Δδ) for one chosen signal of the metalla-
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rectangles R19  R21 (for example HC=C) versus the molar ratio of the guest to the metalla-
rectangle were plotted, (see Figure 25).  
 
 
Figure 25. 
1
H NMR chemical shift changes for the HC=C protons of the bpe ligands versus the 
molar ratio of pyrene to R21 (25 ºC, CD3CN) 
The plot of these chemical shift changes versus the molar ratio of the guest to the 
metalla-rectangle clearly indicates a stoichiometry 1:1 for the host-guest system,
133
 which is 
in accordance with the DOSY experiments previously reported. Then using the Δδ value at 
known guest / host molar ratio with help of the nonlinear least-square fitting program 
winEQNMR2,
134
 the stability constants of association (Ka) together with the free energies 
(Gº) were estimated, (see Table 1). 
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Table 1. Stability constants (Ka ) and free energies (ΔGº ) for the encapsulation of pyrene, 
perylene and coronene in metalla-rectangles R19  R21 (CD3CN at 25 °C, 4.0 mM of host) 
 
The estimated stability constants are comprised between 52000 M
-1
 and 69000 M
-1
, 
which imply a relatively strong affinity between the host and the guest – metalla-rectangle 
and aromatic molecules – which however suggest no selectivity or preference by the metalla-
rectangle among these guests (pyrene, perylene and coronene). This non-specificity of the 
metalla-rectangles R19  R21 for these planar aromatic molecules in acetonitrile was further 
confirmed by a competition experiment in which a 1:1:1:1 mixture of pyrene, perylene, 
coronene and R19 was performed. A DOSY experiment shows that the three potential guest 
molecules are competing equally for the hydrophobic cavity of R19, which is not surprising 
with respect to their comparable stability constants. 
 
To conclude these host-guest studies, we performed a fluorescence emission titration 
of perylene with metalla-rectangle R19. Perylene has been intensively used as fluorescent 
probe and its basic fluorescence is well documented.
135
 The fluorescent quenching of perylene 
via exciplex formation
136
 or energy transfer
137
 in solution has been also studied in detail and 
we propose here to see whether or not such quenching by encapsulation of perylene inside the 
cavity of metalla-rectangle R19 occurred. Thus the emission spectra of a dichloromethane 
solution of perylene (10
-7
 M, 350 nm as excitation wavelength) upon gradual addition of 
metalla-rectangle R19 (0.0 – 10 equivalents) were recorded, (see Figure 26). 
guesthost Ka (10
4
 M
-1
) ΔGº (kcal · mol-1) 
[pyreneR19]
4+ 5.8 ± 0.9 -6.48 ± 0.05 
[peryleneR19]
4+
 5.5 ± 0.4 -6.46 ± 0.02 
[coroneneR19]
4+
 6.9 ± 0.6 -6.60 ± 0.02 
[pyreneR20]
4+
 6.8 ± 0.8 -6.59 ± 0.04 
[peryleneR20]
4+
 5.7 ± 0.5 -6.47 ± 0.02 
[coroneneR20]
4+
 5.6 ± 0.7 -6.47 ± 0.02 
[pyreneR21]
4+
 5.2 ± 0.9 -6.43 ± 0.02 
[peryleneR21]
4+
 5.6 ± 0.4 -6.47 ± 0.02 
[coroneneR21]
4+
 6.2 ± 0.7 -6.53 ± 0.04 
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Figure 26. Fluorescence emission titration of perylene (10
-7
 M in dichloromethane) by 
metalla-rectangle R19 (excitation wavelength = 350 nm) 
A quenching of the perylene fluorescence is clearly observed when R19 is added. This 
quench of the fluorescence of perylene can be explained by two effects. First, as the guest 
goes into the cavity of the metalla-rectangle R19, there is a loss of excitation energy received 
by the guest molecule: A part of the energy can be absorbed by the metalla-rectangle and 
consequently, the perylene molecule encapsulated in the metalla-rectangle is less excited and 
therefore cannot reemit the same energy as compared to its free state. Second, the quenching 
can result from energy transfer from perylene to metalla-rectangle R19. Indeed, due to a good 
spectral overlap of absorbance of metalla-rectangle R19 with the perylene emission, energy 
transfer can spontaneously take place, thus leading to a decrease in the emission energy of 
perylene and ultimately to fluorescence quenching, (see Figure 27).
138
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Figure 27. Overlap between normalized absorbance of R19 and fluorescence emission of 
perylene 
This study
139
 reveals that arene ruthenium metalla-rectangles containing new 
OO∩OO-bridges (5,8-dioxydo-1,4-anthraquinonato, 5,8-dioxydo-1,4-anthraquinonato, 6,11-
dioxydo-5,12-naphthacenedionato) and N∩N-linkers (pyrazine, 4,4’-bipyridine, 1,2-bis(4-
pyridyl)ethylene) can be designed to accommodate guest molecule outside and inside their 
cavity.
140
 Various NMR experiments have shown that the small pyrazine containing metalla-
rectangles R13  R15 do not interact with planar aromatic molecules (anthracene, pyrene, 
perylene, coronene), while the more spacious 4,4’-bipyridine and 1,2-bis(4-pyridyl)ethylene 
containing metalla-rectangles R16  R21 give both in-cavity and out-of-cavity interactions with 
these aromatic molecules. Encapsulation of perylene in the hydrophobic cavity of R19 strongly 
quenches the fluorescence of perylene in solution, which confirms the great potential of such 
metalla-rectangles for applications in host-guest chemistry. 
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2.2 Antiproliferative Activity of Arene Ruthenium Metalla-Rectangles 
2.2.1 General 
As described previously, arene ruthenium complexes have recently received 
considerable attention in the field of supramolecular chemistry.
65-66
 The synthesis of new 
arene ruthenium metalla-rectangles able to interact with small aromatic molecules in a host-
guest fashion is an example of the versatility of these metalla-assemblies.  
On the other hand, arene ruthenium complexes have been widely studied as potential 
antitumoral and antimetastatic agents, in particular by Dyson and Sadler,
 
who contributed to 
the emergence of arene ruthenium in bio-organometallic chemistry.
95b, 96a
 Air-stable and 
water-soluble, arene ruthenium complexes have shown a low general toxicity and a high 
selectivity towards cancer cells.
95d, 141
 Furthermore, the amphiphilic properties due to the 
hydrophobic arene ligand and the hydrophilic metal centre as well as the synthetic diversity of 
the arene ligand explain the flourishing design of arene ruthenium-based anticancer drugs.
142 
Since 2008, our group has pioneered the combination of the supramolecular chemistry 
of arene ruthenium building blocks with their antitumoural and antimetastatic activity.
72
 It has 
been demonstrated that arene ruthenium metalla-assemblies are water-soluble and stable in 
biological medium, and also that they exhibit efficient antiproliferative activity.
 
This approach 
has led to the syntheses of the metalla-rectangles R1  R12 (see Table of Figures), which have 
been tested against cancer cells. The activities of these metalla-rectangles against human 
ovarian cancer cell lines (A2780) were found to be moderate to excellent, depending on the 
size of the linker used as well as the nature of the arene (p-cym vs hmb), with IC50 values as 
low as 4 μM.110 
To further study the impact on the antiproliferative activities of the building blocks 
used for the design of arene ruthenium metalla-rectangles, we proposed to investigate the role 
play by the nature of the N∩N linker as well as the role play by the length of the OO∩OO 
metalla-clip in the cytotoxicity of metalla-rectangles, (see Figure 28).  
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Figure 28. Arene ruthenium metalla-rectangles R9, R19  R31 
Thus, we described the syntheses, the characterisations and the antiproliferative 
properties of metalla-rectangles of general formula [(η6-p-cym)4Ru4(OO∩OO)2(N∩N)2]
4+
 
(OO∩OO = oxalato (ox), dobq, donq, doaq, dotq, oxamido (oxa), oxonico (oxo)); N∩N = bpe, 
1,2-bis(4-pyridyl)ethane (bpa)) (R9, R19  R31, see Table of Figures), prepared from the 
dinuclear complexes C0, C1, C5  C7 and [(η
6
-p-cym)2Ru2(OO∩OO)Cl2] (OO∩OO = oxa and 
oxo)) (C8 and C9). 
2.2.2 Synthesis of a Series of Arene Ruthenium Metalla-Rectangles (R9, R19  R31) 
Metalla-rectangles R22  R31 were synthesised following the procedure previously 
described for metalla-rectangles R13  R21. The infrared spectra of all the arene ruthenium 
metalla-cycles are dominated by absorptions of the coordinated N∩N, OO∩OO and NO∩NO 
ligands, which are only slightly shifted as compared to the infrared absorptions of the free 
ligands. In all metalla-clips as well as in all metalla-rectangles, a significant redshift of about 
20 cm
-1
 is observed for the C=O vibration frequencies as compared to the frequencies of non-
coordinated bridging ligands. This can be attributed to a decrease in the CO bond order upon 
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coordination with ruthenium atoms.
9
 This decrease of the CO bond order leading to a redshift 
of the CO absorption is consistent with the X-ray data of the metalla-clip C5(OH2)2,
143 
for 
which the lengths of the CO bounds are comprised between 1.27 Å and 1.32 Å, suggesting an 
intermediate bond order between single (1.40 Å) and double (1.20 Å).63b Furthermore, in 
metalla-rectangles R23 and R24 as well as in R30 and R31 strong absorptions due to the 
stretching vibrations of C=N oxonico bridging ligands are observed at around 1710 cm
-1
 
alongside the absorptions of the stretching vibrations of the C=O bridging ligands at around 
1600 cm
-1
. In addition, to these CN and CO signals, strong absorptions due to the stretching 
vibrations of the trifluoromethanesulfonate anions (1260(s), 1030(s), 638(m) cm
-1
) are 
observed in the infrared spectra of all the salts [R9][CF3SO3]4 and [R19][CF3SO3]4 – 
[R31][CF3SO3]4.  
The electronic absorption spectra of all the metalla-rectangles are characterised by an 
intense high-energy band centred at 270 nm, which can be attributed to ligand π → π* 
transitions.
144
 A broad, moderately intense absorption band in the visible region is tentatively 
assigned to mixed metal-to-ligand charge transfer (MLCT), intra-ligand charge transfer 
(ILCT) and ligand π → π* transitions, where ILCT refers to intra-ligand charge transfer from 
the bpe or bpa N∩N linkers to the OO∩OO or NO∩NO bridging ligands.145 Moreover, in the 
metalla-rectangles incorporating quinone derivatives (R19  R21 and R27  R29) several bands 
attributed to ILCT are observed in the visible region between 500 and 800 nm. Moreover 
bathochromic shifts are observed between the arene ruthenium metalla-rectangles 
incorporating the 1,2-bis(4-pyridyl)ethylene linkers and the metalla-rectangles incorporating 
the 1,2-bis(4-pyridyl)ethane linkers. This significant bathochromic shift of up to 13 nm of 
λmax in the case of R21:R29 is presumably due to a lower contribution to intra-ligand charge 
transfer transitions from the bpa linkers to the OO∩OO bridging ligands as compared to the 
same ILCT from bpe linkers to the corresponding quinone bridging ligands.
146
 The 
bathochromic shifts of absorption bands of metalla-rectangles R19:R27, R20:R28 and R21:R29 
between 550 and 800 nm are depicted in Figure 29. 
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Figure 29. Bathochromic effect of metalla-rectangles R19 – R21 and R27 – R29 
The 
1
H NMR spectra of R25 and R26 – R29 display two doublets between 7.0 and 9.0 
ppm due to the pyridyl protons of the bpa ligands. Unlike free bpa, where the signals of the 
pyridyl protons are found at δ = 8.54 (H) and 7.21 ppm (H) respectively (CD3CN, 21 °C), 
the signal of H in R25 and R26 – R29 appears slightly to strongly upfield shifted (up to 0.80 
ppm in the case of R25), while the signal of H is either shifted upfield (R25, R26, R27) or 
downfield (R28 and R29). The same behaviour is observed for the metalla-cycles incorporating 
the bpe linkers, where a significant upfield shift of the H signal (up to 0.75 ppm) and either 
an upfield or downfield shift of the H signal are monitored. Singulet associated of the ethane 
protons in all bpa-incorporating compounds (broad in the case of R31) is observed at around 
3.30 ppm. This important upfield shift of about 0.40 ppm for this signal as compared to the 
chemical shift of the ethane signals in free bpa (2.92 ppm in CD3CN, 21 °C) is characteristic 
of the formation of metalla-rectangles.
147
 Indeed, this observation is in accordance with the 
chemical displacement of the ethylene protons observed in bpe-incorporating complexes 
where such an upfield shift ( 0.30 ppm) is observed for the HC=C signals. Finally, the arene 
protons and the protons of the OO∩OO and NO∩NO bridging ligands are not strongly 
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influenced by the cyclisation and show almost the same chemical shifts in both the metalla-
rectangles and the dinuclear metalla-clips.
139
 
It is noteworthy that among the dinuclear arene ruthenium precursors, two are 
potentially chiral, C8 and C9 respectively. These dinuclear complexes possess the ability to 
form racemic and meso stereoisomers, if the coordination of the chlorido ligands is not 
sterically or electronically restricted to a particular position, (see Figure 30).  
 
Figure 30. Racemic and meso stereoisomers of metalla-clip C8 
However, upon formation of the corresponding tetranuclear metalla-rectangles R23:R30 
and R24:R31, and despite the presence of four stereogenic ruthenium centers, only two 
diastereoisomers (S-R R-S and S-R S-R) are observed, (see Figure 31). 
racemic meso 
R-S S-S R-R 
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Figure 31. Schematic representation of the two isomers of R30 
 Consequently, in the 
1
H NMR spectra of metalla-rectangles R23:R30 and R24:R31 the 
presence of these two isomers leads to two distinct sets of signals for the pyridyl protons H 
and H (CD3CN, 21 °C). Furthermore in metalla-rectangles R23:R24 the two sets of signals are 
broad and present almost similar chemical shifts, while in R30:R31 the two sets are less 
broaden and more separated. This different behaviour between bpe and bpa-incorporating 
metalla-rectangles could be explained by a difference of rigidity between bpe and bpa leading 
to different conformations of the metalla-rectangles R23:R24 and R30:R31. Moreover a 
broadening of the singulet associated to the ethane and ethylene protons of the bpa and bpe 
linkers suggests non equivalent signals in these metalla-rectangles.  
2.2.3 Antiproliferative Activity 
The antiproliferative activity of the water-soluble compounds containing the ligands 
1,2-bis(4-pyridyl)ethylene (R9, and R19 – R24) and 1,2-bis(4-pyridyl)ethane (R25 – R31) was 
evaluated against the A2780 and A2780cisR ovarian cancer cell lines. All complexes exhibit 
R-S S-R 
R-S R-S 
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moderate to excellent activity with IC50 values (drug concentration necessary for 50% 
inhibition of cell viability) in the range 2  65 μM, except metalla-rectangle R23 for which the 
antiproliferative activity is not as good with an IC50 > 100 μM, (see Table 2). A remarkable 
trend in these biological results is the evolution of the Resistance Factor (RF = 
IC50(A2780cisR) / IC50(A2780)). Indeed, it is noteworthy that the activity of R19, R23, R26, 
R27, R29, R30, and R31 metalla-rectangle toward the A2780cisR cancer cell line with acquired 
resistance to cisplatin is significantly higher than the corresponding activity toward the A2780 
cisplatin sensitive cancer cells. This phenomenon gives rise to unusually low Resistance 
Factors values.
148
  
Table 2. Cytotoxicity of compounds towards A2780 cells and A2780cisR cells 
 
compound A2780 (IC50, M) A2780cisR (IC50, M) RF 
[R9][CF3SO3]4 26.4 ± 1.0 112.7 ± 17.2 4.3 
[R19][CF3SO3]4 35.5 ± 7.3 20.8 ± 5.3 0.6 
[R20][CF3SO3]4 4.2 ± 0.9 10.3 ± 2.6 2.5 
[R21][CF3SO3]4 65.8 ± 9.6 75.3 ± 9.8 1.1 
[R22][CF3SO3]4 10.3 ± 1.2 23.3 ± 0.2 2.3 
[R23][CF3SO3]4 144.7 ± 12.8 116.3 ± 9.2 0.8 
[R24][CF3SO3]4 10.3 ± 5.4 13.3 ± 6.1 1.3 
[R25][CF3SO3]4 2.4 ± 1.1 5.2 ± 0.7 2.1 
[R26][CF3SO3]4 2.7 ± 1.0 2.5 ± 0.9 0.9 
[R27][CF3SO3]4 2.6 ± 0.5 2.0 ± 0.3 0.7 
[R28][CF3SO3]4 9.4 ± 0.8 13.8 ± 3.6 1.5 
[R29][CF3SO3]4 8.3 ± 0.2 7.6 ± 2.1 0.9 
[R30][CF3SO3]4 9.9 ± 1.8 8.5 ± 0.6 0.9 
[R31][CF3SO3]4 17.5 ± 5.8 5.2 ± 1.4 0.3 
cisplatin 0.7 ± 0.1 4.0 ± 0.5 5.6 
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2.3 Arene Ruthenium Metalla-Rectangles as Templates for [2 + 2] 
Cycloaddition  
2.3.1 General 
The supramolecular control of the solid-state reactivity is a relatively new topic.
149
 The 
use of the solid state as a medium to synthesize molecules needs a pre-organisation of the 
starting materials in order to facilitate the reactions between functional groups.
150
 For 
example, in the case of a photochemical [2 + 2] dimerisation, the proximity of the olefins is a 
crucial factor.
151
 Indeed, these photochemical [2 + 2] cycloadditions of the olefinic double 
bonds are expected to occur with the minimal atomic and molecular movements when they 
are aligned parallel and within the range of 3.0 – 4.1 Å.152 Among different solutions,153 the 
use of a template molecule to assemble two olefins within a supramolecule represents a 
solution to gain a control of reactivity.
154
 
This supramolecular control of reactivity of the olefinic double bonds was used by 
Jin’s group to synthesise two organometallic rectangles of the general formula [(η5-
Cp*)2M2(ox)2(bpe)2]
4+
 incorporating half-sandwich complexes of Rh(III) and Ir(III) 
connected by oxalato and bpe ligands. In the solid state, upon UV irradiation of a crystal, the 
two olefinic double bonds which are positioned parallel to each other undergo intramolecular 
photochemical [2 + 2] cycloaddition, thus giving rise to the corresponding cyclobutane 
derivatives [(η5-Cp*)2M2(ox)2(tpcb)2]
4+
 (tpcb = tetrakis(4-pyridyl)cyclobutane), (see Figure 
29).
155
 
 
Scheme 5. Single-crystal-to-single-crystal [2 + 2] cycloaddition of [η5-Cp*)2M2(ox)2(bpe)2]
4+
 
to give [(η5-Cp*)2M2(ox)2(tpcb)2]
4+ 
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Due to the Brownian motion, the stability of the pre-organisation of the olefinic double 
bonds observed in the solid state could not exist in solution. Therefore, we asked ourselves if 
the supramolecular control of reactivity of the olefins by the formation of an organometallic 
metalla-rectangle would be enough in solution to maintain a sufficient pre-organisation. In 
other words, the challenge was to see whether or not in the case of the arene ruthenium 
metalla-rectangle R22 [(η
6
-p-cym)4Ru4(ox)2(bpe)2]
4+
, published in 1997 by our group, the two 
olefinic double bonds can react in a methanol solution and under UV irradiation, to afford the 
intramolecular [2 + 2] cycloaddition adduct, the metalla-rectangle R32 [(η
6
-p-
cym)4Ru4(ox)2(tpcb)2]
4+
, (see Table of Figures). 
2.3.2 Intramolecular Cycloaddition of [(η6-p-cym)4Ru4(ox)2(bpe)2]
4+
 (R22) 
When a methanol solution of [R22][CF3SO3]4 is irradiated for a period of 60 hours 
using a Hg lamp (180 W), a photochemical [2 + 2] cycloaddition reaction takes place, thus 
giving rise in excellent yield to the cationic cyclobutane derivative R32 [(η
6
-p-
cym)4Ru4(ox)2(tpcb)2]
4+
, (see Scheme 6). The rectangular cation [R32]
4+
 is isolated and 
characterised as its trifluoromethanesulfonate salt ([R32][CF3SO3]4). 
 
Scheme 6. [2 + 2] cycloaddition of R22 in methanol solution to give R32 
The photodimerisation of [R22]
4+
 to give [R32]
4+
 upon UV irradiation can be easily 
monitored by 
1
H NMR spectroscopy, (see Figure 29). The [2 + 2] cycloaddition reaction of 
the olefinic double bonds is followed by the disappearance of the olefinic protons signal at δ = 
7.49 ppm and with the emergence of a new signal at δ = 4.99 ppm which is assigned to the 
cyclobutane protons. Interestingly, upon formation of [R32]
4+
 diastereotopic protons are 
observed for the pyridyl groups suggesting a non-equivalent environment. This is in 
accordance with the X-ray structure analysis of [(η5-Cp*)2Ir2(ox)2(tpcb)2]
4+ 
in which the rctt-
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cyclobutane isomer (rctt-tetrakis(4-pyridyl)cyclobutane) is observed.
155
 Consequently, based 
on the assumption that the same reactivity takes place in solution and using multiple one-
dimensional and two-dimensional NMR experiments (ROESY, COSY, HSQC),
156
 the 
complete assignment of the tpcb proton signals in cation [R32]
4+
 has been determined, (see 
Figure 32). 
 
Figure 32. 
1
H NMR spectra in CD3OD of the photodimerisation reaction over a 60 h including 
the assignment of the rctt-tpcb protons 
The infrared spectra of [R22][CF3SO3]4 and [R32][CF3SO3]4 are almost identical and 
they are dominated by absorptions of the p-cymene, pyridyl, and oxalato groups. In addition, 
strong absorptions attributed to the trifluoromethanesulfonate anions are observed in the 
infrared spectra at 1262(s), 1029 (s) and 638(s) cm
-1
.
157
 It is noteworthy to mention that the 
band corresponding to the stretching vibration of the bpe ethylene groups (νCH=CH) in [R22]
4+
, 
centred at 1595(s) cm
-1
 in free bpe
158
 and observed as a shoulder in [R22]
4+
, disappears during 
the formation of [R32]
4+
, as showed in Figure 33. Moreover, the stretching vibration of the 
C=O oxalato moieties are observed at 1632 cm
-1
 and remains unchanged after the 
photochemical cycloaddition.  
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Figure 33. Infrared (KBr pellets) and UV-visible spectra (10
-5
 M, CH3OH) of metalla-clip C0, 
bpe and metalla-rectangles R22 and R32 
During the photochemical [2 + 2] cycloaddition reaction, the initial orange CH3OH 
solution of [R22]
4+ 
turns dark red upon formation of [R32]
4+
, see inset in Figure 30. The 
absorption spectra of C0, [R22]
4+
,
 
[R32]
4+ 
and uncoordinated bpe are presented in Figure 30. 
The absorbance in the electronic spectrum of [R22]
4+ 
exhibits two UV visible transitions 
which correspond to bpe (π – π*) and [(η6-p-cym)2Ru2(ox)Cl2] (MLCT) transitions.
159
 The 
extinction coefficient attributed to the clip transition increases significantly upon formation of 
rectangle R22. In R32 a hypsochromic shift of the MLCT transition is observed.  
2.3.3 Isolation of the Free Organic Linker  
It is well known that in coordinating solvents ligand exchange can easily occur in 
arene ruthenium complexes. In order to isolate the rctt-tetrakis(4-pyridyl)cyclobutane (tpcb) 
moiety, we heated an acetonitrile solution of [R32]
4+
 for 24 hours in the presence of 
triphenylphosphine. 
160
 After this period the cleavage of the different connectors is observed 
and additional new set of signals observed. Among them, two doublets at δ = 8.4 and 7.5 ppm 
and a singulet at δ = 4.5 ppm which is assigned to free rctt-tpcb molecules: This assignment 
being in accordance with the 
1
H NMR values reported for rctt-tpcb.
160
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In this study,
161
 we have shown a simple and straightforward synthesis of oxalato-
bridged arene ruthenium metalla-rectangle using bpe connectors. The parallel arrangement of 
the olefinic double bonds in this supramolecular assembly allows a facile photochemical [2 + 
2] cycloaddition reaction to form the cyclobutane derivative in solution. These data are in 
agreement with those of the analogous compounds [(η5-Cp*)2M2(ox)2(bpe)2][CF3SO3]4 and 
[(η5-Cp*)2M2(ox)2(tpcb)2][CF3SO3]4 (M = Rh or Ir), for which the structures, before and after 
irradiation, were confirmed by single-crystal X-ray structure analysis. Moreover, if wanted, 
the rctt-tetrakis(4-pyridyl)cyclobutane can be recovered. 
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Chapter 3: Arene Ruthenium Metalla-Prisms 
3.1 Arene Ruthenium Metalla-Prisms as Host Systems  
3.1.1 From Carceplex to Host-Guest Chemistry 
The host-guest chemistry previously described with metalla-rectangles is a part of the 
considerable attention that encapsulations of appropriately sized, shaped and functionalized 
guest molecules into self-assembling supramolecular capsules has recently received.
162
 In 
particular, in the case of three-dimensional cages, a number of different models have been 
reported in the literature over the past few years. Peter Stang,
64a
 Makoto Fujita,
34
 or Kenneth 
Raymond
36
 are some of the most important contributors to this area of supramolecular 
chemistry. For example, to illustrate the work of Stang and Fujita we can quote the nitrate 
encapsulation, both in the solid state and in solution, by a cationic trigonal prismatic host 
reported by Stang,
163
 and the entrapment of sizable neutral molecules, including o-carborane 
and adamantane, by water-soluble truncated tetrahedral capsule described by Fujita.
164
 The 
host ability of these three-dimensional self-assembled aggregates has been largely 
demonstrated and potential uses are still in development.
65
  
The contribution of our group in the encapsulation of guest molecules in three-
dimensional coordination cages begins in 2008. The ability of hexacationic metalla-prism P1 
[(p-cym)6Ru6(dobq)3(tpt)2]
6+
 (tpt = 2,4,6-tri(pyridin-4-yl)-1,3,5-triazine) (see List of 
Structures) built from metalla-clip C1 and possessing a cavity of 7.8 × 11.7 × 11.7 Å
3
, to 
permanently encapsulate square-planar complexes
72
 and aromatic molecules was reported.
73
 
Nevertheless, in these structurally nonlabile systems the portal size was too small or too rigid 
to let the encapsulated compound escape. Moreover, all attempts at introducing a guest into 
the empty cavity of P1 failed, and therefore no host-guest properties were observed with these 
hexacationic metalla-prismatic cages. This type of metalla-prism seems to act only as a 
carceplex system since encapsulation of guest molecule during the synthesis of the metalla-
cage is allowed, but after this synthesis the guest molecule cannot run away from the cavity of 
the host unless if the prism is destroyed.   
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However, the fabrication of larger arene ruthenium metalla-clips [(η6-p-
cym)2Ru2(OO∩OO)Cl2] (OO∩OO = donq, doaq, dotq) (C5  C7) allowed us to cross the 
border between carceplex and host-guest systems, with the synthesis of new arene ruthenium 
metalla-prisms [(η6-p-cym)6Ru6(OO∩OO)3(tpt)2]
6+ 
(OO∩OO = donq, doaq, dotq) (P2  P4), 
(see Figure 34). 
 
Figure 34. Structures of metalla-prisms P2  P4 
These metalla-prisms P2  P4 were found to be capable to interact in a host-guest 
fashion with small aromatic molecules. Therefore, we described the synthesis, the 
characterisation and their ability to permanently encapsulate or to temporary host aromatic 
molecules (phenanthrene, pyrene, triphenylene and coronene) in solution. The corresponding 
binding constants of association for the host-guest systems were estimated.  
3.1.2 Synthesis of a Series of Arene Ruthenium Metalla-Prisms (P2  P4) 
The hexacationic metalla-prisms P2  P4 have been synthesized following a one-pot 
strategy. The corresponding dinuclear arene ruthenium complex [Ru2(η
6
-p-cym)2(donq)Cl2], 
[Ru2(η
6
-p-cym)2(doaq)Cl2] or [Ru2(p-cym)2(dotq)Cl2] reacts in methanol at room temperature 
in the presence of silver trifluoromethanesulfonate (halide scavenger) with tpt (donor ligand) 
to give the metalla-hexanuclear cation [P2]
6+
, [P3]
6+
 or [P4]
6+ 
isolated as 
trifluoromethanesulfonate salt in good yield (≈ 80%), (see Scheme 7). The addition of one 
equivalent of phenanthrene, pyrene, triphenylene or coronene leads to the direct encapsulation 
P2 P3 P4 
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of the aromatic molecule in the metalla-prism, following the same procedure but with a 
slightly better yield (≈ 85%), possibly due to template effect, (see Scheme 7). 
 
Scheme 7. Syntheses of [P2]
6+
, [P3]
6+
 and [P4]
6+ 
(top line) and of [guestP2]
6+
, [guestP3]
6+
 
and [guestP4]
6+
 (bottom line) 
The infrared spectra of P2  P4 are dominated by absorptions of the coordinated 
quinonato ligands, which are only slightly shifted as compared to the infrared absorptions of 
the free ligands. In addition to these signals, strong absorptions due to the stretching 
vibrations of the trifluoromethanesulfonate anions (1260(s), 1030(s), 638(m) cm
-1
) are also 
observed in the infrared spectra of the salts [P2][CF3SO3]6  [P4][CF3SO3]6. In the cases of the 
[guestP]6+ (P = P2  P4) systems, additional absorptions due to the guest molecule are 
observed, and in particular signal at around 1500 cm
-1 
assigned to valence vibrations of 
aromatic Csp
2
-Csp
2
. The electronic absorption spectra of the metalla-prisms P2  P4 are 
[guestP]6+ (P = P2  P4) 
P2  P4 
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characterised by an intense high-energy band centered at around 320 nm, which is assigned to 
ligand–localized or intra-ligand π → π* transition as well as broad low-energy bands 
associated to metal-to-ligand charge transfer (MLCT) transitions. The 
1
H NMR spectra of P2 
 P4 show two doublets due to the tpt protons with an upfield shift of the signals as compared 
to the free tpt molecule in acetone-d6. Similarly, the proton signals of the 5,8-dioxydo-1,4-
naphthoquinonato, 5,8-dioxydo-1,4-anthraquinonato and 6,11-dioxydo-5,12-
naphthacenedionato bridging ligands in metalla-prisms P2  P4 are shifted downfield as 
compared to their parent complexes [(η6-p-cym)2Ru2(donq)Cl2], [(η
6
-p-cym)2Ru2(doaq)Cl2] 
and [(η6-p-cym)2Ru2(dotq)Cl2] while the methyl, isopropyl and phenyl signals of the p-cym 
ligands remain almost unchanged. 
To further study the structural behaviour of cationic metalla-prisms P2  P4 in solution, 
NMR enantiodifferentiation in acetone-d6 was achieved in the presence of the NMR chiral 
solvating agent Λ-trisphat (trisphat = tris(tetrachlorobenzenediolato)-phosphate(V)).165 Upon 
gradual addition of Λ-trisphat (0.1  5.0 equiv.) to an acetone-d6 solution of metalla-prism P2 
 P4, a rapid and effective splitting of all signals of metalla-prisms is observed, (see baseline-
to-baseline separation of p-cym proton signals of 2 in Figure 35). This NMR 
enantiodifferentiation confirms the expected helical chirality of metalla-prisms P2  P4, 
already observed with similar metalla-assemblies.
114, 166
 
 
Figure 35. Splitting of p-cym proton signals of metalla-prism [P4][CF3SO3]6 upon addition of 
Λ-trisphat in acetone-d6 at 21°C; (a) [P4]
6+
 (4.0 mM), (b) [P4]
6+
 + 2.0 equiv. of Λ-trisphat, (c) 
[P4]
6+
 + 5.0 equiv. of Λ-trisphat 
a b c 
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3.1.3 Host-Guest Properties 
The formation of [guestP]6+ (P = P2  P4) can be easily monitored by NMR 
spectroscopy. The signals of the different protons of the guest molecule as well as those of the 
pyridyl protons of the tpt panels are shifted upfield upon formation of the host-guest system, 
whereas the signals of the CH protons of the donq, doaq and dotq bridging ligands are shifted 
downfield. On the other hand, the signals of the protons of the p-cym ligands located at the 
periphery of the prisms are not significantly affected by the presence of a guest molecule in 
the cavities of [P2]
6+
  [P4]
6+
, (see Figure 36). 
 
Figure 36. 
1
H NMR spectra (21°C, CD3CN) of (a) free coronene, (b) 
[coroneneP4][CF3SO3]6 and (c) [P4][CF3SO3]6 
1
H ROESY experiments confirm the encapsulation of aromatic molecules 
(phenanthrene, pyrene, triphenylene and coronene) in metalla-prisms P2  P4. For example, 
the 
1
H ROESY spectrum of [coroneneP4]
6+ 
shows a strong nuclear overhauser effect 
between the irradiated coronene protons and tpt protons (Hbq and Hcq
a 
b 
c 
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nuclear overhauser interaction with the protons of the quinonato bridges (Hbq and Hcq) is as 
well observed, (see Figure 37). 
 
Figure 37. One-dimensional 
1
H ROESY spectrum (21°C, CD3CN) of 
[coroneneP4][CF3SO3]6. The 
1
H NMR spectrum of [coroneneP4][CF3SO3]6 is given below 
In order to evaluate these metalla-cages as potential host-guest systems, we first 
studied the stability of all systems in solution (water, toluene, acetonitrile) at room and 
elevated temperatures. Complexes [triphenyleneP]6+ and [coroneneP]6+ (P = P2  P4) 
show no degradation of the cages or leaching of the guests in all solvents tested, even at reflux 
for 24 h. However, [phenanthreneP]6+ and [pyreneP]6+ (P = P2  P4) show rapid loss of 
their guest molecules in toluene-d8 at 80 °C, while these systems remain intact in acetonitrile 
and water. Therefore, we decided to further study the host-guest chemistry of the metalla-
prisms [P2]
6+
  [P4]
6+
 in CD3CN solution by using NMR spectroscopy. Upon gradual addition 
of guest (either phenanthrene or pyrene) (0.1 – 3.0 equiv.) to an CD3CN solution of metalla-
prism ([P2][CF3SO3]6  [P4][CF3SO3]6) (4.0 mM), the 
1
H NMR spectra show chemical shifts 
of the signals for some protons of the host and of the guest. The broadening and chemical 
shifts of the signals clearly support a rapid inclusion of guest molecule in the hydrophobic 
cavity of metalla-prisms. Plots of these chemical shift changes (Δδ) for the Hβ proton of the 
tpt ligands versus the molar ratio of pyrene/[P]
6+
 (P = P2  P4) indicate the formations of 1:1 
host-guest systems for which association constants are calculated by the nonlinear least-
square fitting program winEQNMR2, (see Table 3). 
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Table 3. Stability constants (Ka) and free energies (ΔGº) for the encapsulation of pyrene and 
phenanthrene in metalla-prisms P2  P4 (21°C, CD3CN, 4.0 mM of host) 
 
In this study,
167
 we described three new cationic metalla-prisms with different portal 
sizes able to allow small aromatic molecules to enter and leave in solution the hydrophobic 
cavity.
168
 However, for planar molecules capable of fitting into the cavity, but too large to exit 
the portal of the cage, permanent encapsulation was observed, thus giving rise to stable 
carceplex systems. More interestingly, the development of three new metalla-prisms P2  P4 
with different portal sizes and able to interact in a host-guest fashion with small aromatic 
molecules was a new way to explore the anticancer behaviour of our arene ruthenium metalla-
systems.  
 
 
guesthost Ka (10
4
 M
-1
) ΔGº (kcal · mol-1) 
[pyreneP2]
6+ 4.0 ± 1.7 -6.28 ± 0.33 
[pyreneP3]
6+
 2.0 ± 0.4 -5.87 ± 0.13 
[pyreneP4]
6+
 2.2 ± 0.5 -5.93 ± 0.63 
[phenanthreneP2]
6+
 2.9 ± 1.1 -6.08 ± 0.20 
[phenanthreneP3]
6+
 2.0 ± 0.7 -5.88 ± 0.22 
[phenanthreneP4]
6+
 2.9 ± 0.9 -6.08 ± 0.20 
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3.2 Arene Ruthenium Metalla-Prisms as Water-Soluble Nano-Capsules 
3.2.1 General 
In recent years the use of host-guest systems to efficiently deliver drugs to cancer cells 
has attracted a lot of interest.
169
 In such systems the physicochemical properties of the host-
guest complex are generally superior to those of the guest leading to improvements in efficacy 
and biocompatibility.
170
 It is not surprising that cisplatin,
98, 171
 the most widely used metal-
based drug in the treatment of cancer, has been encapsulated in various hosts in order to 
reduce the severe side effects associated with this drug.
172
 Indeed, platinum-based drugs have 
been incorporated to hosts including carbon nanotubes,
173
 proteins,
174
 macrocycles
175
 and 
dendrimers.
176
 These large systems tend to accumulate preferentially in tumours due to 
enhanced permeability and retention (the EPR effect) of macromolecules in cancerous 
tissue.
102
 
As explained previously, our group combined the medicinal properties of arene 
ruthenium complexes, a promising class of organometallic drugs,
142
 with aspects of 
supramolecular chemistry,
65
 to generate a new hybrid drug delivery system, [(η6-p-
cym)6Ru6(dobq)3(tpt)2]
6+
 (P1), in which guest molecules were encapsulated in the cavity of 
the host.
177
 This host was found to encapsulate planar aromatic compounds
115
 as well as 
planar Pt and Pd acetylacetonato complexes.
72
 The biological activity of these compounds 
was evaluated on human ovarian cancer cell lines, and the empty cage P1 was found to have 
an IC50 value of 23 μM with the carceplexes being at least an order of magnitude more 
cytotoxic (the guests were not cytotoxic on their own). The ability of this host to deliver guest 
molecules to cells was further confirmed by encapsulation of a fluorescent labelled pyrene-X 
derivative, 1-(4,6-dichloro-1,3,5-triazin-2-yl)pyrene.
116
 Fluorescence experiments used to 
monitor the uptake of pyrene-X into cancer cells demonstrated one order of magnitude greater 
uptake of the carceplex [pyrene-XP1]
6+
 over pyrene-X alone. 
To compare the in vitro biological behaviour of the host-guest systems versus the 
[pyrene-XP1]
6+
 carceplex systems, we encapsulated the same pyrene-X into the new 
metalla-prisms P2  P4. The binding constants of association of the host-guest systems 
involving pyrene-X, were studied in solution by NMR and fluorescence spectroscopy and the 
antiproliferative activity of the empty cages and of the host-guest systems were evaluated on 
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human ovarian cancer cell lines. The uptake and release of pyrene-X by the [pyrene-XP]6+ 
(P = P2  P4) systems were determined and correlated to the portal size of the host molecule. 
We also studied the uptake mechanism of [pyrene-XP2]
6+
. Pd(acac)2 was also encapsulated 
into these three arene ruthenium metalla-prisms. 
3.2.2 Synthesis and Host-Guest Properties of [pyrene-XP]6+ (P = P2  P4) 
The syntheses of the empty arene ruthenium metalla-prisms [P2]
6+
, [P3]
6+
, and [P4]
6+
, 
have been previously described. The encapsulation of Pd(acac)2 and pyrene-X in these cages 
follows the same pathway than the encapsulations of pyrene, phenanthrene, triphenylene and 
coronene previously reported. The formation of [guestP]6+ (P = P2  P4) was monitored by 
1
H NMR spectroscopy. The resonances of the different protons of the guest molecule and the 
pyridyl protons of the tpt panels are shifted upfield upon formation of the encapsulated 
system, whereas the signals of the CH protons of the bridging ligands (donq, doaq, or dotq) 
are shifted downfield. In the 
1
H NMR spectra of [Pd(acac)2P]
6+
 (P = P2  P4) the CH and 
CH3 signals of the acetylacetato ligands are shifted upfield by about 1.7 ppm compared to the 
free complex, and in the spectra of [pyrene-XP]6+ (P = P2  P4) the signals of the CH 
protons of the encapsulated aromatic guest are all shifted upfield relative to the free molecule, 
the frequencies being similar to those observed in [pyrene-X⊂P1]
6+
.
116
 The electronic 
absorption spectra of the systems [guestP]6+ (P = P2  P4) (see Figure 38) are characterised 
by an intense high-energy band centred at around 300 nm, which is assigned to ligand-
localised or intra-ligand π → π* transition as well as broad low-energy bands associated to 
metal-to-ligand charge transfer (MLCT) transitions. 
Chapter 3: Arene Ruthenium Metalla-Prisms 
 
 
68    
 
 
 
Figure 38. UV-visible spectra of [guestP]6+ (P = P2  P4) in CH2Cl2 (10
-5
 M) 
The host-guest properties of the [guestP]6+ (P = P2  P4) systems were studied in 
solution, establishing their stability in water, toluene and acetonitrile, at room and elevated 
temperatures. The [Pd(acac)2P]
6+
 (P = P2  P4) systems show no signs of degradation of the 
cage, or leaching of the guest, in all solvents tested, even at reflux for 24 hours. However, all 
[pyrene-XP]6+ (P = P2  P4) systems show rapid lost of the guest in toluene-d8 at 80 ºC, but 
remain intact in acetonitrile and water. The host-guest interactions between pyrene-X and the 
metalla-prisms [P2]
6+
  [P4]
6+
 were further studied by diffusion-ordered NMR spectroscopy 
(DOSY). As an example, the DOSY spectra of pyrene-X, [P2]
6+
 and pyrene-X + [P2]
6+
 in 
CD3CN at room temperature are presented in Figure 39. These experiments clearly show that 
at room temperature, [P2]
6+
 and pyrene-X + [P2]
6+
 possess an almost identical diffusion 
coefficients, which confirm the encapsulation of pyrene-X in the hydrophobic cavity of [P2]
6+
. 
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Figure 39. DOSY NMR spectra of pyrene-X, [P2]
6+
 and [P2]
6+
 + 1 eq. of pyrene-X in CD3CN 
at 21°C 
The host-guest properties of the [pyrene-XP]6+ (P = P2  P4) systems were further 
studied in CD3CN by 
1
H NMR titrations. Upon gradual addition of pyrene-X (0.1 – 3.0 
equivalents) to a CD3CN solution of the host (4.0 mM), chemical shift changes for some 
protons are observed. 
1
H NMR spectra obtained from the titration experiments with [P4]
6+
 at 
21 ºC in CD3CN are shown in Figure 40. The broadening and chemical shifts of the signals 
are indicative of rapid inclusion of the pyrene-X into the hydrophobic cavity of [P4]
6+
. 
 
Figure 40. 
1
H NMR titration of pyrene-X in a CD3CN solution of [P4][CF3SO3]6 at 21 °C, (a) 
[P4]
6+
 (4.0 mM), (b) [P4]
6+
 + 0.5 eq. of pyrene-X, and (c) [P4]
6+
 + 1.0 eq. of pyrene-X 
b 
a 
c 
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Plots of the chemical shift changes (Δδ), for the Hβ proton of the tpt ligands versus the 
molar ratio of pyrene-X to the prisms [P2]
6+
  [P4]
6+
, indicate the formation of 1:1 
stoichiometric host-guest systems (see Figure 41). From these plots, stability constants of 
association were estimated using the non-linear least square fitting program winEQNMR2 
(see Table 4). The binding free energies (ΔGº) for the [pyrene-XP]6+ (P = P2  P4) systems 
were determined from the corresponding association constants obtained at 21 ºC in CD3CN. 
 
Figure 41. 
1
H NMR chemical shift changes for the signal of the Hβ protons of the tpt ligands 
versus the molar ratio of pyrene-X/[P2]
6+
  [P4]
6+
 in CD3CN at 21 °C 
Table 4. Stability constants (Ka) and free energies (ΔGº ) for the encapsulation of pyrene-X in 
metalla-prisms P2  P4 (21°C, CD3CN, 4.0 mM of host) 
 
As opposed to the carceplex system, [pyrene-XP1]
6+
, in which the fluorescence of 
the pyrene-X guest is totally quenched upon encapsulation, some fluorescence remains in the 
guesthost Ka (10
4
 M
-1
) ΔGº (kcal · mol-1) 
[pyrene-X  P2]
6+
 4.1 ± 0.6 -6.27 ± 0.42 
[pyrene-X  P3]
6+
 2.0 ± 0.3 -5.86 ± 0.12 
[pyrene-X  P4]
6+
 1.2 ± 0.7 -5.56 ± 0.58 
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host-guest systems [pyrene-XP]6+ (P = P2  P4) (see Figure 42). Indeed, the fluorescence of 
the pyrenyl part is quenched but the triazin-2-yl group does not entirely lose its fluorescent 
properties. Spectral overlap between the emission of the pyrenyl part and the absorbance of 
the metalla-prism is encountered for the fluorescence quenching of pyrene.
 
 
Figure 42. Fluorescence emission spectra of pyrene-X and [pyrene-XP]6+ (P = P2  P4) in 
H2O:DMSO (99.5:0.5; V:V) solution (10
-7
 M) at 21 °C, excitation 350 nm 
However, the fluorescence of the triazin-2-yl unit remains almost at the same energy 
state. This partial quench of the fluorescence of pyrene-X in metalla-prisms [P2]
6+
  [P4]
6+
 is 
illustrated by emission spectra from fluorescence titrations. Upon gradual addition of 
[P2][CF3SO3]6  [P4][CF3SO3]6 (0.1 – 6.0 equivalents) to a H2O:DMSO (99.5:0.5; V:V) 
solution of pyrene-X (10
-7
 M), the emission spectra (excitation: 350 nm, 21 °C) show a strong 
quenching of the band associated to the pyrenyl part, while the band associated to the triazin-
2-yl arm is not affected by addition of [P2]
6+
  [P4]
6+
 (see Figure 43). 
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Figure 43. Fluorescence titration at 21 °C of [P3][CF3SO3]6 (0.1 – 6.0 equivalents) in 
H2O:DMSO (99.5:0.5; V:V) solution (10
-7
 M) containing pyrene-X (excitation 350 nm) 
3.2.3 Antiproliferative Study 
In order to determine the impact of the structure of the different metalla-prisms on the 
cytotoxicity of the host-guest systems, the portal size of these systems were evaluated. Indeed, 
the size of the cavity is equivalent in P2, P3 and P4. However, the use of different OO∩OO 
connectors controls the portal size of the systems, thus modulating the dynamic of the host-
guest systems. Molecular modelling using HyperChem in the gas phase was applied to 
equilibrate each metalla-prism, and the output of the simulation was then minimized to full 
convergence.
178
 This molecular dynamics simulation was performed to estimate the portal 
size of these cages in the gas phase (see Figure 44). The largest portal, estimated to be 
approximately 7.4 Å (height) by 10.2 Å (width), is found in [pyrene-XP2]
6+
 which shows 
highest fluorescence, i.e. most facile loss of the pyrene-X guest. Compound [pyrene-XP3]
6+
 
which contains the smallest portal (7.4 x 7.8 Å
2
) exhibits least fluorescence corresponding to 
a more stable host-guest system. Indeed, these results correlate very nicely with the 
association constants determined for the three systems. 
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Figure 44. HyperChem simulations of metalla-prisms [P2]
6+
  [P4]
6+
 
The cytotoxicity of the compounds was established in the A2780 human ovarian 
cancer cell line, (see Table 5). The toxicity of the pyrene-X or Pd(acac)2 inside the cage 
systems is systematically higher than that of the corresponding cages and pyrene-X or 
Pd(acac)2 alone. Moreover, the [Pd(acac)2P]
6+
 (P = P2  P4) systems are more cytotoxic 
than the corresponding [pyrene-XP]6+ (P = P2  P4) systems, which is consistent with 
previously published supramolecular systems.
116
 
Table 5. Cytotoxicity of compounds towards A2780 cells 
[a] Standard Deviation 
Uptake of ruthenium into the cells was determined with the [pyrene-XP]6+ (P = P2  
P4) systems by inductively coupled plasma mass spectroscopy (ICP-MS) which reveals that 
compound IC50 (μM) SD (μM)
[a]
 
pyrene-X ND ND 
Pd(acac)2 ND ND 
[P2][CF3SO3]6 3.2 1.1 
[P3][CF3SO3]6 13.1 1.1 
[P4][CF3SO3]6 4.1 0.1 
[pyrene-XP2][CF3SO3]6 1.9 0.1 
[pyrene-XP3][CF3SO3]6 2.3 0.6 
[pyrene-XP4][CF3SO3]6 1.1 0.2 
[Pd(acac)2P2][CF3SO3]6 <0.3 ND 
[Pd(acac)2P3][CF3SO3]6 0.9 0.3 
[Pd(acac)2P4][CF3SO3]6 <0.3 ND 
[P2]
6+ [P3]
6+ [P4]
6+ 
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all compounds enter the cells to essentially the same extent (see Figure 45), indicating a 
similar uptake mechanism for the three compounds. However, release of the pyrene-X guest 
following uptake is not constant and varies for the three systems. As previously reported, the 
fluorescence of pyrene-X is quenched inside the ruthenium cage,
116
 and consequently 
fluorescence can be used to evaluate the release of free pyrene-X inside the A2780 cells. Flow 
cytometry was used to study the fluorescence of cells incubated with [pyrene-XP]6+ (P = P2 
 P4), (see Figure 45) and shows that the portal size of the host influences the release of 
pyrene-X. Cells were incubated with [P2][CF3SO3]6
 
and [pyrene-XP2][CF3SO3]6
   [pyrene-
XP4][CF3SO3]6
  
at 2 µM for 24 hours. 
 
Figure 45. Fluorescence recorded by flow cytometry of [pyrene-XP]6+ (P = P2  P4) 
indicative of pyrene-X release from the host (black), ruthenium uptake determined by ICP-
MS (grey) 
The uptake mechanism of [pyrene-XP]6+ (P = P2  P4) was also studied, with uptake 
found to be both temperature and wortmannin-sensitive, (see Figure 46). Wortmannin blocks 
specific endocytic mechanisms and has been widely used to study intracellular transport 
mechanisms.
179
 Combined, these data indicate that the uptake of [pyrene-XP2]
6+
 involves 
endocytosis/macropinocytosis, rather than passive diffusion across the cell membrane. 
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Figure 46. Intracellular fluorescence quantification by flow cytometry of A2780 incubated 
with [pyrene-XP2]
6+
 either after 1 h pre-incubation in culture medium (untreated), or pre-
incubated at 4 °C, or wortmannin. Results represent the percentage of fluorescence 
Following release of pyrene-X from the host, confocal microscopy was used to show 
that the pyrene-X stains vesicle-like cytoplasmic organelles, and accumulates in the 
intracellular vesicle part of the cell endocytotic system.
180
 In order to identify the organelles, 
their fluorescence pattern was compared to that of the lysosomal dye lysotracker Red and the 
fluid phase endocytosis marker FITC-dextran.
181
 This study shows that the free pyrene-X does 
not enter lysosomal compartments and does not accumulate in the endocytic compartments 
that are enriched in FITC-dextran. Consequently, these data suggest that pyrene-X 
accumulates in endocytic compartments rather than lytic compartments. 
In this study,
182
 we described the synthesis, characterisation, host-guest properties and 
in vitro activity of a modular and adjustable supramolecular drug delivery system based on 
arene ruthenium metalla-prisms. The cellular uptake of the host-guest systems is likely to 
involve an active transport mechanism, and that following uptake into the cell, the rate of 
release of the guest molecule depends on the portal size of the host. This study paves the way 
for the rational design of host-guest systems that can function in a time-controlled manner. 
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3.3 Arene Ruthenium Metalla-Prisms and Dendrimers 
3.3.1 General 
Dendrimers are a polymeric class of compounds that can possess different shapes 
(spherical, ellipsoidal or cylindrical), different sizes and structures depending of the 
dendrimer generation, and different cores and peripheral groups.
183
 This high number of 
possibilities in designing dendrimers has a strong impact on the physical and chemical 
properties of these molecules.
184
 Moreover, since their development in the 1980s, many 
efforts have been made by chemists in order to facilitate the synthesis of these “cascade 
molecules”. In particular Newkome,185 Tomalia,186 Fréchet,187 have provided numerous new 
strategies to synthesise dendritic systems. The versatility and the accessibility of dendrimers 
have found several applications, in liquid-crystal chemistry,
188
 in materials,
189
 and also in 
biochemistry.
190
 From antibacterial drugs by copper’s polypropylenimine (PPI) dendrimers,191 
to antiviral drugs by Majoral’s poly-(phosphor-hydrazone) dendrimers with terminal 
phosphonic acid and alkyl chain groups,
192
 many examples of dendrimers used as biological 
agents can be found in the literature. Among others, we can cite Tomalia’s polyamidoamine 
(PAMAM),
186
 Denkewalter’s poly-(L-lysine),193 Newkome’s polyamide,189 Vögtle’s 
polypropylenimine,
194
 and Hult’s poly-(2,2-bis(hydroxymethyl) propionic acid (bis-MPA)195 
dendrimers. The host-guest properties of some dendrimers have even allowed their successful 
utilisation as drug carriers,
196
 while their combination with metallic atoms has led to the 
discovery of new possible anticancer agents with novel mechanisms of action.
176c
 
On the other hand, the previously described modular and adjustable supramolecular 
drug delivery system based on arene ruthenium metalla-prisms led to the biological 
determination of the antiproliferative activities of different host-guest systems (see section 3-
2).
197
 In this study, the impact of the portal size of three different metalla-prisms (P2  P4) on 
the association constants was studied in the presence of one guest molecule pyrene-X and was 
correlated to the biological activities of the host-guest systems. Now we set out to study the 
impact of the size of the guest molecule, without modifying the structure of the host metalla-
prism. Therefore, a series of large pyrenyl-containing dendrimers of different generations 
were prepared, i.e. 4'-cyanobiphenyl-4-yl-4-(10-(4-(pyren-1-
yl)butanoyloxy)decyloxy)benzoate (pyrene-G0), bis(10-(4-((4'-cyanobiphenyl-4-
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yloxy)carbonyl)phenoxy)decyl)-5-(4-(pyren-1-yl)butanoyloxy)isophthalate (pyrene-G1), and 
bis(di(10-(4-((4'-cyanobiphenyl-4-yloxy)carbonyl)phenoxy)decyl)5-hydroxyisophthalate)-5-
(4-(10-(4-(pyren-1-yl)butanoyloxy)decyloxy)benzoyloxy)isophtalate (pyrene-G2). The 
pyrenyl units were encapsulated in the hydrophobic cavity of the hexanuclear arene ruthenium 
metalla-prism [(η6-p-cym)6Ru6(donq)3(tpt)2]
6+ 
(P2). The cytotoxicity of these resulting host-
guest systems, [pyrene-G0P2]
6+
, [pyrene-G1P2]
6+
, and [pyrene-G2P2]
6+
, was evaluated 
and correlated to their size. 
3.3.2 Encapsulation of Pyrenyl-Modified Dendrimers and Host-Guest Properties 
The synthesis of the guest molecules pyrene-G0, pyrene-G1, and pyrene-G2 involves 
different generations of cyanobiphenyl dendritic precursors, 4'-cyanobiphenyl-4-yl-4-(10-
hydroxydecyloxy)benzoate (G0), bis(10-(4-((4'-cyanobiphenyl-4-
yloxy)carbonyl)phenoxy)decyl) 5-hydroxyisophthalate (G1) and bis(di(10-(4-((4'-
cyanobiphenyl-4-yloxy)carbonyl)phenoxy)decyl)-5-hydroxyisophthalate)-5-(4-(10-
hydroxydecyloxy)benzoyloxy)isophtalate (G2). The precursors G0, G1 and G2 have been 
reported previously,
198
 and pyrene-G0, pyrene-G1, and pyrene-G2 were prepared by an 
esterification reaction between 1-pyrenebutyric acid and the different generations of 
cyanobiphenyl dendrimers, (see Scheme 8). In the case of G2, an arm comprising an aliphatic 
C10H20 chain was included to provide flexibility to this large dendritic moiety and to increase 
the yield of the coupling reaction. 
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Scheme 8. Syntheses of pyrene-G0, pyrene-G1, and pyrene-G2 (dcc = N,N’-
dicyclohexylcarbodiimide, dpts = 4-(dimethylamino)pyrimidium para-toluenesulfonate) 
The esterification reactions were monitored by NMR spectroscopy with signals of 
protons H26, H27, and H28 of the pyrenyl unit being shifted slightly upfield (by up to 0.05 ppm 
relative to 1-pyrenebutyric acid) after coupling (see Scheme 1 for assignment). Additionally, a 
strong modification of the chemical environment of protons H24 and H23 of the dendritic part 
leads to a significant upfield shift of 0.44 ppm of the resonance in the case of proton H24, and 
by 0.05 ppm for H23, confirming the formation of pyrene-G0, pyrene-G1, and pyrene-G2. 
Encapsulation of the pyrenyl moiety into metalla-prism [P2]
6+
 is straightforward with 
P0 and P1; addition of silver trifluoromethanesulfonate to the dinuclear metalla-clip [(
6
-p-
cym)2Ru2(donq)Cl2] in the presence of tpt panels and the guest molecule leads to the 
formation of [pyrene-G0P2][CF3SO3]6 and [pyrene-G1P2][CF3SO3]6, respectively. In the 
case of pyrene-G2, direct encapsulation requires 2 days and dichloromethane is needed to 
solubilise pyrene-G2 and to afford the desired system [pyrene-G2P2][CF3SO3]6. All the 
complexes were isolated as trifluoromethanesulfonate salts and are highly soluble in apolar 
solvents such as dichloromethane, but also in polar solvents and in particular in water. 
Molecular modelling was performed with HyperChem to estimate the shape and size of all 
these complexes in the gas phase, (see Figure 47). 
pyrene-G0  pyrene-G1  pyrene-G2  
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Figure 47. Hyperchem simulation of [pyrene-G2P2]
6+
, arene ligands omitted for clarity 
 The HyperChem simulations show, as expected, the dendritic arm extending from the 
cavity with the pyrene moiety encapsulated in the cavity of the prism. The complexes also 
possess two distinct regions, a hydrophilic head constituted by the hexacationic metalla-cage 
and a lipophilic tail formed by the dendritic part. Such amphiphilicity is highly relevant with 
respect to the biological properties of these compounds.
199
 
 The host-guest properties of the complexes were studied in solution by a combination 
of NMR, UV-visible and fluorescence spectroscopy. 
1
H NMR titrations of pyrene-G0, pyrene-
G1 in the presence of [P2]
6+ 
were performed in CD3CN at room temperature. In the case of 
pyrene-G2 broadening of the signals precludes such an analysis.  
Upon gradual addition of guest molecule pyrene-G0 or pyrene-G1 (0.1 – 3.0 
equivalents) to a CD3CN solution of [P2][CF3SO3]6 (4.0 mM), the 
1
H NMR spectra show 
displacements of the chemical shifts of some of the protons of both the host and the guest. 
The broadening and chemical shifts of the signals support a rapid inclusion of the guest 
molecule into the cavity of [P2]
6+
. Plots of these chemical shift changes, Δδ, for the Hβ proton 
of the tpt ligands versus the molar ratio of pyrene-G0 or pyrene-G1 to the prism [P2]
6+
 indicate 
a 1:1 stoichiometry of the host-guest systems. From these plots, stability constants of 
association, Ka, were estimated by using the non-linear least square fitting program 
winEQNMR2 (see Table 6). The binding free energies, ΔGº, for [pyrene-G0⊂P2]
6+
 and 
[pyrene-G1⊂P2]
6+
 were determined from the corresponding association constants obtained at 
21 ºC in CD3CN and in all cases ΔGº is inferior to -5.80 kcal · mol
-1
. 
[P2]
6+ 
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Table 6. Association constants (Ka) and free energies for the encapsulation of pyrene-G0, 
pyrene-G1 and pyrene-G2 in [P2]
6+
 determined by 
1
H NMR titration (CD3CN at 21°C, 4.0 mM 
concentration of [P2]
6+
) and by UVvisible method (CH2Cl2 at 21°C) 
 
[a] determined by NMR [b] determined by UV-visible 
Since the association constant of [pyrene-G2⊂P2]
6+
 could not be determined by NMR 
titration due to broadening of the signals, this constant was estimated using UVvisible 
spectroscopy, employing a widely used method for the study of binding phenomena 
(particularly suited to 1:1 host-guest systems).
200
 Aliquots of a CH2Cl2 solution of guest 
molecule pyrene-G2 were added to a CH2Cl2 solution of [P2][CF3SO3]6 ([P2]/[pyrene-G2] = 0 
to 2 eq), and the mixtures were analysed by UV–vis spectroscopy at 21 ºC. Based on changes 
to the absorbance (see Figure 48 for the UVvis titration of [P2]
6+
 with pyrene-G2), and 
applying the Rose and Drago equation,
201
 the association constant of [pyrene-G0⊂P2]
6+
, 
[pyrene-G1⊂P2]
6+
 and [pyrene-G2⊂P2]
6+
 was estimated (see Table 6). The Ka values for 
[pyrene-G0⊂P2]
6+ 
and [pyrene-G1⊂P2]
6+ 
obtained using UVvisible spectroscopy are 
consistent with the values estimated by 
1
H NMR titrations. 
guest  host Ka (10
4
 M
-1
)
[a] 
Ka (10
4
 M
-1
)
[b]
 ΔGº (kcal · mol-1) 
pyrene-G0⊂P2 4.1 7.8 -6.29 
pyrene-G1⊂P2 1.9 2.7 -5.83 
pyrene-G2⊂P2 ND 0.8 -5.36 
Chapter 3: Arene Ruthenium Metalla-Prisms 
 
 
  81 
  
 
 
Figure 48. UVvis titration of [P2]
6+
 in a CH2Cl2 solution of pyrene-G2 (10
-5
 M) at 21 °C 
A decrease of the kinetics of encapsulation is observed with the increase of the 
generation of dendrimer precursors graft onto the pyrene moiety. This can be easily 
understood since the pyrenyl part of the molecule is less accessible for the encapsulation with 
a larger generation than with a shorter generation. The association constants are quite high 
and free energies (ΔG° up to -5.3 kcal · mol-1) demonstrate a preference for the encapsulated 
systems over the dissociated systems. 
3.3.3 Antiproliferative Study 
The antiproliferative activity of the pyrenyl-containing dendrimers pyrene-G0, pyrene-
G1, and pyrene-G2, the complex [P2][CF3SO3]6 and the host-guest systems [pyrene-G0⊂P2]
6+
, 
[pyrene-G1⊂P2]
6+
 and [pyrene-G2⊂P2]
6+
 were evaluated against the A2780 (cisplatin 
sensitive) and A2780cisR (cisplatin resistant) human ovarian cancer cell lines. Their 
cytotoxicities, in comparison to cisplatin, are presented in Table 7. The pyrenyl-containing 
dendrimers pyrene-G0, pyrene-G1, and pyrene-G2 are inactive against both A2780 and 
A2780cisR cancer cells, probably due to poor water solubility resulting in their precipitation 
from the cell culture medium. The water-soluble metalla-prism [P2]
6+
 is quite cytotoxic and 
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the host-guest systems are even more cytotoxic, in the case of [pyrene-G0⊂P2][CF3SO3]6 the 
IC50 value (0.4 M) is an order of magnitude more cytotoxic than the empty cage. The IC50 
values of [pyrene-G1⊂P2][CF3SO3]6 and [pyrene-G2⊂P2][CF3SO3]6 are similar to the IC50 
value of the empty cage alone [P2][CF3SO3]6. High generations of dendritic systems are 
known to be biocompatible,
 
and tend to show different levels of cytotoxicity,
202
 however due 
to the lipophilic nature of pyrene-Gn, their intrinsic cytotoxicity could not be established in 
this study. It is noteworthy that [P2]
6+
 and the host-guest compounds show similar 
cytotoxicities on both the cisplatin sensitive and the cisplatin resistant cancer cell lines, 
indicating that they do not share the same mechanism of action than the reference drug 
cisplatin. 
Table 7. IC50 values of pyrenyl-containing dendrimers pyrene-G0, pyrene-G1, pyrene-G2 and 
complexes [P2][CF3SO3]6 and [pyrene-G0  pyrene-G2P2][CF3SO3]6 on A2780 and 
A2780cisR cell lines 
 
The synthesis of three new pyrenyl-containing dendrimers and their encapsulation into 
a water-soluble arene-ruthenium metalla-prism was described.
197
 The host-guest systems, 
[pyrene-Gn⊂P2][CF3SO3]6, are remarkably stable in solution as shown from NMR, 
UVvisible and fluorescence spectroscopic studies. The cytotoxicity of the host-guest systems 
have been evaluated on human ovarian A2780 and A2780cisR cancer cell lines and an 
increase by one order of magnitude in cytotoxicity was observed for [pyrene-
G0⊂P2][CF3SO3]6 compared to the empty metalla-prism. The cytotoxicity of the higher 
generations of encapsulated dendrimers, [pyrene-G1⊂P2][CF3SO3]6 and [pyrene-
compound A2780 (IC50, M)  A2780cisR (IC50, M)  
pyrene-G0 ND ND 
pyrene-G1 ND ND 
pyrene-G2 ND ND 
[P2][CF3SO3]6 3.1 ± 1.0 4.6 ± 0.5 
[pyrene-G0P2][CF3SO3]6 0.4 ± 0.1 0.5 ± 0.4 
[pyrene-G1P2][CF3SO3]6 2.2 ± 1.1 2.4 ± 0.8 
[pyrene-G2P2][CF3SO3]6 2.6 ± 0.8 2.8 ± 1.0 
cisplatin 1.6 ± 0.6 8.6 ± 0.6 
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G2⊂P2][CF3SO3]6, was found to be equivalent to that of the cage alone. Notably, for the first 
time, this study demonstrated that metalla-cage host systems are able to deliver hydrophobic 
guest molecules with extremely large appendages into cancer cells. 
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Chapter 4: Arene Ruthenium Metalla-Cubes 
4.1 Antiproliferative Activity of Arene Ruthenium Metalla-Cubes 
4.1.1 General 
Most solid tumours possess a unique extracellular environment comprising a 
hypervasculature, a defective vascular architecture, and impaired lymphatic drainage. The 
resulting enhanced vascular permeability of solid tumours has become an effective way to 
target cancer cells. While the normal endothelial layer surrounding the blood vessels feeding 
healthy cells restricts the size of molecules that can diffuse from the blood, the endothelial 
layer of blood vessels in diseased tissues is more porous towards large molecules providing 
access to the surrounding cancer cells. Moreover, diseased tissue does not usually have a 
lymphatic drainage system, so once large molecules have entered the tumour environment 
they are more likely to be retained. This passive targeting of tumours by large molecules is 
referred to as the “enhanced permeability and retention” (EPR) effect.102  
On the other hand, due to the clinical success of platinum-based cancer drugs, 
macromolecular derivatives have been evaluated in an attempt to target tumours more 
effectively to reduce the severe toxic side effects and to overcome resistance associated with 
platinum agents.
203 
In particular, in recent years ruthenium compounds have been shown to 
exhibit promising anticancer activity, since ruthenium complexes are believed to bind with 
large biomolecules
204
 in the plasma and consequently could take advantages of the EPR 
effect. However, larger multinuclear ruthenium complexes could potentially use the EPR 
effect without having to bind to biomolecules. 
The deve lopment of arene ruthenium metalla-rectangles and arene ruthenium metalla-
prisms led to the synthesis of large structures that show a pronounced size effect and that are 
possibly able to selectively target cancer cells via the EPR effect. The cytotoxicity of these 
metalla-assemblies being promising we decided to synthesize larger metalla-assemblies. Thus, 
we synthesised a series of octanuclear metalla-cubes Q1 – Q8, of general formula [(η
6
-
arene)8Ru8(OO∩OO)4(NN∩NN)2]
8+
 (arene = p-cym (Q1 – Q6), indane (Q7), nonylbenzene 
(Q8); OO∩OO = ox (Q1 – Q3), dobq (Q4 – Q8); NN∩NN = 5,10,15,20-tetra(4-
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pyridyl)porphyrin (tpp-2H) (Q1, Q4, Q7 and Q8), 5,10,15,20-tetra(4-pyridyl)porphyrin-Ni(II) 
(tpp-Ni) (Q2 and Q5), 5,10,15,20-tetra(4-pyridyl)porphyrin-Zn(II) (tpp-Zn) (Q3 and Q6), (see 
Figure 49). Thus, two new arene ruthenium dinuclear metalla-clips (C0, C1, [(η
6
-
indane)2Ru2(dobq)Cl2] (C10), [(η
6
-nonylbenzene)2Ru2(dobq)Cl2] (C11)) were also synthesised, 
(see List of Structures).  
 
Figure 49. Metalla-cubes Q1 – Q8 
The antiproliferative activity of these metalla-cubes was established in vitro on human 
ovarian cancer cell lines. We also studied the formation of unsymmetrical metalla-cubes 
constructed from mixtures of different porphyrin panels during the synthesis of the cubes. 
4.1.2 Synthesis and Characterisation of Arene Ruthenium Metalla-Cubes (Q1  Q8) 
As shown previously, the synthesis of arene ruthenium metalla-cubes Q1  Q8 is 
straightforward.
 
Addition of silver trifluoromethanesulfonate to the dinuclear metalla-clips C0, 
C1, C10 and C11 in the presence of tpp-2H, tpp-Ni and tpp-Zn leads in good yield to the 
formation of Q1  Q8, (see Scheme 9).
205
 All the metalla-cubes were isolated as their 
trifluoromethanesulfonate salts and characterised by IR, NMR, ESI-MS and by elemental 
analysis (see below and Experimental). The metalla-cubes are quite soluble in 
dichloromethane, acetonitrile, acetone and DMSO and slightly soluble in methanol and water. 
The stability of the metalla-cubes in D2O:DMSO-d6 (90:10) was monitored by 
1
H NMR 
spectroscopy and following 48 hours of heating at 60°C no degradation was observed. 
Chapter 4: Arene Ruthenium Metalla-Cubes 
 
 
  87 
  
 
 
Scheme 9. Synthesis of metalla-cubes Q1  Q8 from metalla-clips C0, C1, C10 and C11 
The 
1
H NMR spectra (in CD3CN or CD2Cl2) of Q1  Q8 display a similar signal 
pattern to the corresponding porphyrin (tpp-2H, tpp-Ni or tpp-Zn) and arene protons. In the 
case of metalla-cubes Q1  Q8 (arene = p-cym) four doublets are observed in the region 6.2  
5.9 ppm for the arene protons, whereas in Q7 (arene = indane) two doublets and two triplets 
and in Q8 (arene = nonylbenzene) one doublet of doublets, two doublets and one triplet are 
observed in the same region. In Q1, Q4, Q7 and Q8, an additional signal at δ ∼ -6.96 ppm 
corresponding to the N-H protons of the tpp-2H porphyrin panels are observed, while in Q4  
Q8 the benzoquinonato singulet is observed at around 6.2 ppm. Moreover, the tpp panels give 
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between 9.5 and 7.0 ppm a total of six multiplets corresponding to four pyridyl and two 
pyrrole protons, (see Figure 50 for a COSY spectrum (7.3 ppm  9.0 ppm) of Q4).  
 
Figure 50. COSY spectrum (7.3 ppm  9.0 ppm) of Q4 
The non-equivalence of the inner and outer pyridyl protons can be surprising, but it is 
explained by helical chirality, (see Scheme 10).
206
 Indeed, the presence of diastereotopic 
protons is attributed to a tilt of the dinuclear metalla-clips and a twist of the two porphyrins 
panels, thus leading to a P  M helical conversion in “double rosette”-type architecture.207 
  
Scheme 10. Chiral conformation of metalla-cubes Q1  Q8 
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Under the conditions of electrospray mass spectrometry (ESI-MS), all the metalla-
cubes Q1  Q8 are remarkably stable. The ESI-MS spectra of Q2  Q8 show peaks 
corresponding to [Q2 + (CF3SO3)4]
4+
, [Q3 + (CF3SO3)4]
4+
, [Q4 + (CF3SO3)4]
4+
, [Q5 + 
(CF3SO3)4]
4+
, [Q6 + (CF3SO3)4]
4+
, [Q7 + (CF3SO3)4]
4+
 and [Q8 + (CF3SO3)4]
4+
, at m/z 1045.0, 
1048.7, 1067.3, 1095.5, 1099.3, 1035.5 and 1207.8, respectively, which are assigned 
unambiguously on the basis of their characteristic Ru8 isotope pattern. Figure 51 shows the 
ESI-MS spectrum of [Q7][CF3SO3]8 in acetonitrile. 
 
Figure 51. ESI-MS spectrum of [Q7][CF3SO3]8 
Electronic absorption spectra of Q1  Q8 as well as the porphyrin panels (tpp-2H, tpp-
Ni and tpp-Zn) were acquired in dichloromethane at 10
-5 
M concentration in the range 250–
800 nm. The UV-visible spectra of all compounds are characterised by intense absorptions 
due to the porphyrin panels, including the Soret Band at around 400 nm and a series of Q 
bands between 500 and 700 nm. In all complexes, as compared to the free porphyrins, the 
Soret band is blue shifted and the full width at half-maximum (Δν) increased. In the case of 
metalla-cube Q7, the full width at half-maximum (Δν = 1471 cm
-1
) is 33% larger than the 
width of tpp-2H (1106 cm
-1
). In all metalla-cubes a weak hypsochromic shift of the Soret 
band and a strong bathochromic shift of the Q bands are observed with respect to the free 
porphyrins. These photophysical changes in the UV-visible spectra of the metalla-cubes are 
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characteristic of sandwich-type porphyrin dimers.
208
 UV-visible spectra in dichloromethane at 
10
-5 
M of metalla-cubes Q2, Q5, Q7 and Q8 as well as tpp-2H and tpp-Ni are shown as 
example in Figure 52. 
 
Figure 52. UV-visible spectra of tpp-2H, tpp-Ni and metalla-cubes Q2, Q5, Q7 and Q8 in 
CH2Cl2 (10
-5
 M) 
4.1.3 Unsymmetrical Metalla-Cubes (Q9  Q11) 
As mentioned above, arene ruthenium metalla-cubes Q1  Q8 are particularly stable 
under the conditions of ESI-MS. For this reason, we used this technique to investigate the 
formation of unsymmetrical metalla-cubes, i.e. the formation of metalla-cubes built from two 
different porphyrin panels. Consequently, a stock solution of the dinuclear metalla-clip [(η6-p-
cym)2Ru2(dobq)Cl2] with silver trifluoromethanesulfonate was freshly prepared in methanol. 
Next, mixtures containing equimolar amount of porphyrin panels (Mx1: tpp-2H + tpp-Ni; 
Mx2: tpp-2H + tpp-Zn; Mx3: tpp-Ni + tpp-Zn; Mx4: tpp-2H + tpp-Ni + tpp-Zn) were added to 
four fractions of the stock solution and heated at reflux for 48 hours leading to the formation 
of statistical mixtures of symmetrical and unsymmetrical metalla-cubes (in Mx1: Q4 + Q5 + 
Q9; Mx2: Q4 + Q6 + Q10; Mx3: Q5 + Q6 + Q11; Mx4: Q4 + Q5 + Q6 + Q9 + Q10 + Q11). The 
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precipitates obtained were directly analysed by ESI-MS without further purification or 
separation. All attempts to separate the metalla-cubes were unsuccessful. The proposed 
structures of the unsymmetrical metalla-cubes Q9, Q10 and Q11 are presented in Figure 53. 
 
Figure 53. The unsymmetrical metalla-cubes Q9  Q11 
The ESI-MS spectrum of a solution of Mx1 shows the formation of the expected 
metalla-cubes [Q4]
8+
 and [Q5]
8+
 as well as the formation of the unsymmetrical metalla-cube 
[(η6-p-cym)8Ru8(dobq)4(tpp-2H)(tpp-Ni)]
8+
 ([Q9]
8+
). In the same way, the formations of [(η6-
p-cym)8Ru8(dobq)4(tpp-2H)(tpp-Zn)]
8+
 ([Q10]
8+
) and [(η6-p-cym)8Ru8(dobq)4(tpp-Zn)(tpp-
Ni)]
8+
 ([Q11]
8+
) are observed in mixtures Mx2 and Mx3, respectively. Finally, in Mx4, the 
formation of all unsymmetrical and symmetrical metalla-cubes can be observed by ESI-MS, 
(see Figure 54). 
Q9 Q10 Q11 
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Figure 54. ESI-MS of Mx4 showing the presence of Q4, Q5, Q6, Q9, Q10 and Q11 
4.1.4 Antiproliferative Study 
The antiproliferative activity of the isolated metalla-cubes Q1  Q8, the stoichiometric 
mixtures of metalla-cubes Q4  Q6 (entries 13 to 16) and the mixtures Mx1 – Mx4 containing 
the unsymmetrical metalla-cubes (entries 9 to 12) were evaluated against the A2780 (cisplatin 
sensitive) and A2780cisR (cisplatin resistant) human ovarian cancer cell lines. Their 
cytotoxicities, in comparison to cisplatin, are presented in Table 8. All compounds show 
similar cytotoxicities towards both cisplatin sensitive and cisplatin resistant cancer cell lines, 
suggesting that they do not share the same mechanisms of action than the reference drug, i.e. 
cisplatin. Moreover, among the compounds tested, additional trends can be drawn from these 
results: The oxalato containing metalla-cubes Q1  Q3 are at least an order of magnitude less 
cytotoxic than the 2,5-dioxydo-1,4-benzoquinonato analogues Q4  Q6, indicating that the 
nature of the OO∩OO connecting spacer plays a crucial role. Similarly, the nature of the 
arene ligand can influence the cytotoxicity of the metalla-cubes. Indeed, the indane and 
nonylbenzene derivatives, Q7 and Q8 respectively, are significantly less cytotoxic than the 
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corresponding p-cym analogue Q4. In contrast, metallation of the porphyrin core with the Zn
2+
 
ion (metalla-cube Q6) does not modify the activity while metallation with Ni
2+
 (metalla-cube 
Q5) slightly reduces the cytotoxicity of the compound. 
Table 8. IC50 values of complexes Q1  Q8, Mx1 – Mx4 and stoichiometric mixtures of Q4  
Q6 in A2780 and A2780cisR cell lines 
 
Interestingly, the mixtures Mx1 – Mx4 containing the unsymmetrical metalla-cubes 
(entries 9 to 12) are the most cytotoxic, with activities comparable to cisplatin or superior to 
cisplatin in the resistant cancer cell line A2780cisR. This distinctive activity is most probably 
due to the presence of the unsymmetrical metalla-cubes Q9, Q10 and Q11 but not due to an 
additive effect of the metalla-cubes as the stoichiometric mixtures of the symmetrical metalla-
cubes (entries 13 to 16) clearly show, as expected, a cytotoxicity averaging the activity of the 
parent complexes Q4  Q6 (entries 4 to 6). It is not clear at the moment the reason for such a 
 compound A2780 (IC50, M)  A2780cisR (IC50, M)  
1 Q1 57.6 ± 1.9 44.2 ± 5.6 
2 Q2 41.5 ± 5.8 49.5 ± 8.9 
3 Q3 34.5 ± 7.5 35.7 ± 8.0 
4 Q4 8.0 ± 4.5 7.0 ± 4.5 
5 Q5 15.5 ± 4.5 14.8 ± 4.5 
6 Q6 7.6 ± 0.6 9.8 ± 0.4 
7 Q7 19.4 ± 4.5 21.5 ± 3.8 
8 Q8 21.2 ± 2.5 24.1 ± 5.2 
9 Mx1 (Q4 + Q5 + Q9) 3.3 ± 1.1 2.2 ± 0.9 
10 Mx2 (Q4 + Q6 + Q10) 2.8 ± 0.1 2.0 ± 0.5 
11 Mx3 (Q5 + Q6 + Q11) 5.4 ± 1.3 4.3 ± 0.3 
12 Mx4 (Q4 + Q5 + Q6 + Q9 + Q10 + Q11) 3.2 ± 0.4 2.5 ± 0.3 
13 Q4 + Q5 14 ± 3.9 16.2 ± 5.0 
14 Q4 + Q6 7.1 ± 1.5 9.2 ± 0.5 
15 Q5 + Q6 13.8 ± 5.2 16.4 ± 4.3 
16 Q4 + Q5 + Q6 12.4 ± 1.4 16.5 ± 1.3 
17 cisplatin 2.2 ± 0.8 12.2 ± 1.2 
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different activity of the unsymmetrical metalla-cubes compared to their symmetrical 
counterparts, but it could be linked to a better internalisation of the products, to a different 
mode of interaction in the cell, or to a greater or lesser overall stability in the cellular 
environment. Nevertheless, these results are quite unexpected and further studies will be 
needed to provide an explanation for this difference in cytotoxicity between symmetrical and 
unsymmetrical metalla-cubes. 
The synthesis of water-soluble metalla-cubes and of their in vitro anticancer activity 
against the A2780 and A2780cisR ovarian cancer cell lines showed that the larger assemblies 
were found to be highly active and equally potent on both cell lines.
209
 It is likely that these 
large complexes would be taken up more efficiently by tumours due to the enhance 
permeability and retention effect of cancer cells, thus providing a degree of selectivity and 
ultimately giving a better efficacy. Further studies will be done to delineate the surprisingly 
low IC50 values observed for the unsymmetrical metalla-cubes. 
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4.2 Arene Ruthenium Metalla-Cubes as G-Quadruplex Binders 
4.2.1 Background to G-Quadruplexes 
Since the Nobel Prize in Physiology or Medicine 2009 was awarded jointly to 
Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak “for the discovery of how 
chromosomes are protected by telomeres and the enzyme telomerase”,210 more than 5500 
articles have been dedicated to the nature and the biological role of G-quadruplex, G-
quadruplex stabilisers or telomerase. To understand the importance of this area of research, a 
definition of a G-quadruplex structure and the potential utilisation of such structure in 
medicine is needed. 
Self-association of guanosine has been observed in solution already in the 19th century 
by the ready formation of polycrystalline gels. In the 1960’s Gellert showed by 
crystallographic methods that this association of guanine bases is a tetrameric arrangement 
and Gellert described it as a G-quartet arrangement.
211
 More precisely, the four guanine bases 
form a co-planar square where each base is both a hydrogen bond donor and a hydrogen bond 
acceptor. Utilisation of both the N1 and N2 of one face with the O6 and N7 of the second face 
on guanosine yields eight hydrogen bonds per planar G-quartet, giving to the structure a 
remarkable stability, (see Figure 55). Additional interactions stabilise this structure and the 
presence of a small cation like potassium or sodium is crucial.  
 
Figure 55. A guanine quartet with hydrogen bonds, including the central potassium cation. 
Deoxyribose sugars are removed for clarity 
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 More interestingly, at millimolar concentrations of guanines in solution, a stacking of 
these quartets is observed. The driving force between the tetrads is the    stacking, and an 
energetic equilibrium is found when three quartets are stack on top of each other. This 
structure of three quartets of four guanines is called a G-quadruplex structure, (see Figure 
56).
212
 
 
Figure 56. Schematic representation of a G-quadruplex 
In reality, G-quadruplex structures are not simple arrangements of three quartets of 
four guanines. Indeed, these stacked tetrads align themselves with a regular rise and twist 
between the tetrad planes. This shape of the stacking leads to the generation of a right-handed 
helical twist. In this case the phosphate backbones, linking the nucleosides together, generate 
four grooves of variable width instead of two. This motif is called G-quadruplex DNA motif 
and possesses a similar appearance to that of duplex DNA, (see Figure 57). 
Chapter 4: Arene Ruthenium Metalla-Cubes 
 
 
  97 
  
 
 
Figure 57. Duplex DNA and G-quadruplex DNA 
 A major breakthrough was made in the early 1990’s by the chemist Blackburn with the 
discovery of guanine-rich repetitive sequences located at the end of chromosomes 
(telomeres), and the identification of a protein, with a reverse transcriptase activity, involved 
in their maintenance.
213
 Then, it was quickly realised that these guanine-rich repetitive 
telomeric DNA sequences could form higher ordered structures, such as G-quadruplex, and 
they are likely to be involved in chromosomal maintenance. From this major discovery to 
nowadays, many studies have revealed several topologies for G-quadruplex DNA, depending 
on various factors such as the DNA sequence and the templating metal cation. For example, a 
very nice structure of G-quadruplex established by X-ray crystallography was published by 
Neidle in 2002, (see Figure 58).
214
 
 
Figure 58. G-quadruplex structure 
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4.2.2 Biological Relevance of G-quadruplex DNA 
Recent bio-informatic studies have shown that in the human genome there are 
approximately 350 000 guanine-rich sequences that can potentially form G-quadruplex DNA 
structures.
215
 Some of these sequences have been identified as potential anticancer drug 
targets. For example, the formation of G-quadruplexes in human telomeric DNA has been 
shown to inhibit telomerase – an enzyme over-expressed in 85-90% of cancer cells, which 
plays an important role in cancer cell immortalization.
216
 On the other hand, formation of G-
quadruplex DNA structures in the promoter region of certain oncogenes (e.g. c-myc and c-kit) 
has been shown to control transcription of these genes and as a consequence their 
expression.
217
 
An ongoing challenge in this area is to develop molecules that can interact strongly 
with G-quadruplex DNA but weakly with duplex DNA. Achieving this selectivity is essential 
to realise the potential advantages of G-quadruplex-targeting anticancer drugs. Most G-
quadruplex DNA stabilisers reported to date are based on planar poly-aromatic compounds 
that interact with guanine quartets via    stacking.218 In addition, these molecules are often 
substituted with positively charged groups (e.g. protonated amines) to increase their solubility 
and also electrostatic interaction with the loops and grooves of DNA. However, often planar 
poly-aromatic molecules not only stack on top of the guanine quartet of G-quadruplexes, but 
also intercalate in between base-pairs of duplex DNA, thus reducing their selectivity for G-
quadruplex versus duplex DNA.  
 
Figure 59. Metal salphen complexes as G-quadruplex DNA stabilisers 
With the aim of reducing the undesired interactions between G-quadruplex-binding 
molecules and duplex DNA, square-based pyramidal metal complexes have been recently 
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reported as G-quadruplex DNA stabilisers, (see Figure 59).
219
 The axial ligand in these 
complexes is proposed to reduce their ability to intercalate in between base pairs of duplex 
DNA. Polymetallic complexes where the metals are positioned outside the guanine quartet 
have also been recently reported to increase G-quadruplex DNA affinity and selectivity.
220
 
Cationic porphyrin derivatives have also attracted a great interest as G-quadruplex DNA 
stabilisers.
221
 This interest is particularly due to a large surface for potential  stacking 
interactions with tetrads of guanines.
222
 Finally, complexes from supramolecular chemistry 
have also been studied as G-quadruplex binders, in particular the palladium metalla-rectangle 
[Pt(ethylenediamine)(4,4′-bipyridyl)]4 synthesised by Fujita.
223
  
4.2.3 Synthesis of Arene Ruthenium Metalla-Cubes Q12 and Q13 
The arene ruthenium metalla-cubes previously described Q1  Q8 are built from 
porphyrin derivatives (tpp-2H, tpp-Ni and tpp-Zn). Porphyrins are known to bind strongly to 
G-quadruplex DNA, but their selectivity is usually poor since they also bind strongly to 
duplex DNA. We hypothesised that by linking two porphyrin rings via coordination bonds, 
their quadruplex binding ability would be retained, but their ability to intercalate in between 
bases of duplex DNA would be greatly reduced. Moreover, the arene ruthenium metalla-
boxes are octoacationic and are water-soluble. Therefore we synthesised two new toluene 
ruthenium metalla-cubes Q12 and Q13 of general formula [(η
6
-
toluene)8Ru8(dobq)4(NN∩NN)2]
6+
 (NN∩NN = tpp-2H (Q12), tpp-Zn (Q13)), (see Figure 60).  
 
Figure 60. Arene ruthenium metalla-cubes Q12 and Q13 
Q12 Q13 
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 The synthesis of these two arene ruthenium metalla-cubes involves the reaction of four 
equivalents of new arene ruthenium dinuclear metalla-clip C12 of formula [(η
6
-
toluene)2Ru2(dobq)(Cl)2] with eight equivalents of halide scavenger in the presence of two 
equivalents of porphyrin panel (either tpp-2H or tpp-Zn), (see Scheme 11). 
 
Scheme 11. Synthesis of arene ruthenium metalla-cubes Q12 and Q13 
The 
1
H NMR spectra of Q12 and Q13 display signals of diastereotopic protons 
suggesting the same helical-type chirality previously observed with arene ruthenium metalla-
cubes Q1  Q8. Under conditions of electro-spray mass spectrometry, the cationic cubes Q12 
and Q13 show a remarkable stability (see Figure 61): the ESI-MS spectra show peaks 
corresponding to [Q12 + (CF3SO3)4]
4+
 and [Q13 + (CF3SO3)4]
4+
 at m/z 983.0 and 1014.7, 
respectively. These peaks can be assigned unambiguously on the basis of their characteristic 
Ru8 and Ru8Zn2 isotope patterns. Furthermore, in the ESI-MS spectra of [Q12][CF3SO3]8 and 
[Q13][CF3SO3]8 the second major peak corresponding to [Q12][CF3SO3]8 and [Q13 + 
(CF3SO3)5]
3+
 is observed at m/z 1359.3 and 1402.6, respectively. 
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Figure 61. ESI-MS spectrum of [Q13][CF3SO3]8 
4.2.4 Interactions of some Arene Ruthenium Metalla-Cubes with DNA 
In order to evaluate the ability of toluene ruthenium complexes Q12 and Q13 to interact 
with G-quadruplex and duplex DNA, fluorescence intercalation displacement (FID) assays 
were carried out.
224
 Moreover, in order to compare the influence of the peripheric arene ligand 
on these interactions, corresponding para-cymene ruthenium metalla-cubes Q4 and Q6 were 
also tested.  
In this recently reported assay thiazole orange (TO) is mixed with G-quadruplex DNA 
with which it interacts in a single-site manner and with high affinity. The fluorescence of this 
dye is quenched in solution, however, upon interaction with G-quadruplex DNA, it displays 
up to a 3000-fold increase in its emission. Therefore, displacement of TO by another molecule 
provides a measure of the affinity of the compound for G-quadruplex or duplex DNA, (see 
Figure 62).  
Chapter 4: Arene Ruthenium Metalla-Cubes 
 
 
102    
 
 
 
Figure 62. Representation of the TO displacement from Htelo (■), c-myc (▲) G-quadruplex 
DNA and ds (●) duplex DNA upon increasing concentration of Q4 (0.1252.5 μM) 
In order to quantify the displacement, the compound’s concentration at which TO 
fluorescence decreases by 50% (assumed to be 50% displacement of TO), is calculated 
(
G4DC50). Table 9 summarises the DC50 values obtained by FID for the interactions of 
complexes Q4, Q6, Q12 and Q13 with two different G-quadruplex DNA sequences (Htelo and c-
myc) and one duplex DNA sequence (ds). From these DC50 values it is possible to conclude 
that the octanuclear arene ruthenium metalla-cubes are able to displace TO at very low 
concentrations (μM), which suggests that they interact strongly with G-quadruplex DNA 
(both telomeric and c-myc). In addition, complexes Q4, Q6, Q12 and Q13 show good selectivity 
for G-quadruplex versus duplex DNA binding. 
Table 9. 
HteloDC50, 
c-myc
DC50 and 
ds
DC50 values (μM) determined using FID assays for Q4, Q6, 
Q12 and Q13  
 TO displacement selectivity 
compound 
HteloDC50 
(μM) 
c-myc
DC50 
(μM) 
ds
DC50 
(μM) 
ds
DC50 / 
HteloDC50  
ds
DC50 /  
c-myc
DC50  
c-myc
DC50 / 
HteloDC50 
Q4 0.15 0.32 0.72 4.8 2.3 2.1 
Q6 0.22 0.27 0.94 4.3 3.5 1.2 
Q12 0.33 0.70 1.25 3.8 1.8 2.1 
Q13 0.20 0.37 0.65 3.3 1.8 1.9 
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Among the four complexes, Q4 shows the highest binding and selectivity towards G-
quadruplex DNA. No discrimination between toluene and para-cymene metalla-cubes can be 
observed, suggesting that the influence of the arene ligand on the binding is minor. In the 
same way, the difference of binding and selectivity between metalla-cubes built from tpp-2H 
and tpp-Zn is also not observable. Finally, the results also suggest that all the metalla-cubes 
are equipotent for the two G-quadruplex sequences under study (Htelo and c-myc). However, 
the main point of this study
225
 is the selectivity observed between the binding of G-
quadruplex and duplex DNA by arene ruthenium metalla-cubes. This selectivity (up to four) 
confirms the starting hypothesis that stated that by linking two porphyrin rings via 
coordination bonds, their G-quadruplex binding ability would be retained but their ability to 
intercalate in-between bases of duplex DNA would be greatly reduced. 
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4.3 Open Arene Ruthenium Metalla-Cubes  
4.3.1 General 
Arene ruthenium metalla-cubes showed great interest for biological applications. Their 
antiproliferative properties and their ability to bind strongly G-quadruplex DNA are two 
potential applications for this type of octanuclear complexes. Moreover, these water-soluble 
metalla-cages are robust, easy to synthesise and stable in biological medium. By using 
different porphyrin panels, arene and OO∩OO linkers it is even possible to modify their 
chemical structure and consequently their physical and chemical properties, without any 
difficulties. Furthermore, these complexes can target cancer cells via EPR effect thanks to 
their high molecular weight. 
In order to modify charge and rigidity of these arene ruthenium metalla-cubes, we 
extended the strategy to new arene ruthenium metalla-assemblies incorporating poly-
pyridylporphyrin panels, 5,15-bis(4-pyridyl)-10,20-diphenylporphyrin (bpp) and 5,10,15-
tris(4-pyridyl)-20-phenylporphyrin (tpp). These open arene ruthenium metalla-cubes were 
connected by the arene ruthenium dinuclear metalla-clips C0 and C1 to afford the tetracationic 
[(η6-p-cym)4Ru4(OO∩OO)2(bpp)2]
6+
 (OO∩OO = ox (Q14), dobq (Q15)) and the hexacationic 
[(η6-p-cym)4Ru4(OO∩OO)2(tpp)2]
6+
 (OO∩OO = ox (Q16), dobq (Q17)) metalla-assemblies, 
(see Figure 60). 
4.3.2 Synthesis of a Series of Arene Ruthenium Metalla-Cubes Q14  Q17  
The tetranuclear arene ruthenium metalla-assemblies [(η6-p-
cym)4Ru4(OO∩OO)2(bpp)2]
6+
 (OO∩OO = ox (Q14), dobq (Q15)) (see Figure 63) are readily 
prepared from the dinuclear complexes [(η6-p-cym)2Ru2(ox)Cl2] (C0) and [(η
6
-p-
cym)2Ru2(dobq)Cl2] (C1) and the commercially available porphyrin derivative 5,15-bis(4-
pyridyl)-10,20-diphenylporphyrin (bpp). The coordinatively unsaturated intermediates, [(η6-p-
cym)2Ru2(ox)]
2+
 and [(η6-p-cym)2Ru2(dobq)]
2+
, formed upon addition of silver 
trifluoromethanesulfonate, react at room temperature in the presence of the bpp ligands to 
give the corresponding tetranuclear cations Q14 and Q15. These open metalla-assemblies are 
isolated as trifluoromethanesulfonate salts, i.e. [(η6-p-cym)4Ru4(OO∩OO)2(bpp)2][CF3SO3]4 
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(OO∩OO = ox (Q14), dobq (Q15)). Despite a molecular weight of 2946.9 g·mol
-1
 for 
[Q14][CF3SO3]4 and 3047.0 g·mol
-1
 for [Q15][CF3SO3]4, and their relatively high charge, these 
two tetranuclear metalla-assemblies are quite soluble in (CH3)2CO, CH3CN and DMSO and 
sparingly soluble in CH2Cl2, CHCl3 and H2O. 
 
Figure 63. Open arene ruthenium metalla-cubes Q14 and Q15 
The hexanuclear derivatives Q16 and Q17 are obtained following the same strategy, but 
using the tridentate porphyrin panels, 5,10,15-tris(4-pyridyl)-20-phenylporphyrin (tpp). 
Cations Q16 and Q17 are also isolated as trifluoromethanesulfonate salts, i.e. [(η
6
-p-
cym)6Ru6(OO∩OO)3(bpp)2][CF3SO3]6 (OO∩OO = ox (Q16), dobq (Q17)), (see Figure 64). 
Despite their higher charge, Q16 and Q17 possess a similar solubility to Q14 and Q15, with the 
molecular weight of the salts being 3803.6 and 3953.8 g·mol
-1
 for [Q16][CF3SO3]6 and 
[Q17][CF3SO3]6, respectively. 
Q14 Q15 
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Figure 64. Open arene ruthenium metalla-cubes Q16 and Q17 
The IR spectra of [Q14 – Q15][CF3SO3]4 and [Q16 – Q17][CF3SO3]6 are dominated by 
absorptions of the coordinated poly-pyridylporphyrin panels with, in particular, the in-plane 
NH deformation around 1220 cm-1,226 and the bands assigned to the C=C and C=N skeletal 
modes of the porphyrins located between 1620 and 1400 cm
-1
.
227 
Moreover, the bands 
associated to the OO∩OO bridges, including the strong C=O stretching vibration (≈ 1630 cm-
1
), are only slightly shifted as compared to the dinuclear complexes C0 and C1. In addition to 
the porphyrin and OO∩OO absorptions, strong stretching vibrations due to the 
trifluoromethanesulfonate anions (1260(s), 1030(s), 638(m) cm
-1
) are also observed in the IR 
spectra of the salts [Q14 – Q15][CF3SO3]4 and [Q16 – Q17][CF3SO3]6. 
The metalla-assemblies Q14 – Q17 are stable in water at 60°C for 48 h, in which no 
degradation was observed by NMR spectroscopy. The 
1
H NMR spectra of Q14 and Q15 show a 
similar chemical shift pattern for the protons of the bpp and p-cym ligands despite the 
different length of the bridging OO∩OO ligands. In the tetranuclear complexes Q14 and Q15, 
large and broad signals are observed for the pyridyl and pyrrole protons of the porphyrin 
panels as well as for the signal of the N-H protons. In addition, the aromatic protons of the p-
cym ligands appear as four superimposed doublets in the region 6.5 to 6.0 ppm. In Q15, an 
additional singulet is observed at δ = 6.17 ppm corresponding to the dobq protons. The 1H 
NMR spectra of Q16 – Q17 are somewhat more complicated, not only due to the presence of 
diastereotopic protons in solution, which is in agreement with a chiral conformation as 
Q16 Q17 
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previously observed in related metalla-assemblies, but as well due to the lost of a symmetry 
element present in Q14 and Q15.  
Indeed, each proton of Q16 and Q17 resonates at a distinct chemical shift, and 
accordingly the 
1
H NMR spectrum of Q17 contains 142 distinct resonances. Due to their chiral 
conformation the chemical shift patterns for the protons of the bpp and p-cym ligands, as well 
as for the pyridyl and pyrrole protons of the porphyrin panels cannot be compared to the 
patterns observed in the case of the tetranuclear complexes Q14 and Q15. Rather than 
attempting a partial attribution of some resonances, several 10-ppm HSQC experiments were 
recorded in order to improve the spectral resolution and determine the number of carbon 
signals at a given proton chemical shift. In usual heteronuclear 
1
H13C NMR experiments, 
recorded with the full spectral width, the signals possess a typical width as large as 1 ppm in 
the 
13
C dimension, making it impossible to distinguish between close signals. The use of 
10-ppm experiments resolves the overlap problem and allows the determination of the correct 
13
C chemical shifts, which is straightforward in these types of aliased spectra.
228
 For instance, 
Figure 65 shows an excerpt of a 10-ppm HSQC recorded on Q17 displaying the region of the 
Hα of the pyridyl groups. In the Figure, the difficulty to distinguish between closed 
13
C signals 
in a standard 
1
H-
13
C HSQC experiment is readily demonstrated (top), in which only ten 
distinct cross peaks are identified. Moreover, the 10-ppm HSQC experiment increases the 
resolution in the 
13
C dimension by a factor of about 25, thus enabling all resonances to be 
separated, and the twelve independent signals of the Hα of the pyridyl groups could be 
resolved. The other resonances present in the 10-ppm spectrum arise from signals that are 
back-folded into the smaller window. Therefore, the discrimination of the resonances and the 
determination of the chemical shifts in a 10-ppm spectrum become straightforward. 
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Figure 65. Excerpts of the full-width HSQC (top) and 10-ppm HSQC (bottom) NMR spectra 
in CD3CN of the metalla-assembly [Q17][CF3SO3]6, showing the twelve independent signals 
of the Hα of the pyridyl groups (the question marks indicate unknown values) 
Another example demonstrating the usefulness of the 10-ppm HSQC approach is 
presented in Figure 66. This Figure shows an excerpt of a 10-ppm HSQC recorded on 
[Q17][CF3SO3]6 displaying the region of the dobq bridging and p-cym ligands together with an 
excerpt of a usual HSQC recorded with the full spectral width. In the 10-ppm HSQC 
spectrum, the six independent cross peaks of the dobq bridging ligands, labelled 1  6, may be 
readily assigned. In the standard HSQC experiment, on the other hand, the signals possess a 
typical width of about 1 ppm in the 
13
C dimension, making it impossible to distinguish 
between the six close signals. 
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Figure 66. 10-ppm HSQC NMR spectrum in CD3CN of the metalla-assembly 
[Q17][CF3SO3]6, showing the six independent signals of the dobq (Hq) bridging ligands 
Electronic absorption spectra of the multinuclear metalla-assemblies Q14 – Q17 as well 
as the poly-pyridylporphyrin panels (bpp and tpp) were acquired in acetone at 10
-5 
M 
concentration in the range 250 – 800 nm, (see Figure 67). The UV-visible spectra of all 
compounds are characterised by intense absorptions due to the porphyrin panels, including the 
Soret Band at around 400 nm and a series of Q bands between 500 and 700 nm. In complexes 
Q14 – Q17, as compared to the free porphyrins bpp and tpp, the Soret band is blue shifted and 
the full width at half-maximum (Δν) increases. In the case of metalla-assembly Q17, the full 
width at half-maximum (Δν = 1870 cm-1) is twice the width of bpp (865 cm-1) and the Soret 
band is blue shifted by 712 cm
-1
. Moreover, a clear red shift of the Q bands is observed in the 
metalla-assemblies Q14 – Q17. These photophysical changes in the UV-visible spectra of Q14 – 
Q17 are characteristic of sandwich-type dimeric structure of porphyrins,
208 
which is consistent 
with the proposed structures. 
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Figure 67. UV-visible spectra of bpp, tpp and the metalla-assemblies Q14 – Q17 in acetone (10
-
5
 M) 
Furthermore, the metalla-assemblies Q14 – Q17 were characterised by electrospray 
mass spectrometry with the four metalla-assemblies showing remarkable stability. The ESI-
MS spectra show among others, peaks corresponding to [Q14]
4+
, [Q14 + CF3SO3]
3+
, [Q15]
4+
, 
[Q15 + CF3SO3]
3+
, [Q16 + (CF3SO3)2]
4+
, [Q16 + (CF3SO3)3]
3+
, [Q17 + (CF3SO3)2]
4+
 and [Q17 + 
(CF3SO3)3]
3+
 at m/z 587.9, 833.5, 612.8, 866.8, 802.3, 1119.8, 839.9 and 1169.5, respectively, 
(see Figure 68). These peaks are assigned unambiguously on the basis of their characteristic 
Ru4 and Ru6 isotope patterns. 
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Figure 68. Selected peaks from the ESI-MS spectra of [Q14][CF3SO3]4 – [Q17][CF3SO3]4 
4.3.3 Antiproliferative Study 
The putative antitumour activity of compounds [Q14 – Q15][CF3SO3]4 and [Q16 – 
Q17][CF3SO3]6 was evaluated on A2780 (cisplatin sensitive) and A2780cisR (cisplatin 
resistant) human ovarian cancer cells. Although these compounds are highly charged, it has 
been shown that highly charged metal complexes cannot only traverse cell membranes, but 
some of them do it more effectively that neutral complexes or cations with low charges.
229
 
The cytotoxicities of the tetranuclear complexes Q14 and Q15 and the hexanuclear arene 
ruthenium complexes Q16 and Q17 are presented in Table 10. All compounds display good 
cytotoxicity towards both the sensitive and resistant cell lines with quite similar IC50 values. It 
is noteworthy, however, that the hexanuclear complexes Q16 and Q17 are slightly more 
cytotoxic than their tetranuclear counterparts Q14 and Q15, which is consistent with the 
number of ruthenium centres per metalla-assemblies. In general, for arene ruthenium 
complexes an additive effect is observed as the number of ruthenium centres increases.
176c
 
However, an additive effect is not always observed, for example, binuclear arene ruthenium 
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complexes (connected via pyridone-based chelators) were found to be highly active in a 
colorectal carcinoma cell line in the absence of any activity for the mononuclear 
counterparts.
230
 Complexes Q15 and Q17 that contain the dobq ligand are more cytotoxic than 
the oxalato derivatives Q14 and Q16, indicating that the length of the spacer is a relevant 
parameter in the design of these types of compounds. 
Table 10. IC50 values of Q14 – Q17 in A2780 and A2780cisR cell lines 
  
This study
231
 shows a series of cationic open metalla-cubes based on arene ruthenium 
dinuclear clips and poly-pyridylporphyrin panels. The compounds are stable, and based on 
promising results obtained for analogous ruthenium compounds, were evaluated for in vitro 
anticancer activity. Large compounds such as these could potentially exploit the EPR effect 
for tumour targeting but as yet an in vivo study has not been performed to gauge this 
possibility. From the in vitro study, however, it was found that the number of ruthenium 
centres and the type of spacer used influence the cytotoxicity of these metalla-assemblies. 
 
compound A2780 (IC50, M)  A2780cisR (IC50, M)  
Q14 11.0 ± 0.2 12.7 ± 3.0 
Q15 5.6 ± 0.4 10.1 ± 1.2 
Q16 3.1 ± 1.0 10.7 ± 2.6 
Q17 2.1 ± 0.3 3.8 ± 0.8 
cisplatin 1.6 8.6 
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Chapter 5: General Conclusion and Perspectives 
5.1 Arene Ruthenium Metalla-Rectangles 
The synthesis of arene ruthenium metalla-clips of the general formula [(η6-p-
cym)2Ru2(OO∩OO)Cl2] (OO∩OO = 5,8-dioxydo-1,4-naphthoquinonato (donq), 5,8-dioxydo-
1,4-anthraquinonato (doaq), and 6,11-dioxydo-5,12-naphthacenedionato (dotq)) (C5, C6 and 
C7) allowed the development of a new generation of arene ruthenium metalla-rectangles R13  
R21 [(η
6
-p-cym)4Ru4(OO∩OO)2(N∩N)2]
4+
 (OO∩OO = donq (R13, R16, R19), doaq (R14, R17, 
R20), dotq (R15, R18, R21); N∩N = pyr (R13, R14, R15), bpy (R16, R17, R18), bpe (R19, R20, 
R21)). The potential of such metalla-rectangles for applications in host-guest chemistry was 
studied with a series of planar aromatic molecules (anthracene, pyrene, perylene, coronene) 
and results clearly underlined the great interest of these metalla-rectangles for host-guest 
chemistry.  
 
Moreover, this type of arene ruthenium metalla-rectangles can be easily designed to 
accommodate guest molecule outside and inside their cavities as it was determined by various 
NMR experiments, UV-visible and fluorescence spectroscopy. For a future project, extension 
of the length of the N∩N linker as well as a modification of its flexibility or rigidity could 
strongly modify the properties of arene ruthenium metalla-rectangles as host systems. In the 
same way, the synthesis of new arene ruthenium dinuclear metalla-clips could also modify the 
hosting ability of these tetranuclear metalla-assemblies.  
On the other hand, the water-solubility, the robustness in biological media as well as a 
facile and straightforward synthetic pathway are some of the numerous properties of arene 
ruthenium metalla-rectangles. These characteristics allowed the antiproliferative testing of a 
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series of metalla-rectangles [(η6-p-cym)4Ru4(OO∩OO)2(N∩N)2]
4+
 (OO∩OO = oxalato (ox), 
dobq, donq, doaq, dotq, oxamido (oxa), oxonico (oxo)); N∩N = bpe, 1,2-bis(4-pyridyl)ethane 
(bpa)) (R9, R19  R31). The cytotoxicity of the compounds was established on A2780 and 
A2780cisR human ovarian cancer cell lines by the group of Prof. Dyson (EPFL). The activity 
of all complexes was found to be moderate to excellent, depending of the nature of the linker 
as well as the nature of the length of the metalla-clip. Interestingly enough, some metalla-
rectangles were found to be more active for cisplatin resistant cancer cells A2780cisR than on 
A2780 cancer cells. This result suggests that the biological mechanism involved in the 
anticancer activity of metalla-rectangles differs from the biological mechanism of cisplatin. 
Furthermore, this selectivity toward cisplatin resistant cancer cells of certain arene ruthenium 
metalla-rectangles is unusual and highly promising.  
Finally, arene ruthenium metalla-rectangles were also used to pre-organise two 
olefinic double bonds with a parallel arrangement that allowed a facile photochemical [2 + 2] 
cycloaddition reaction. This photoreaction in solution led to the synthesis of rctt-tetrakis(4-
pyridyl)cyclobutane compound. 
 
In conclusion, host-guest chemistry, anticancer therapy and supramolecular control of 
reactivity are some examples developed in this thesis for potential applications for arene 
ruthenium metalla-rectangles.  
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5.2 Arene Ruthenium Metalla-Prisms 
The versatility of metalla-rectangles allowed very different applications for this type of 
complexes. In the case of arene ruthenium metalla-prisms, this versatility is well illustrated by 
the Trojan horse concept. The association of six arene ruthenium units in a large water-soluble 
metalla-cage (P1) potentially able to target tumours via EPR effect with a non water-soluble 
drug encapsulated into the hydrophobic cavity of this carceplex metalla-prism was developed 
by our group before this thesis. The ability of the host P1 to deliver guest molecules to cells 
was further confirmed by encapsulation of a fluorescent labelled pyrene-X derivative, 1-(4,6-
dichloro-1,3,5-triazin-2-yl)pyrene and fluorescence experiments were used to monitor the 
uptake of pyrene-X into cancer cells. This uptake was found to be one order of magnitude 
greater for the carceplex system over pyrene-X alone. 
The present work developed this approach and the synthesis of new arene ruthenium 
metalla-prisms [(η6-p-cym)6Ru6(OO∩OO)3(tpt)2]
6+ 
(OO∩OO = donq, doaq, dotq) (P2  P4) 
strongly modified the host ability of the prisms. Indeed these metalla-prisms allowed the 
encapsulation of small aromatic molecules either in a carceplex way or in a host-guest 
fashion. More precisely, these cationic metalla-prisms possess different portal sizes able to 
allow small aromatic molecules to enter and leave in solution the hydrophobic cavity, with 
different rate of release of the guest molecule depending on the portal size of the host. 
However, for planar molecules capable of fitting into the cavity, but too large to exit the 
portal of the cage, permanent encapsulation was observed, thus giving rise to stable carceplex 
systems. But maybe more interestingly, the development of these metalla-prisms P2  P4 with 
different portal sizes and able to interact in a host-guest fashion with small aromatic 
molecules was a new way to explore the anticancer behaviour of our arene ruthenium metalla-
systems. 
In particular, the in vitro characterisation of this modular and adjustable 
supramolecular drug delivery system based on these three arene ruthenium metalla-prisms 
was described. The antiproliferative effect on A2780 and A2780cisR cancer cells of the 
empty metalla-cages was found to be efficient while the host-guest and the carceplex systems 
exhibited excellent IC50, some of them being in the nanomolar scale. The cellular uptake of 
the host-guest systems was also studied and seems to involve an active transport mechanism, 
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and the rate of release of the guest molecule was found to depend on the portal size of the 
host. 
Finally, the impact of the size of the guest molecule on the cytotoxicity of the host-
guest systems was studied. A series of large pyrenyl-containing dendrimers of different 
generations (pyrene-G0, pyrene-G1, and pyrene-G2) were prepared, and after encapsulation of 
the pyrenyl units in the hydrophobic cavity of the hexanuclear arene ruthenium metalla-prism 
P2, the cytotoxicity of these resulting host-guest systems, [pyrene-G0P2]
6+
, [pyrene-
G1P2]
6+
, and [pyrene-G2P2]
6+
, was evaluated and correlated to their size.  
 
Results indicated that metalla-cage host systems are able to deliver hydrophobic guest 
molecules with extremely large appendages into cancer cells. Moreover, this study suggested 
that the most cytotoxic system was [pyrene-G0P2]
6+
, thus indicating the absence of a size 
effect of the guest molecule on the antiproliferative effect of the host-guest system. 
Nevertheless, [pyrene-G1P2]
6+
, and [pyrene-G2P2]
6+
 have higher molecular weights than 
[pyrene-G0P2]
6+
, and therefore could have a better selectivity for cancer cells than for 
healthy cells thanks to the EPR effect. This hypothesis needs to be confirmed by in vivo 
studies.  
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5.3 Arene Ruthenium Metalla-Cubes 
Arene ruthenium metalla-rectangles and arene ruthenium metalla-prisms are possibly 
able to selectively target cancer cells via the EPR effect. In order to extend this strategy to 
larger metalla-assemblies we developed arene ruthenium metalla-cubes of the general formula 
[(η6-arene)8Ru8(OO∩OO)4(NN∩NN)2]
6+
 where NN∩NN is a tetra-pyridylprophyrin derivative 
(tpp-2H, tpp-Ni or tpp-Zn). The antiproliferative activity of these metalla-cubes was 
established in vitro on human ovarian cancer cell lines.  
 
We also studied the formation of unsymmetrical metalla-cubes constructed from 
mixtures of different porphyrin panels during the synthesis of the cubes. All compounds 
showed similar cytotoxicities towards both cisplatin sensitive and cisplatin resistant cancer 
cell lines, suggesting that they do not share the same mechanisms of action than the reference 
drug, i.e. cisplatin. Moreover, among the compounds tested, additional trends were drawn 
from these results. In particular, the mixtures containing the unsymmetrical metalla-cubes are 
the most cytotoxic, with activities comparable to cisplatin or superior to cisplatin in the 
resistant cancer cell line A2780cisR. Further studies will be needed to provide an explanation 
for this difference in cytotoxicity between symmetrical and unsymmetrical metalla-cubes. 
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We also modified charge and rigidity of these arene ruthenium metalla-cubes, with the 
synthesis of open arene ruthenium metalla-assemblies incorporating bis-pyridylporphyrin and 
tris-pyridylporphyrin panels. These tetracationic and hexacationic open arene ruthenium 
metalla-cubes were evaluated for in vitro anticancer activity. It was found that the number of 
ruthenium centres and the type of spacer used influence the cytotoxicity of these metalla-
assemblies, but in all cases, the complexes were found to be stable in biological medium 
suggesting a great potential for the tuning of such molecules. 
Finally, as porphyrins are known to bind strongly to G-quadruplex DNA but with an 
usually poor selectivity since they also bind strongly to duplex DNA, we hypothesised that by 
linking two porphyrin rings via coordination bonds, their G-quadruplex binding ability would 
be retained but their ability to intercalate in-between bases of duplex DNA would be greatly 
reduced. In order to confirm or rule out this hypothesis we tested four arene ruthenium 
metalla-cubes as potential G-quadruplex DNA binders, in collaboration with the group of Dr. 
Vilar (Imperial College of London).  
A noticeable selectivity was indeed observed between the binding of G-quadruplex 
and duplex DNA by arene ruthenium metalla-cubes. This selectivity (up to four) confirms the 
starting hypothesis that stated that by linking two porphyrin rings via coordination bonds, 
their G-quadruplex binding ability would be retained but their ability to intercalate in-between 
bases of duplex DNA would be reduced. 
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5.4 Perspectives 
The development of host-guest chemistry with arene ruthenium metalla-assemblies 
and small aromatic molecules presented in this thesis opened a new chapter in the research of 
our group. The construction of new systems in thermodynamic exchanges, the 
characterisation of the equilibrium state and the potential application of such systems in 
medicinal chemistry were some of the features investigated in this work. In other words, the 
passage from carceplex to host-guest metalla-cages was certainly the main contribution of this 
thesis to the general project initiated in 2006 by our group.  
As a consequence, a possible perspective is the development of this host-guest 
chemistry with new and larger arene ruthenium metalla-cages built either from new dinuclear 
metalla-clips or from new linkers. This natural perspective is already in progress,
146
 and the 
increase of the cavity size of the host molecule could then allow the encapsulation of different 
guest molecules, such as non-planar, non-aromatic or even non-hydrophobic molecules. Using 
the same concept, we could imagine an enantiodifferentiation of chiral guest molecules with 
the construction of metalla-cages designed with chiral and enantiopure panels. We could also 
develop reactions between two guest molecules inside the cavity of the water-soluble metalla-
cages. This could be interesting for the synthesis of non-water-soluble molecules in water, and 
therefore find applications in green chemistry. Concerning the medicinal applications, 
encapsulations of drugs or biological relevant molecules would also beneficiate from the 
development of new arene ruthenium metalla-cages. As a recent example, encapsulations of 
photosensitisers, such as porphyrins or phthalocyanines were achieved by our group.
232
 The 
study of the antiproliferative behaviour of the systems as well as their potential utilisation as 
photodynamic therapy agents is under investigation. Thus, the development of the hosting 
ability of arene ruthenium metalla-cages could find applications as sensors, storage molecules, 
water-soluble reactors, but also as separator for racemic mixture of organic compounds or 
cargo for the delivery of biological relevant guest molecules into cancer cells. 
Another possibility would be the utilisation of other transition metals than ruthenium 
for the construction of metalla-assemblies. In particular, osmium complexes are currently 
actively explored as novel chemotherapeutic agents.
233
 Therefore it could be interesting to 
synthesise arene osmium metalla-assemblies and to evaluate their antiproliferative ability as 
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well as their hosting potential. An initiation of this project was realised during this thesis with 
the synthesis of arene osmium metalla-rectangles.
234
 
If the replacement of ruthenium by osmium, or by other transition metals is relatively 
easy and imaginable, the construction of hetero-metallic dinuclear metalla-clips (Ru-Os, Ru-
Ir, Ru-Rh for examples) would be a very interested progress. Indeed, the mix of different 
transition metals inside a unique structure could give rise to surprising chemical and physical 
properties, but also biological properties. 
Finally, the metalla-cages and the corresponding host-guest systems developed by our 
group are synthesised via coordination-driven self-assembly and weak intermolecular 
interactions such as    stacking and hydrophobic interactions, and therefore are part of the 
vast family of the supramolecular objects. A potential direction could be then the synthesis of 
nano-objects as for example organic-organometallic catenanes. These mechanically-
interlocked molecular architectures consisting of two or more interlocked organic 
macrocycles and arene ruthenium metalla-cycles could find applications as molecular 
electronic devices or molecular sensors. We could also imagine organic-organometallic 
rotaxanes or different nano-objects where an organic macrocycle could be replaced by an 
organometallic metalla-cycle. 
Eventually, the great adaptability of arene ruthenium metalla-assemblies, the 
versatility of their properties and their unique physical and chemical behaviours allow 
numerous possible developments for the kind of host-guest systems presented in this thesis.   
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Chapter 6: Experimental  
6.1 General Remarks 
6.1.1 Solvents, Lamp and Products 
Solvents of analytical grade purchased from Acros organics or VWR International 
S.A.S were used for synthesis and not degassed prior to use. The photoreactions upon UV 
irradiation were performed with a Hg lamp (180 W). The silica used for column 
chromatography (32-63, 60Å) was purchased from Brunshwig AG. 2,4,6-tris(4-pyridyl)-
1,3,5-triazine (tpt)
235
 was synthesized according to published method. All organic starting 
materials were purchased from Acros organics, Sigma-Aldrich, Fluka, Alfa Aesar, Strem or 
TCI-Europe and used as received. The porphyrin derivatives were commercially available 
(Sigma-Aldrich, TriPorTech GmbH or Frontier Scientific) and used as received. RuCl3 
hydrate was a generous loan from Johnson-Matthey. The dimeric complexes [(η6-p-
cym)RuCl2]2,
16
 [(η6-hmb)RuCl2]2,
16
 [(η6-toluene)RuCl2]2,
236
 and [(η6-indane)RuCl2]2
237
 were 
synthesized according to published methods. [(η6-nonylbenzene)RuCl2]2 was prepared by a 
Birch-type reduction
18
 of the commercially available (Sigma-Aldrich) nonylbenzene. 
Addition of RuCl3 ∙ n H2O in ethanol to the non-isolated 3-nonylcylohexa-1,4-diene using 
standard reaction and purification conditions afforded the dimer. 
1
H NMR (400 MHz, 
CDCl3): δ (ppm) = 5.66 (dd, 4 H, Hphenyl), 5.56 (t, 2 H, Hphenyl), 5.36 (d, 4 H, Hphenyl), 2.52 (t, 4 
H, CH2), 1.53 (m, 4 H, CH2), 1.27 (m, 24 H, CH2), 0.86 (t, 6 H, CH3). 
13
C(
1
H) NMR
 
(100 
MHz, CDCl3): δ (ppm) = 102.8 (Cphenyl), 80.4 (CHphenyl), 79.9 (CHphenyl), 78.4 (CHphenyl), 33.8 
(CH2), 32.6 (CH2), 30.2 (CH2), 30.1 (CH2), 30.0 (CH2), 30.0 (CH2), 23.4 (CH2), 14.4 (CH3). 
Pyrene-G0, pyrene-G1, and pyrene-G2 were synthesised by co-worker.
197
 The arene ruthenium 
metalla-clips C0,
120
 C1,
72
 C2,
73
 C3,
73
 C4,
73
 C6,
131
 and C9
112
 were synthesized according to 
published methods. The arene ruthenium metalla-rectangles R1  R12,
110-111
 and R22
120
 were 
synthesized according to published methods. The arene ruthenium metalla-cube Q1 was 
synthesized according to published method.
205a
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6.1.2 NMR Experiments 
The 
1
H, 
13
C,
 13
C(
1
H), COSY, HSQC, 10-ppm HSQC, ROESY and DOSY NMR 
spectra were recorded on a Bruker AvanceII 400 spectrometer using the residual protonated 
solvent as internal standard. For all DOSY experiments, the temperature was regulated at 298 
or 233 K, the airflow was increased to 670 L × min
-1
, and the NMR tube was spun. The 
diffusion NMR experiments were performed with a standard pulsed-gradient stimulated echo 
(LED-PFGSTE) sequence and a bipolar gradient.
132
 DOSY Spectra were generated by using 
the TopSpin 2.0 software package (Bruker). Experimental parameters were ∆ = 50.0 ms 
(diffusion delay), and τ = 1.0 ms (gradient recovery delay), and Te = 5.0 ms (eddy current 
recovery delay). For each data set, 4096 complex points were collected, and the gradient 
dimension was sampled using 16 experiments in which the gradient strength was 
exponentially incremented from 1.0 to 50.8 G × cm
-1
. The gradient duration δ/2 was adjusted 
to observe a near complete signal loss at 50.8 G × cm
-1
. Typically, the δ/2 delay was chosen in 
the 1.2 - 2.0 ms range. A 1.0 s recycle delay was used between scans for data shown. For each 
data set, the spectral axis was processed with an exponential function (3  5 Hz line 
broadening), and Fourier transform was applied in order to obtain 4096 real points. The 
DOSY reconstruction was realised  with 256 points in the diffusion dimension. The number of 
scans ranged from 8 to 64 and was adapted to each sample. The experimental time ranged 
from 4 to 30 min.  
For the ROESY experiments, the temperature was regulated at 233 K, and the NMR 
tube was not spun. The ROESY NMR experiment was performed using a gradient selected 
ROESY experiment
238
 using the Tr-ROESY scheme for efficient TOCSY transfer 
suppression. Experimental parameters were m = 200 ms (mixing time),  = 500 s (gradient 
length), G0 = 1.0 G × cm
-1
, G1 = 3.0 G × cm
-1
, G2 = 6.0 G × cm
-1
 (gradient strength) and p = 
100 ms (selective pulse, Seduce
-1
). 8192 complex points were collected. A 3 s recycle delay 
was used. The spectral axis was processed with an exponential function (3 Hz line 
broadening), and Fourier transform was applied in order to obtain 8192 real points. The 
number of scans was 1024 and the experimental time approximately 90 min.  
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6.1.3 Analytical Instruments 
Infrared spectra were recorded as KBr pellets on a Perkin-Elmer FTIR 1720-X 
spectrometer. UV-visible absorption spectra were recorded on an Uvikon 930 
spectrophotometer using precision cells made of quartz (1 cm). Fluorescence spectra were 
recorded on a Perkin-Elmer-LS50B luminescence spectrometer using precision cells made of 
quartz (1 cm). Electrospray ionization mass spectrometry conditions were recorded on a 
Bruker APEX II 9.4-tesra FT-ICR-MS equipped with an Apollo II electrospray ion source: 
sample condition 10-50 μmol/l in methanol at 30ºC, end plate voltage 3500v, and capillary 
voltage. Elemental analyses were done by Laboratoire de chimie pharmaceutique de 
l’Université de Genève (Switzerland) or by Mikroelementar-analytisches Laboratorium de 
ETH Zürich (Switzerland). 
6.1.4 Biological Studies 
All the biological studies were performed by the group of Professor Dyson (EPFL).  
Culture and Inhibition of Cell Growth. Human A2780 ovarian carcinoma cells were 
obtained from the European Centre of Cell Cultures (ECACC, Salisbury, UK) and maintained 
in culture as described by the provider. The cells were routinely grown in RPMI 1640 
medium containing 10% foetal calf serum (FCS) and antibiotics at 37°C and 5% CO2. For the 
evaluation of growth inhibition tests, the cells were seeded in 96-well plates (25000 cells per 
well) and grown for 24 h in complete medium. Compounds were added to the required 
concentration and added to the cell culture for 72 h incubation. Solutions of the compounds 
were applied by diluting a freshly prepared stock solution of the corresponding compound in 
DMSO, with the final concentration of 0.05 % in the medium. The 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) test was performed in the last 2 h without 
changing the culture medium. Following drug exposure, MTT (from Sigma) was added to the 
cells at a final concentration of 0.2 mg/ml and incubated for 2 h, then the culture medium was 
aspirated and the violet formazan precipitate dissolved in DMSO. The optical density was 
quantified at 540 nm using a multiwell plate reader (iEMS Reader MF, Labsystems, USA), 
and the percentage of surviving cells was calculated from the ratio of absorbance of treated to 
untreated cells. The IC50 values for the inhibition of cell growth were determined by fitting 
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the plot of the percentage of surviving cells against the drug concentration using a sigmoidal 
function (Origin v7.5). 
Microscopy Experiments. Cells were grown for 24 h on chambered coverglass (Lab-Tek, 
NUNC) slides in complete medium at a density of 1.10
4
 and later exposed to the appropriate 
compound at 37°C in the dark. Cells were stained with lysotracker Red DND-99 (Invitrogen, 
Molecular Probes) and 10 kDa FITC-dextran (Invitrogen, Molecular Probes) for 30 min at 
37°C. Excess complex was washed away with PBS, fixed with 4% formaldehyde in PBS for 
30 min in the dark and rinsed twice with PBS before observation. Cells were mounted in PBS 
before being observed by confocal microscopy using a Zeiss LSM 700 inverted microscope 
equipped with a 40X oil immersion objective. Filters used for excitation and detection of 
fluorescent guest molecule were 405 nm and 492 nm respectively, 488 nm and 559 nm for 
detection of FITC-dextran, 555 nm and 587 nm for detection of lysotracker Red DND-99. 
Fluorescence signal intensities were evaluated using Zen
©
 software (Carl Zeiss MicroImaging 
GmbH). 
Flow Cytometry. Cells were detached from culture with EDTA (0.48 mM in PBS) and 
incubated at 1 × 10
6
 cells/mL with complex salts (added from a concentrated DMSO stock) 
under conditions described above and then placed on ice. The fluorescence of ∼20000 cells 
was measured using a BD LSR II analyser, exciting with the 355 nm laser for fluorescent 
guest molecule. Emission was observed at 45040 nm. Fluorescence data were analysed using 
the FlowJo 8 software. 
Inhibition of Endocytosis. Wortmannin (Applichem GmbH) was dissolved in DMSO and 
diluted to 500 nM in the culture medium. Cells were pre-incubated for 30 min either at 4 °C 
or with wortmannin at 37 °C before adding complex salts for 4 hours. 
6.1.5 DNA Interactions 
FID studies were performed by the group of Dr. Vilar (Imperial College of London).  
Stock solution preparation. Complexes Q4 and Q6 were dissolved in acetone to give 10 mM 
stock solutions. Complexes Q9 and Q10 were dissolved in acetone to give 1 mM stock 
solutions. Thiazole Orange (TO, Sigma-Aldrich) was prepared as a 10 mM stock solution in 
DMSO. These stock solutions were freshly prepared prior to use and were further diluted to 
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final concentrations using 60 mM potassium cacodylate buffer (pH 7.4) (the potassium 
cacodylate buffer also contains 50 mM KCl). 
Fluorescence Intercalator Displacement (FID) assay. The FID assays were performed on a 
Varian Cary Eclipse Spectrometer following a reported procedure.
224
 The oligonucleotides 22 
AG human telomeric DNA, 5’-AGGG TTA GGG TTA GGG TTA GGG-3’; 17bp duplex-
DNA: [5’-CCAGTTCGTAGTAACCC-3’]/[5’-GGGTTACTACGAACTGG- 3’]; and 21bp c-
myc: 5’-GGG-GAG-GGT-GGG-GAG-GGT-GGG-3’ were purchased from Eurogentec and 
used without any further purification. The corresponding oligonucleotides were dissolved in 
MilliQ water to yield 20 μM stock solutions. These were diluted to yield 500 nM solutions 
using a 60 mM potassium cacodylate buffer (pH 7.4) and annealed to 90
o 
C for 5 min and then 
allowed to cool at room temperature overnight. An increasing concentration of the metal 
complex (ligand) (from 0.125 µM to 2.5 µM which correspond to 0.5 to 10 equivalent) was 
added onto a mixture of pre-folded G-quadruplex DNA (0.25 μM of either Htelo or c-myc) or 
duplex DNA (17bp, 0.25 μM) and thiazole orange (0.50 μM), in a 60 mM potassium 
cacodylate (pH 7.4). After 3 minutes equilibration time, the corresponding emission spectrum 
(between 510 and 750 nm) with an excitation wavelength of 501 nm was recorded. The 
fluorescence area (FA, 510-750 nm) of each spectrum obtained was converted to percentage 
of displacement in which % TO displacement = 100 – [(fluorescence area upon ligand 
addition /fluorescence area of standard) × 100], where fluorescence area of standard being 
fluorescence area before addition of ligand. The FA was plotted against the concentration of 
added ligand, from which the ability of ligand to induce TO displacement is expressed as 
DC50 (
Htelo
DC50 for Htelo DNA, 
ds
DC50 for duplex DNA and 
c-myc
DC50 for c-myc DNA) value 
which is the required concentration to displace 50% of TO from the DNA (either Htelo, c-myc 
or duplex DNA). The selectivities for Htelo- and c-myc-DNA over duplex-DNA are expressed 
by 
ds
DC50 /
HteloDC50 value and 
ds
DC50 /
c-myc
DC50 value, respectively. 
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6.2 Syntheses and Characterisations 
6.2.1 Arene Ruthenium Metalla-Clips C5, C7, C9, C10, C11, and C12 
General procedure for metalla-clips C5 and C7: A mixture of [(η
6
-p-cym)RuCl2]2 (145.0 mg, 
0.23 mmol), anhydrous sodium acetate (38.4 mg, 0.46 mmol) and quinone derivative (C5: 5,8-
dihydroxy-1,4-naphthoquinone (43.7 mg, 0.23 mmol); C7: 6,11-dihydroxy-5,12-
naphtacenedione (66.8 mg, 0.23 mmol) in ethanol (25 mL) is stirred at reflux for 12 h, then 
the precipitate is filtered and washed with ethanol, water, acetone, diethyl ether and pentane to 
afford green (C5) and blue (C7) solids. 
C5: Yield 154 mg (92 %): UV-vis (1.0 × 10
-5
 M, CHCl3): λmax 354 nm (ε = 1.17 × 10
4
 M
-1∙cm-
1), λmax 439 nm (ε = 1.50 × 10
4
 M
-1
·cm
-1), λmax 483 nm (ε = 1.30 × 10
4
 M
-1
·cm
-1), λmax 520 nm 
(ε = 1.30 × 104 M-1·cm-1), λmax 719 nm (ε = 0.80 × 10
4
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3071 (w, 
CHaryl), 1535 (s, C=O). 
1
H NMR (400 MHz, CDCl3): δ = 6.98 (s, 4 H, Hq), 5.50 (d, 4 H, 
Hcym), 5.23 (d, 4 H, Hcym), 2.87 (sept, 2 H, CH(CH3)2), 2.16 (s, 6 H, CH3), 1.58 (d, 12 H, 
CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CDCl3): δ = 170.9 (CO), 137.0 (CHq), 111.9 (Cq), 
100.3 (Ccym), 98.0 (Ccym), 82.8 (CHcym), 79.6 (CHcym), 30.7 (CH(CH3)2), 22.4 (CH(CH3)2), 
17.9 (CH3) ppm. Anal. Calc. for C30H32Cl2O4Ru2 (729.6): C 49.38, H 4.42; Found: C 49.39, H 
4.37. 
C7: Yield 177 mg (93 %): UV-vis (1.0 × 10
-5
 M, CHCl3): λmax 326 nm (ε = 3.06 × 10
4
 M
-1∙cm-
1), λmax 384 nm (ε = 2.04 × 10
4
 M
-1
·cm
-1), λmax 416 nm (ε = 1.02 × 10
4
 M
-1
·cm
-1), λmax 594 nm 
(ε = 1.19 × 104 M-1·cm-1), λmax 648 nm (ε = 0.16 × 10
4
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3055 (w, 
CHaryl), 1546 (s, C=O). 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 8.50 (d, 4 H, Hq), 7.72 (d, 4 
H, Hq), 5.68 (d, 4 H, Hcym), 5.33 (d, 4 H, Hcym), 3.06 (sept, 2 H, CH(CH3)2), 2.42 (s, 6 H, 
CH3), 1.57 (d, 12 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CDCl3): δ (ppm) = 169.4 (CO), 
134.5 (CHq), 131.1 (CHq), 126.8 (Cq), 99.8 (Ccym), 97.4 (Ccym), 83.1 (CHcym), 79.3 (CHcym), 
30.9 (CH(CH3)2), 23.0 (CH(CH3)2), 18.0 (CH3). Anal. Calc. for C38H36Cl2O4Ru2 (829.7): C 
55.01, H 4.37; Found: C 55.98, H 4.98. 
Procedure for metalla-clip C9: n-BuLi (0.30 mL, 0.48 mmol) is added to a solution of N,N′-
dimethyloxamide (27.9 mg, 0.24 mmol) in THF (15 mL) at -78°C. The reaction mixture is 
stirred and warmed to room temperature (2 h). Then the mixture is added to a solution of [(η6-
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p-cym)RuCl2]2 (146.9 mg, 0.24 mmol) in THF (5 mL), and stirred overnight. The solvent is 
evaporated and the product is washed with water and pentane. 
C9: Yield 96 mg (61 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 306 nm (ε = 2.96 × 10
5
 M
-1∙cm-
1
). IR (KBr, cm
-1
): 3060 (w, CHaryl), 1609 (s, C=O). 
1
H NMR (400 MHz, CD2Cl2): δ (ppm) = 
5.35 (d, 2 H, Hcym), 5.32 (d, 2 H, Hcym), 5.26 (d, 2 H, Hcym), 5.06 (d, 2 H, Hcym), 3.27 (s, 6 H, 
CH3), 2.71 (sept, 2 H, CH(CH3)2), 2.12 (s, 6 H, CH3), 1.21 (d, 6 H, CH(CH3)2), 1.19 (d, 6 H, 
CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD2Cl2): δ (ppm) = 170.3 (CO), 100.8 (Ccym), 95.8 
(Ccym), 81.9 (CHcym), 81.3 (CHcym), 80.9 (CHcym), 79.6 (CHcym), 38.0 (CH3), 31.5 (CH(CH3)2), 
22.6 (CH(CH3)2), 22.5 (CH(CH3)2), 18.7 (CH3). Anal. Calc. for C24H34Cl2N2O2Ru2 (655.6): C 
43.97, H 5.23, N 4.27; Found: C 43.86, H 5.22, N 4.27. 
General procedure for metalla-clips C10 and C11: A mixture of [(η
6
-arene)RuCl2]2 (C10: 
indane, 500 mg, 0.86 mmol; C11: nonylbenzene, 647 mg, 0.86 mmol) and 2,5-dihydroxy-1,4-
benzoquinone (120 mg, 0.86 mmol) in ethanol (100 mL) was stirred at reflux for 24 h, then 
filtered. The black precipitate was washed with cold ethanol, pentane, and dried under 
vacuum. 
C10: Yield 528 mg (95 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 268 nm (ε = 2.83 × 10
4
 M
-
1
·cm
-1
). IR (KBr, cm
-1
): 3070 (w, CHaryl), 1629 (s, C=O). 
1
H NMR (400 MHz, CDCl3): δ 
(ppm) = 6.31 (d, 8 H, Hindane), 6.22 (d, 8 H, Hindane), 6.15 (s, 8 H, Hq), 6.12 (t, 8 H, Hindane), 
6.05 (t, 8 H, Hindane), 3.06 (m, 16 H, CH2indane), 2.95 (m, 8 H, CH2indane). 
13
C(
1
H) NMR (100 
MHz, CDCl3): δ (ppm) = 184.0 (CO), 104.2 (Cindane), 103.7 (Cindane), 102.0 (CHq), 83.0 
(CHindane), 82.7 (CHindane), 82.5 (CHindane), 82.4 (CHindane), 30.3 (CH2indane), 23.4 (CH2indane). 
Anal. Calc. for C24H22Cl2O4Ru2 (647.5): C 44.52, H 3.42; Found: C 44.46, H 3.32. 
C11: Yield 690 mg (98 %). UV-vis (1.0 × 10
-5
 M, (CH2Cl2): λmax 275 nm (ε = 2.81 × 10
4
 M
-
1
·cm
-1
). IR (KBr, cm
-1
): 3068 (w, CHaryl), 1630 (s, C=O). 
1
H NMR (400 MHz, CDCl3): δ 
(ppm) = 5.65 (dd, 4 H, Hphenyl), 5.56 (t, 2 H, Hphenyl), 5.37 (d, 4 H, Hphenyl), 2.51 (t, 4 H, CH2), 
1.53 (m, 4 H, CH2), 1.27 (m, 24 H, CH2), 0.85 (t, 6 H, CH3). 
13
C(
1
H) NMR (100 MHz, 
CDCl3): δ (ppm) = 184.2 (CO), 102.5 (Cphenyl), 80.5 (CHphenyl), 79.9 (CHphenyl), 78.4 
(CHphenyl), 33.8 (CH2), 32.8 (CH2), 30.2 (CH2), 30.1 (CH2), 30.0 (CH2), 29.9 (CH2), 23.4 
(CH2), 14.5 (CH3). Anal. Calc. for C36H50Cl2O4Ru2 (819.8): C 52.74, H 6.15; Found: C 52.66, 
H 5.97. 
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Procedure for metalla-clip C12: A mixture of [Ru(
6
-C6H5Me)2Cl2]2 (500 mg, 0.95 mmol) and 
2,5-dihydroxy-1,4-benzoquinone (133 mg, 0.95 mmol) in MeOH (100 mL) is stirred at room 
temperature for 2 h, then filtered. The blood-red precipitate is filtered, washed with diethyl 
ether, and dried under vacuum.  
C12: Yield 452 mg (80 %). UV-vis (1.0 × 10
-5
 M, (CH2Cl2): λmax 280 nm (ε = 3.1 × 10
4
 M
-
1
·cm
-1
). IR (KBr, cm
-1
): 3054 (w, CHaryl), 1506 (s, C=O), 1269 (s, CH3). 
1
H NMR (400 MHz, 
(CD3)2SO): δ (ppm) = 7.20 (m, 2 H, Hq), 6.14 (m, 2 H, Htol), 5.70 (m, 3 H, Htol), 2.13 (s, 6 H, 
CH3). 
13
C(
1
H) NMR (100 MHz, (CD3)2SO): δ (ppm) = 175.5 (CO), 175.2 (CO), 128.7 (CHq), 
95.5 (CCH3), 89.4 (CHtol), 84.8 (CHtol), 82.2 (CHtol), 16.1 (CH3). Anal. Calc. for 
C20H18Cl2O4Ru2 (595.4): C 40.34, H 3.02; Found: C 40.57, H 3.32. 
6.2.2 Arene Ruthenium Metalla-Rectangles R13  R32 
General procedure for metalla-rectangles R13  R21: A mixture of one equivalent of C5  C7 
(0.21 mmol), two equivalents of silver trifluoromethanesulfonate (0.43 mmol) and one 
equivalent of the corresponding N∩N linker (0.21 mmol) in methanol (40 mL) is stirred at 
60°C for 24 hours and then the solution is filtered to remove silver chloride. The solvent is 
removed under vacuum and the residue is taken up in dichloromethane (3 mL) and diethyl 
ether is added to precipitate the products as green or blue solids. 
R13: Yield 191 mg (85 %): UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 306 nm (ε = 3.60 × 10
5
 M
-
1
.cm
-1), λmax 434 nm (ε = 0.27 × 10
5
 M
-1
.cm
-1), λmax 633 nm (ε = 0.12 × 10
5
 M
-1
.cm
-1), λmax 
692 nm (ε = 0.12 × 105 M-1.cm-1). IR (KBr, cm-1): 3066 (w, CHaryl), 1538 (s, C=O), 1263 (s, 
CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.56 (s, 8 H, Hpyrazine), 7.17 (s, 8 H, Hq), 5.77 
(d, 8 H, Hcym), 5.72 (d, 8 H, Hcym), 2.85 (sept, 2 H, CH(CH3)2), 2.14 (s, 12 H, CH3), 1.47 (d, 
24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 171.0 (CO), 148.8 
(CHpyrazine), 137.4 (CHq), 111.5 (Cq), 105.3 (Ccym), 100.0 (Ccym), 84.1 (CHcym), 84.0 (CHcym), 
30.8 (CH(CH3)2), 21.9 (CH(CH3)2), 16.8 (CH3). Anal. Calc. for C72H72F12N4O20Ru4S4 
(2073.8): C 41.70, H 3.49, N 2.70; Found: C 41.02, H 3.16, N, 2.38. 
R14: Yield 169 mg (74 %): UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 304 nm (ε = 3.52 × 10
5
 M
-
1∙cm-1), λmax 442 nm (ε = 0.25 × 10
5
 M
-1∙cm-1), λmax 625 nm (ε = 0.12 × 10
5
 M
-1∙cm-1), λmax 
696 nm (ε = 0.11 × 105 M-1∙cm-1). IR (KBr, cm-1): 3055 (w, CHaryl), 1546 (s, C=O), 1261 (s, 
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CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.82 (d, 2 H, Hq), 8.59 (d, 2 H, Hq’), 8.58 (s, 8 
H, Hpyrazine), 7.93 (d, 2 H, Hq), 7.82 (d, 2 H, Hq’), 7.17 (s, 2 H, Hq), 7.05 (s, 2 H, Hq’), 5.91 (d, 
4 H, Hcym), 5.86 (d, 4 H, Hcym), 5.82 (m, 8 H, Hcym), 2.82 (sept, 4 H, CH(CH3)2), 2.13 (s, 12 H, 
CH3), 1.45 (d, 24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 172.3 (CO), 
171.2 (CO), 145.7 (CHpyrazine), 139.2 (CHq), 132.7 (CHq), 133.3 (Cq), 133.0 (Cq), 128.1 (CHq), 
104.2 (Ccym), 100.1 (Ccym), 85.9 (CHcym), 85.1 (CHcym), 83.2 (CHcym), 83.8 (CHcym), 31.5 
(CH(CH3)2), 22.7 (CH(CH3)2), 17.6 (CH3). Anal. calc. for C80H76F12N4O20Ru4S4 (2173.4): C 
44.21, H 3.52, N 2.58; Found: C 43.05, H 3.22, N, 2.41. 
R15: Yield 178 mg (73 %): UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 312 nm (ε = 3.68 × 10
5
 M
-
1∙cm-1), λmax 380 nm (ε = 0.42 × 10
5
 M
-1∙cm-1), λmax 530 nm (ε = 0.14 × 10
5
 M
-1∙cm-1), λmax 
568 nm (ε = 0.21 × 105 M-1∙cm-1), λmax 613 nm (ε = 0.24 × 10
5
 M
-1∙cm-1). IR (KBr, cm-1): 
3060 (w, CHaryl), 1542 (s, C=O), 1260 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.57 
(d, 8 H, Hq), 8.47 (s, 8 H, Hpyrazine), 7.82 (d, 8 H, Hq), 5.90 (d, 8 H, Hcym), 5.76 (d, 8 H, Hcym), 
2.93 (sept, 4 H, CH(CH3)2), 2.16 (s, 12 H, CH3), 1.29 (d, 24 H, CH(CH3)2). 
13
C(
1
H) NMR 
(100 MHz, CD3CN): δ (ppm) = 169.9 (CO), 149.4 (CHpyrazine), 134.2 (CHq), 128.4 (CHq), 
107.8 (Cq), 107.8 (Ccym), 106.1 (Ccym), 100.7 (Cq), 84.6 (CHcym), 84.5 (CHcym), 31.3 
(CH(CH3)2), 22.4 (CH(CH3)2), 17.8 (CH3). Anal. calc. for C88H80F12N4O20Ru4S4 (2273.50): C 
46.49, H 3.52, N 2.46; Found: C 47.65, H 3.78, N 2.80. 
R16: Yield 180 mg (77 %): UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 306 nm (ε = 3.58 × 10
5
 M
-
1
.cm
-1), λmax 434 nm (ε = 0.25 × 10
5
 M
-1
.cm
-1), λmax 633 nm (ε = 0.11 × 10
5
 M
-1
.cm
-1), λmax 
692 nm (ε = 0.11 × 105 M-1.cm-1). IR (KBr, cm-1): 3070 (w, CHaryl), 1536 (s, C=O), 1261 (s, 
CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.43 (s, 8 H, Hbipyridine), 7.69 (d, 8 H, 
Hbipyridine), 7.17 (s, 8 H, Hq), 5.69 (d, 8 H, Hcym), 5.48 (d, 8 H, Hcym), 2.83 (sept, 4 H, 
CH(CH3)2), 2.16 (s, 12 H, CH3), 1.37 (d, 24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, 
CD3CN): δ (ppm) = 171.9 (CO), 153.9 (CHbipyridine), 145.8 (Cbipyridine), 138.4 (CHq), 123.9 
(CHbipyridine), 114.8 (Cq), 104.7 (Ccym), 100.5 (Ccym), 85.2 (CHcym), 84.0 (CHcym), 31.5 
(CH(CH3)2), 23.1 (CH(CH3)2), 17.3 (CH3). Anal. calc. for C84H80F12N4O20Ru4S4 (2226.0): C 
45.32, H 3.62, N 2.52; Found: C 44.82, H 3.48, N 2.42. 
R17: Yield 192 mg (77 %): UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 312 nm (ε = 3.58 × 10
5
 M
-
1∙cm-1), λmax 418 nm (ε = 0.39 × 10
5
 M
-1∙cm-1), λmax 608 nm (ε = 0.16 × 10
5
 M
-1∙cm-1), λmax 
658 nm (ε = 0.18 × 105 M-1∙cm-1). IR (KBr, cm-1): 3069 (w, CHaryl), 1539 (s, C=O), 1260 (s, 
CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.62 (m, 4 H, Hq + Hq’), 8.46 (d, 8 H, Hα), 7.93 
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(m, 4 H, Hq + Hq’), 7.60 (d, 8 H, Hβ), 7.21 (s, 2 H, Hq), 7.20 (s, 2 H, Hq’), 5.78 (d, 4 H, Hcym), 
5.73 (d, 4 H, Hcym), 5.56 (m, 8 H, Hcym), 2.85 (sept, 4 H, CH(CH3)2), 2.11 (s, 12 H, CH3), 1.30 
(d, 24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 171.2 (CO), 170.3 (CO), 
153.8 (CHα), 145.7 (Cbipy), 138.7 (CHq), 134.4 (CHq), 134.0 (Cq), 133.9 (Cq), 128.3 (CHq), 
123.9 (CHβ), 104.6 (Ccym), 100.5 (Ccym), 85.2 (CHcym), 84.9 (CHcym), 83.7 (CHcym), 83.7 
(CHcym), 31.4 (CH(CH3)2), 22.5 (CH(CH3)2), 17.6 (CH3). Anal. calc. for 
C92H84F12N4O20Ru4S4 (2325.55): C 47.52, H 3.61, N 2.41; Found: C 45.48, H 3.27, N 2.21. 
R18: Yield 211 mg (81 %): UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 312 nm (ε = 3.58 × 10
5
 M
-
1∙cm-1), λmax 384 nm (ε = 0.34 × 10
5
 M
-1∙cm-1), λmax 533 nm (ε = 0.14 × 10
5
 M
-1∙cm-1), λmax 
573 nm (ε = 0.19 × 105 M-1∙cm-1), λmax 618 nm (ε = 0.20 × 10
5
 M
-1∙cm-1). IR (KBr, cm-1): 
3071 (w, CHaryl), 1543 (s, C=O), 1262 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.69 
(d, 8 H, Hq), 7.93 (d, 8 H, Hα), 7.57 (d, 8 H, Hβ), 7.52 (d, 8 H, Hq), 5.85 (d, 8 H, Hcym), 5.63 
(d, 8 H, Hcym), 2.88 (sept, 4 H, CH(CH3)2), 2.16 (s, 12 H, CH3), 1.37 (d, 24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 170.0 (CO), 153.7 (CHα), 134.5 (Cbipy), 134.0 
(CHq), 128.2 (CHβ), 123.9 (CHq), 108.0 (Cq), 104.7 (Ccym), 100.7 (Ccym), 85.1 (CHcym), 83.5 
(CHcym), 31.4 (CH(CH3)2), 22.4 (CH(CH3)2), 17.8 (CH3). Anal. calc. for 
C100H88F12N4O20Ru4S4 (2425.64): C 49.52, H 3.63, N 2.31; Found: C 51.20, H 3.75, N 2.80. 
R19: Yield 178 mg (73 %): UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 314 nm (ε = 3.76 × 10
5
 M
-
1
.cm
-1), λmax 438 nm (ε = 0.33 × 10
5
 M
-1
.cm
-1), λmax 608 nm (ε = 0.14 × 10
5
 M
-1
.cm
-1), λmax 
650 nm (ε = 0.13 × 105 M-1.cm-1), 713 nm (ε = 0.13 × 105 M-1.cm-1). IR (KBr, cm-1): 3067 (w, 
CHaryl), 1537 (s, C=O), 1272 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.28 (d, 8 H, 
Hpyridine), 7.45 (d, 8 H, Hpyridine), 7.31 (s, 4 H, HC=C), 7.15 (s, 8 H, Hq), 5.66 (d, 8 H, Hcym), 5.46 
(d, 8 H, Hcym), 2.79 (sept, 4 H, CH(CH3)2), 2.17 (s, 12 H, CH3), 1.29 (d, 24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 171.8 (CO), 153.2 (CHpyridine), 146.9 (Cpyridine), 
138.3 (CHq), 132.1 (Cethylene), 124.2 (CHpyridine), 112.3 (Cq), 104.5 (Ccym), 100.2 (Ccym), 85.1 
(CHcym), 84.0 (CHcym), 31.4 (CH(CH3)2), 22.3 (CH(CH3)2), 17.3 (CH3). Anal. calc. for 
C88H84F12N4O20Ru4S4 (2278.0): C 46.40, H 3.72, N 2.46; Found: C 45.59, H 3.32, N 2.60. 
R20: Yield 189 mg (74 %): UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 313 nm (ε = 3.75 × 10
5
 M
-
1∙cm-1), λmax 416 nm (ε = 0.35 × 10
5
 M
-1∙cm-1), λmax 608 nm (ε = 0.14 × 10
5
 M
-1∙cm-1), λmax 
658 nm (ε = 0.16 × 105 M-1∙cm-1). IR (KBr, cm-1): 3068 (w, CHaryl), 1538 (s, C=O), 1260 (s, 
CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.63 (m, 4 H, Hq + Hq’), 8.33 (d, 8 H, Hα), 7.92 
(m, 4 H, Hq + Hq’), 7.38 (d, 8 H, Hβ), 7.23 (s, 4 H, HC=C), 7.18 (s, 2 H, Hq), 7.17 (s, 2 H, Hq’), 
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5.76 (d, 4 H, Hcym), 5.69 (d, 4 H, Hcym), 5.53 (d, 4 H, Hcym), 5.51 (d, 4 H, Hcym), 2.85 (sept, 4 
H, CH(CH3)2), 2.11 (s, 12 H, CH3), 1.29 (d, 24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, 
CD3CN): δ (ppm) = 171.3 (CO), 170.4 (CO), 153.1 (CHα), 146.8 (Cethylene), 138.6 (CHq), 
134.2 (CHq), 134.1 (Cq), 132.0 (Cq), 128.3 (CHq), 128.2 (CH=CH), 124.1 (CHβ), 110.6 (CF3), 
104.5 (Ccym), 100.3 (Ccym), 85.1 (CHcym), 84.8 (CHcym), 83.8 (CHcym), 83.7 (CHcym), 31.4 
(CH(CH3)2), 22.5 (CH(CH3)2), 17.6 (CH3). Anal. calc. for C96H88F12N4O20Ru4S4 (2377.61): C 
48.50, H 3.70, N 2.35; Found: C 46.87, H 3.96, N 2.62. 
 R21: Yield 199 mg (75 %): UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 315 nm (ε = 3.84 × 10
5
 M
-
1∙cm-1), λmax 382 nm (ε = 0.46 × 10
5
 M
-1∙cm-1), λmax 531 nm (ε = 0.12 × 10
5
 M
-1∙cm-1), λmax 
570 nm (ε = 0.20 × 105 M-1∙cm-1), λmax 618 nm (ε = 0.24 × 10
5
 M
-1∙cm-1). IR (KBr, cm-1): 
3070 (w, CHaryl), 1543 (s, C=O), 1259 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.69 
(d,
 
8 H, Hq), 8.37 (d, 8 H, Hα), 7.92 (d, 8 H, Hq), 7.30 (d, 8 H, Hβ), 7.14 (s, 4 H, HC=C), 5.81 
(d, 8 H, Hcym), 5.60 (d, 8 H, Hcym), 2.90 (sept, 4 H, CH(CH3)2), 2.13 (s, 12 H, CH3), 1.28 (d, 
24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 170.4 (CO), 153.0 (CHα), 
146.8 (Cethylene), 134.6 (CHq), 133.9 (Cq), 133.8 (Cq), 131.9 (CHq), 128.1 (CH=CH), 124.1 
(CHβ), 100.4 (Ccym), 84.9 (CHcym), 83.5 (CHcym), 31.4 (CH(CH3)2), 22.5 (CH(CH3)2), 17.9 
(CH3). Anal. calc. for C104H92F12N4O20Ru4S4 (2477.69): C 50.41, H 3.71, N 2.26; Found: C 
48.22, H 3.51, N 2.38. 
 General procedure for metalla-rectangles R23  R31: AgCF3SO3 (149.0 mg, 0.58 mmol) is 
added to a suspension of [(η6-p-cym)2Ru2(OO∩OO)Cl2] (OO∩OO = oxa (R23, R30; 190.1 
mg), oxo (R24, R31; 202.6 mg), ox (R25; 182.6 mg), dobq (R26; 196.9 mg), donq (R27; 211.4 
mg), doaq (R28; 225.9 mg), dotq (R29; 240.4 mg); 0.29 mmol) in methanol (100 mL) at 60 °C 
and stirred for 12 h, followed by filtration to remove AgCl. Then, 1,2-bis(4-pyridyl)ethylene 
(R23, R24; 52.8 mg, 0.29 mmol) or 1,2-bis(4-pyridyl)ethane (R25  R31; 53.4 mg, 0.29 mmol) 
is added to the filtrate. The solution is stirred at 60 °C for 24 h. The solvent is removed and 
the residue extracted with dichloromethane. The filtrate is concentrated to about 2 mL and 
diethyl ether is added. The precipitate is washed with diethyl ether (3 × 50 mL) and pentane 
(3 × 50 mL) and dried in vacuo to give the corresponding product as powder. 
R23: Yield 200 mg (65 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 269 nm (ε = 3.15 × 10
5
 M
-
1
·cm
-1), λmax 340 nm (ε = 0.61 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3070 (m, CHar), 1616 (s, 
C=O), 1256 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 7.95 (m, 8 H, Hα), 7.53 (m, 8 
H, Hβ), 7.40 (s, 4 H, HC=C), 5.80 (m, 8 H, Hcym), 5.30 (m, 8 H, Hcym), 3.51 (s, 12 H, CH3), 2.75 
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(m, 4 H, CH(CH3)2), 1.96 (s, 12 H, CH3), 1.30 (m, 24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 
MHz, CD3CN): δ (ppm) = 170.6 (CO), 152.8 (CHα), 145.8 (Cpyr), 132.0 (HC=CH), 123.4 
(CHβ), 102.4 (Ccym), 99.7 (Ccym), 86.5 (CHcym), 84.5 (CHcym), 81.7 (CHcym), 78.4 (CHcym), 
37.9 (CH3), 31.0 (CH(CH3)2), 21.6 (CH(CH3)2), 16.9 (CH3). Anal. calc. for 
C76H88F12N8O16Ru4S4 (2130.1): C 42.85, H 4.16, N 5.26; Found: C 42.76, H 4.30, N 5.18. 
R24: Yield 208 mg (65 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 265 nm (ε = 3.00 × 10
5
 M
-
1
·cm
-1), λmax 331 nm (ε = 0.51 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3077 (m, CHar), 1712 (s, 
C=N), 1612 (s, C=O), 1259 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 7.95 (m, 8 H, 
Hα), 7.53 (m, 8 H, Hβ), 7.40 (s, 4 H, HC=C), 5.80 (m, 8 H, Hcym), 5.30 (m, 8 H, Hcym), 3.51 (s, 
12 H, CH3), 2.75 (m, 4 H, CH(CH3)2), 1.96 (s, 12 H, CH3), 1.30 (m, 24 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 178.9 (CO), 162.4 (CN), 154.6 (CHα), 146.1 
(Cpyr), 132.1 (HC=CH), 124.0 (CHβ), 106.0 (Ccym), 99.4 (Ccym), 83.9 (CHcym), 83.7 (CHcym), 
83.6 (CHcym), 80.7 (CHcym), 30.9 (CH(CH3)2), 21.5 (CH(CH3)2), 17.0 (CH3). Anal. calc. for 
C76H78F12N10O20Ru4S4 (2212.0): C 41.27, H 3.55, N 6.33; Found: C 41.20, H 3.66, N 6.22. 
R25: Yield 205 mg (68 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 267 nm (ε = 2.89 × 10
5
 M
-
1
·cm
-1
). IR (KBr, cm
-1
): 3070 (m, CHar), 1533 (s, C=O), 1259 (s, CF3). 
1
H NMR (400 MHz, 
CD3CN): δ (ppm) = 7.74 (d, 8 H, Hα), 7.00 (d, 8 H, Hβ), 5.82 (d, 8 H, Hcym), 5.69 (d, 8 H, 
Hcym), 3.25 (s, 8 H, Hbpa), 2.80 (sept, 4 H, CH(CH3)2), 2.15 (s, 12 H, CH3), 1.30 (d, 24 H, 
CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 173.0 (CO), 151.8 (CHα), 145.2 
(Cpyr), 127.3 (CHβ), 100.2 (Ccym), 98.7 (Ccym), 84.9 (CHcym), 83.7 (CHcym), 33.0 (CHbpa), 32.2 
(CH(CH3)2), 22.7 (CH(CH3)2), 19.2 (CH3). Anal. calc. for C72H80F12N4O20Ru4S4 (2081.9): C 
41.54, H 3.87, N 2.69; Found: C 41.45, H 4.03, N 2.65. 
R26: Yield 259 mg (82 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 265 nm (ε = 3.01 × 10
5
 M
-
1
·cm
-1), λmax 317 nm (ε = 0.46 × 10
5
 M
-1
·cm
-1), λmax 510 nm (ε = 0.43 × 10
5
 M
-1
·cm
-1
). IR 
(KBr, cm
-1
): 3068 (m, CHar), 1530 (s, C=O), 1260 (s, CF3). 
1
H NMR (400 MHz, CD3CN) : δ 
(ppm) = 7.78 (d, 8 H, Hα), 7.13 (d, 8 H, Hβ), 5.92 (d, 8 H, Hcym), 5.86 (d, 8 H, Hcym), 5.48 (s, 4 
H, Hq), 3.26 (s, 8 H, Hbpa), 2.85 (sept, 4 H, CH(CH3)2), 2.10 (s, 12 H, CH3), 1.30 (d, 24 H, 
CH(CH3)2).
 13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 171.4 (CO), 153.2 (CHα), 150.7 
(Cpyr), 130.1 (CHβ), 114.6 (CHq), 108.2 (Cq), 102.1 (Ccym), 99.8 (Ccym), 84.2 (CHcym), 84.0 
(CHcym), 29.3 (CHbpa), 30.0 (CH(CH3)2), 20.9 (CH(CH3)2), 17.4 (CH3). Anal. calc. for 
C80H84F12N4O20Ru4S4 (2182.1): C 44.03, H 3.88, N 2.57; Found: C 43.92, H 4.00, N 2.50. 
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R27: Yield 248 mg (75 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 266 nm (ε = 2.99 × 10
5
 M
-
1
·cm
-1), λmax 327 nm (ε = 0.30 × 10
5
 M
-1
·cm
-1
), λmax 454 nm (ε = 0.22 × 10
5
 M
-1
·cm
-1), λmax 
720 nm (ε = 0.08 × 105 M-1·cm-1). IR (KBr, cm-1): 3070 (m, CHar), 1529 (s, C=O), 1259 (s, 
CF3). 
1
H NMR (400 MHz, CD3CN) : δ (ppm) = 7.94 (d, 8 H, Hα), 7.03 (d, 8 H, Hβ), 6.96 (s, 8 
H, Hq), 5.66 (d, 8 H, Hcym), 5.44 (d, 8 H, Hcym), 3.21 (s, 8 H, Hbpa), 2.82 (sept, 4 H, 
CH(CH3)2), 2.10 (s, 12 H, CH3), 1.30 (d, 24 H, CH(CH3)2).
 13
C(
1
H) NMR (100 MHz, 
CD3CN): δ (ppm) = 170.3 (CO), 152.9 (CHα), 151.9 (Cpyr), 137.2 (CHβ), 125.8 (CHq), 111.3 
(Cq), 103.4 (Ccym), 99.0 (Ccym), 83.7 (CHcym), 82.8 (CHcym), 31.1 (CHbpa), 30.6 (CH(CH3)2), 
21.4 (CH(CH3)2), 16.5 (CH3). Anal. calc. for C88H88F12N4O20Ru4S4 (2282.2): C 46.31, H 3.89, 
N 2.45; Found: C 46.16, H 3.99, N 2.39. 
R28: Yield 266 mg (77 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 264 nm (ε = 3.01 × 10
5
 M
-
1
·cm
-1), λmax 324 nm (ε = 0.32 × 10
5
 M
-1
·cm
-1), λmax 417 nm (ε = 0.25 × 10
5
 M
-1
·cm
-1), λmax 
683 nm (ε = 0.13 × 105 M-1·cm-1). IR (KBr, cm-1): 3070 (m, CHar), 1528 (s, C=O), 1260 (s, 
CF3). 
1
H NMR (400 MHz, CD3CN) : δ (ppm) = 8.46 (d, 8 H, Hα), 8.01 (d, 8 H, Hβ), 7.90 (m, 
4 H, Hq), 7.06 (s, 4 H, Hq), 5.78 (d, 4 H, Hcym), 5.73 (d, 4 H, Hcym), 5.54 (d, 4 H, Hcym), 5.50 
(d, 4 H, Hcym), 3.21 (s, 8 H, Hbpa), 2.92 (sept, 4 H, CH(CH3)2), 2.11 (s, 12 H, CH3), 1.34 (d, 12 
H, CH(CH3)2), 1.30 (d, 12 H, CH(CH3)2).
 13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 171.5 
(CO), 170.7 (CO), 155.4 (CHα), 151.9 (Cpyr), 139.9 (CHq), 138.3 (CHβ), 136.6 (CHq), 134.3 
(Cq), 132.0 (Cq), 128.2 (CHq), 104.7 (Ccym), 100.3 (Ccym), 85.4 (CHcym), 84.8 (CHcym), 83.9 
(CHcym), 82.0 (CHcym), 29.2 (CHbpa), 31.2 (CH(CH3)2), 21.2 (CH(CH3)2), 21.0 (CH(CH3)2), 
17.0 (CH3). Anal. calc. for C96H92F12N4O20Ru4S4 (2382.3): C 48.40; H 3.89; N 2.35; Found: C 
48.22; H 4.001; N, 2.30. 
R29: Yield 255 mg (71 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 267 nm (ε = 3.07 × 10
5
 M
-
1
·cm
-1), λmax 327 nm (ε = 0.44 × 10
5
 M
-1
·cm
-1), λmax 379 nm (ε = 0.38 × 10
5
 M
-1
·cm
-1), λmax 
409 nm (ε = 0.29 × 105 M-1·cm-1), λmax 588 nm (ε = 0.16 × 10
5
 M
-1
·cm
-1), λmax 636 nm (ε = 
0.19 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3068 (m, CHar), 1532 (s, C=O), 1260 (s, CF3). 
1
H NMR 
(400 MHz, CD3CN) : δ (ppm) = 8.53 (d, 8 H, Hα), 7.97 (d, 8 H, Hq), 7.89 (d, 8 H, Hβ), 6.88 (d, 
8 H, Hq), 5.85 (d, 8 H, Hcym), 5.61 (d, 8 H, Hcym), 3.33 (s, 8 H, Hbpa), 3.00 (sept, 4 H, 
CH(CH3)2), 2.12 (s, 12 H, CH3), 1.37 (d, 24 H, CH(CH3)2).
 13
C(
1
H) NMR (100 MHz, 
CD3CN): δ (ppm) = 170.4 (CO), 153.1 (CHα), 152.5 (Cpyr), 139.1 (CHβ), 134.7 (CHq), 133.6 
(Cq), 133.5 (Cq), 132.4 (CHq), 100.2 (Ccym), 96.0 (Ccym), 84.7 (CHcym), 83.9 (CHcym), 32.3 
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(CHbpa), 31.3 (CH(CH3)2), 19.8 (CH(CH3)2), 17.0 (CH3). Anal. calc. for 
C104H96F12N4O20Ru4S4 (2482.4): C 50.32, H 3.90, N 2.26; Found: C 50.11, H 3.97, N 2.20. 
R30: Yield 191 mg (62 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 727 nm (ε = 3.08 × 10
5
 M
-
1
·cm
-1), λmax 342 nm (ε = 0.65 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3073 (m, CHar), 1620 (s, 
C=O), 1259 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 7.89 (d, 4 H, Hα), 7.67 (d, 4 H, 
Hα), 7.09 (d, 4 H, Hβ), 6.84 (d, 4 H, Hβ), 5.81 (d, 4 H, Hcym), 5.73 (d, 4 H, Hcym), 5.45 (d, 4 H, 
Hcym), 5.31 (d, 4 H, Hcym), 3.36 (s, 12 H, CH3), 2.70 (sept, 4 H, CH(CH3)2), 2.28 (br, 8 H, 
Hbpa), 1.81 (s, 12 H, CH3), 1.78 (d, 12 H, CH(CH3)2), 1.22 (d, 12 H, CH(CH3)2). 
13
C(
1
H) 
NMR (100 MHz, CD3CN): δ (ppm) = 170.1 (CO), 153.8 (CHα), 153.5 (CHα), 152.8 (Cpyr), 
150.6 (Cpyr), 129.1 (CHβ), 128.0 (CHβ), 103.5 (Ccym), 99.8 (Ccym), 86.7 (CHcym), 84.7 (CHcym), 
82.6 (CHcym), 79.3 (CHcym), 38.5 (CH3), 36.0 (CHbpa), 22.5 (CH(CH3)2), 22.4 (CH(CH3)2), 
18.1 (CH3). Anal. calc. for C76H92F12N8O16Ru4S4 (2134.1): C 42.77, H 4.35, N 5.25; Found: C 
42.68, H 4.48, N 5.16. 
R31: Yield 251 mg (78 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax 269 nm (ε = 2.81 × 10
5
 M
-
1
·cm
-1), λmax 374 nm (ε = 0.20 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3077 (m, CHar), 1709 (s, 
C=N), 1594 (s, C=O), 1260 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 9.98 (s, 2 H, 
NH), 8.02 (m, 4 H, Hα), 7.42 (m, 4 H, Hα), 7.06 (m, 4 H, Hβ), 6.92 (m, 4 H, Hβ), 6.02 (m, 8 H, 
Hcym), 5.90 (m, 4 H, Hcym), 5.80 (m, 4 H, Hcym), 3.24 (s, 8 H, Hbpa), 2.73 (m, 4 H, CH(CH3)2), 
2.09 (s, 12 H, CH3), 1.23 (m, 12 H, CH(CH3)2), 1.15 (m, 12 H, CH(CH3)2).
 13
C(
1
H) NMR 
(100 MHz, CD3CN): δ (ppm) = 178.9 (CO), 162.4 (CN), 154.6 (CHα), 146.2 (Cpyr), 124.1 
(CHβ), 106.1 (Ccym), 99.3 (Ccym), 84.0 (CHcym), 83.8 (CHcym), 83.7 (CHcym), 83.6 (CHcym), 
30.9 (CH(CH3)2), 21.5 (CH(CH3)2), 17.1 (CH3). Anal. calc. for C76H82F12N10O20Ru4S4 
(2216.0): C 41.19, H 3.73, N 6.32; Found: C 41.15, H 3.87, N 6.23. 
Procedure for metalla-rectangle R32: A solution of metalla-rectangle R22 (100 mg, 0.05 mmol) 
in methanol (10 mL) is stirred close to the Hg lamp (180 W) for 60 h. The solvent is removed 
ant the powder is washed with dichloromethane to give R32. 
R32: Yield 83 mg (83 %). UV-vis (1.0 × 10
-5 
M, CH3OH): λmax 266 nm (ε = 3.4 × 10
5 
M
-1
·cm
-
1
). IR (KBr, cm
-1
): 3077 (m, CHar), 1628 (s, C=O), 1262 (s, CF3). 
1
H NMR (400 MHz, 
CD3OD): δ (ppm) = 8.05 (d, 4 H, Hpyr), 7.94 (d, 4 H, Hpyr), 7.55 (dd, 4 H, Hpyr), 7.21 (dd, 4 H, 
Hpyr), 5.97 (d, 8 H, Hcym), 5.79 (d, 8 H, Hcym), 4.99 (s, 4 H, CH-CH), 2.84 (sept, 4 H, 
CH(CH3)2), 2.20 (s, 12 H, CH3), 1.35 (d, 24 H, CH(CH3)2).
 13
C(
1
H) NMR (100 MHz, 
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CD3OD): 171.9 (CO), 154.3 (CHpyr), 153.5 (CHpyr), 152.9 (Cpyr),128.9 (CHpyr), 125.6 (CHpyr), 
103.9 (Ccym), 98.6 (Ccym), 83.2 (CHcym), 82.8 (CHcym), 44.9 (CH-CH), 32.5 (CH(CH3)2), 22.5 
(CH(CH3)2), 18.0 (CH3). 
6.2.3 Arene Ruthenium Metalla-Prisms P2  P4 
General procedure for metalla-prisms P2  P4: A mixture of [(η
6
-p-cym)2Ru2(OO∩OO)Cl2] 
(OO∩OO = donq 46.6 mg, doaq 50.0 mg, dotq 53.3 mg; 0.064 mmol), AgCF3SO3 (33.0 mg, 
0.128 mmol) and tpt (13.4 mg, 0.043 mmol) in MeOH (20 mL) is heated under reflux for 24h, 
and then filtered. The solvent is removed and the dark residue is dissolved in CH2Cl2 (3 mL) 
and diethyl ether is added to precipitate a dark green solid. The solid is filtered and dried 
under vacuum.  
P2: Yield 60 mg (80 %). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 308 nm (ε = 3.93 × 10
5
 M
-
1
·cm
-1), λmax 437 nm (ε = 0.53 × 10
5
 M
-1
·cm
-1), λmax 643 nm (ε = 0.18 × 10
5
 M
-1
·cm
-1), λmax 
700 nm (ε = 0.19 × 105 M-1·cm-1). IR (KBr, cm-1): 3064 (w, CHaryl), 1536 (s, C=O), 1259 (s, 
CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.58 (d, 12 H, Hpyr), 8.47 (d, 12 H, H’pyr), 7.22 
(s, 12 H, Hq), 5.73 (d, 12 H, Hcym), 5.52 (d, 12 H, Hcym), 2.85 (sept, 6 H, CH(CH3)2), 2.10 (d, 
18 H, CH3), 1.33 (d, 36 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 171.8 
(CO), 170.7 (Ctpt), 154.3 (CHpyr), 145.2 (Ctpt), 138.4 (CHq), 125.0 (CH’pyr), 112.5 (Cq), 104.9 
(Ccym), 100.5 (Ccym), 85.2 (CHcym), 84.2 (CHcym), 31.5 (CH(CH3)2), 23.1 (CH(CH3)2), 22.3 
(CH(CH3)2), 17.3 (CH3). Anal. calc. for C132H120F18N12O30Ru6S6 (3495.2): C 45.32, H 3.43, N 
4.81; Found: C 45.10, H 3.44, N 4.65. 
P3: Yield 59 mg (76%). UV-Vis (1.0  10
-5
 M, (CH2Cl2)): λmax 372 nm (ε = 4.30 × 10
5
 M
-
1
·cm
-1), λmax 401 nm (ε = 4.01 × 10
5
 M
-1
·cm
-1), λmax 552 nm (ε = 1.33 × 10
5
 M
-1
·cm
-1), λmax 
601 nm (ε = 1.91 × 105 M-1·cm-1). IR (KBr, cm-1): 3065 (w, CHaryl), 1539 (s, C=O), 1261 (s, 
CF3). 
1
H NMR (400 MHz, CD3CN): δ = 8.70 (m, 3 H, Hbq), 8.66 (m, 3 H, Hbq), 8.61 (dd,
 
6 H, 
Hα), 8.59 (dd, 6 H, Hα), 8.38 (dd, 6 H, Hβ), 8.35 (dd, 6 H, Hβ), 7.99 (m, 3 H, Hcq), 7.95 (m, 3 
H, Hcq), 7.27 (d, 3 H, Haq), 7.23 (d, 3 H, Haq), 5.81 (m, 6 H, Hcym), 5.75 (m, 6 H, Hcym), 5.58 
(m, 12 H, Hcym), 2.89 (sept, 6 H, CH(CH3)2), 2.12 (m, 18 H, CH3), 1.31 (m, 36 H, CH(CH3)2) 
ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 171.5 (CO), 170.6 (Ctpt), 170.5 (CO), 154.2 
(CHα), 145.1 (Ctpt), 138.7 (CHaq), 134.4 (CHcq), 134.0 (Cq), 128.3 (CHbq), 124.9 (CHβ), 110.7 
(Cq), 104.8 (Ccym), 100.6 (Ccym), 85.3 (CHcym), 85.0 (CHcym), 83.9 (CHcym), 83.8 (CHcym), 31.4 
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(CH(CH3)2), 22.5 (CH(CH3)2), 22.3 (CH(CH3)2), 17.6 (CH3) ppm. Anal. calc. for 
C144H126F18N12O30Ru6S6 (3645.5): C 47.44, H 3.48, N 4.61; Found C 47.51, H 3.60, N 4.63. 
P4: Yield 62 mg (77%). UV-Vis (1.0  10
-5
 M, (CH2Cl2)): λmax 370 nm (ε = 4.20 × 10
5
 M
-
1
·cm
-1), λmax 398 nm (ε = 3.42 × 10
5
 M
-1
·cm
-1), λmax 558 nm (ε = 1.06 × 10
5
 M
-1
·cm
-1), λmax 
602 nm (ε = 1.91 × 105 M-1.cm-1). IR (KBr, cm-1): 3070 (w, CHaryl), 1540 (s, C=O), 1260 (s, 
CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.74 (br, 12 H, Hbq), 8.62 (br, 12 H, Hα), 8.27 
(br, 12 H, Hβ), 7.97 (br, 12 H, Hcq), 5.88 (d, 12 H, Hcym), 5.66 (d, 12 H, Hcym), 2.93 (sept, 6 H, 
CH(CH3)2), 2.13 (s, 18 H, CH3), 1.30 (d, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, 
CD3CN): δ = 170.5 (Ctpt), 170.0 (CO), 154.1 (CHα), 145.0 (Ctpt), 134.6 (Cq), 134.1 (CHcq), 
128.2 (CHbq), 124.9 (CHβ), 108.1 (Cq), 104.9 (Ccym), 100.7 (Ccym), 85.1 (CHcym), 83.6 
(CHcym), 31.5 (CH(CH3)2), 22.5 (CH(CH3)2), 17.8 (CH3) ppm. Anal. calc. for 
C156H132F18N12O30Ru6S6 (3795.6): C 49.36, H 3.51, N 4.43; Found C 49.88, H 3.70, N 4.44. 
6.2.4 Host-Guest and Carceplex Systems [guestP][CF3SO3]6 (P = P2  P4) 
General procedure for [guestP2][CF3SO3]6  [guestP4][CF3SO3]6: [(η
6
-p-
cym)2Ru2(OO∩OO)Cl2] (OO∩OO = donq 46.6 mg, doaq 50.0 mg, dotq 53.0 mg; 0.064 
mmol), and AgCF3SO3 (33.0 mg, 0.128 mmol) in MeOH (20 mL), tpt (13.4 mg, 0.043 mmol) 
and guest molecule (0.023 mmol) is added. The mixture is stirred at reflux for 24h, and then 
filtered. The solvent is removed and the dark residue is dissolved in CH2Cl2 (3 mL). Diethyl 
ether is added to precipitate a dark green solid. The solid is filtered and dried under vacuum. 
[phenanthreneP2][CF3SO3]6: Yield 65 mg (83%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): max = 
348 nm (4.2  105 M-1·cm-1), 383 nm (4.3  105 M-1·cm-1), 550 nm (1.6  104 M-1·cm-1), 612 
nm (3.2  104 M-1·cm-1). IR (KBr, cm-1): 3070 (w, CHaryl), 1532 (s, C=O), 1260 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.58 (d, 12 H, Hα), 8.08 (m, 12 H, Hβ), 7.48 (s, 12 H, Hq), 
6.70 (br, 2 H, Hphenanthrene), 5.95 (d, 12 H, Hcym), 5.80 (br, 2 H, Hphenanthrene), 5.60 (d, 12 H, 
Hcym), 5.59 (br, 2 H, Hphenanthrene), 5.10 (br, 2 H, Hphenanthrene), 4.58 (br, 2 H, Hphenanthrene), 2.91 
(sept, 6 H, CH(CH3)2), 1.99 (s, 18 H, CH3), 1.28 (d, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR 
(100 MHz, CD3CN): δ = 171.0 (CO), 153.1 (CHα), 132.3 (Cq), 127.9 (CHq), 120.2 (CHβ), 
104.1 (Cq), 103.2 (Ccym), 99.9 (Ccym), 84.2 (CHcym), 83.9 (CHcym), 30.0 (CH(CH3)2), 21.9 
(CH(CH3)2), 17.3 (CH3) ppm. Anal. calc. for C146H130F18N12O30Ru6S6 (3673.5): C 47.74, H 
3.57, N 4.58; Found C 47.68, H 3.62, N 3.61. 
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[pyreneP2][CF3SO3]6: Yield 65 mg (83 %). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 308 nm 
(ε = 3.92 × 105 M-1·cm-1), λmax 334 nm (ε = 1.21× 10
5
 M
-1
·cm
-1), λmax 437 nm (ε = 0.47 × 10
5
 
M
-1
·cm
-1), λmax 643 nm (ε = 0.16 × 10
5
 M
-1
·cm
-1), λmax 700 nm (ε = 0.16 × 10
5
 M
-1
·cm
-1
). IR 
(KBr, cm
-1
): 3062 (w, CHaryl), 1537 (s, C=O), 1260 (s, CF3), 713 (w, C=C). 
1
H NMR (400 
MHz, CD3CN): δ (ppm) = 8.41 (d, 12 H, Hpyr), 7.81 (m, 12 H, H’pyr), 7.44 (s, 12 H, Hq), 6.61 
(m, 4 H, Hpyrene), 6.14 (m, 4 H, Hpyrene), 5.69 (d, 12 H, Hcym), 5.47 (d, 12 H, Hcym), 5.20 (m, 2 
H, Hpyrene), 2.83 (sept, 6 H, CH(CH3)2), 2.09 (d, 18 H, CH3), 1.32 (d, 36 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 171.8 (CO), 170.7 (Ctpt), 154.3 (CHpyr), 145.2 
(Ctpt), 138.4 (CHq), 130.0 (Cpyrene), 127.5 (CHpyrene), 126.1 (CHpyrene), 125.5 (Cpyrene), 125.0 
(CH’pyr), 112.5 (Cq), 104.9 (Ccym), 100.5 (Ccym), 85.2 (CHcym), 84.2 (CHcym), 31.5 
(CH(CH3)2), 23.1 (CH(CH3)2), 22.3 (CH(CH3)2), 17.3 (CH3). Anal. calc. for 
C148H130F18N12O30Ru6S6 (3697.5): C 48.04, H 3.52, N 4.54; Found: C 48.10, H 3.55, N 4.50. 
[triphenyleneP2][CF3SO3]6: Yield 68 mg (86 %). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 
308 nm (ε = 3.92 × 105 M-1·cm-1), λmax 437 nm (ε = 0.51 × 10
5
 M
-1
·cm
-1), λmax 643 nm (ε = 
0.16 × 10
5
 M
-1
·cm
-1), λmax 700 nm (ε = 0.17 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3064 (w, 
CHaryl), 1536 (s, C=O), 1258 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.36 (d, 12H, 
Hpyr), 7.82 (d, 12 H, H’pyr), 7.45 (s, 12 H, Hq), 7.29 (m, 6 H, Htriphenylene), 5.70 (d, 12 H, Hcym), 
5.48 (d, 12 H, Hcym), 4.66 (m, 6 H, Htriphenylene), 2.83 (sept, 6 H, CH(CH3)2), 2.04 (d, 18 H, 
CH3), 1.31 (d, 36 H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 170.9 (CO), 
167.8 (Ctpt), 152.2 (CHpyr), 143.1 (Ctpt), 137.8 (CHq), 128.0 (Ctriphenylene), 125.8 (CHtriphenylene), 
123.7 (CH’pyr), 122.5 (CHtriphenylene), 111.4 (Cq), 103.9 (Ccym), 99.8 (Ccym), 84.5 (CHcym), 83.2 
(CHcym), 30.5 (CH(CH3)2), 21.5 (CH(CH3)2), 16.4 (CH3). Anal. calc. for 
C150H132F18N12O30Ru6S6: C 48.35, H 3.54, N 4.51; Found: C 48.10, H 3.52, N 4.45. 
[coroneneP2][CF3SO3]6: Yield 65 mg (81%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): max = 301 
nm (4.1  105 M-1·cm-1), 340 nm (3.2  105 M-1·cm-1), 370 nm (5.8  104 M-1·cm-1), 622 nm 
(3.1  104 M-1·cm-1). IR (KBr, cm-1): 3071 (w, CHaryl), 1540 (s, C=O), 1260 (s, CF3) cm
-1
. 
1
H 
NMR (400 MHz, CD3CN): δ = 8.42 (d,
 
12 H, Hα), 8.02 (d, 12 H, Hβ), 7.42 (s, 12 H, Hq), 6.21 
(s, 12 H, Hcoronene), 5.80 (d, 12 H, Hcym), 5.65 (d, 12 H, Hcym), 2.90 (sept, 6 H, CH(CH3)2), 
2.00 (s, 18 H, CH3), 1.32 (d, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 
170.2 (CO), 158.0 (Ctpt), 151.1 (CHα), 141.4 (Ctpt), 132.4 (CHq), 127.0 (Ccoronene), 124.4 
(CHcoronene), 120.5 (CHβ), 120.2 (Ccoronene), 106.1 (Cq), 104.2 (Ccym), 100.7 (Ccym), 85.3 
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(CHcym), 84.9 (CHcym), 30.1 (CH(CH3)2), 21.9 (CH(CH3)2), 17.2 (CH3) ppm. Anal. calc. for 
C156H132F18N12O30Ru6S6 (3795.5): C 49.36, H 3.51, N 4.43; Found C 49.91, H 3.62, N 4.22. 
[Pd(acac)2P2][CF3SO3]6: Yield 64 mg (80 %). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 308 
nm (ε = 3.91 × 105 M-1.cm-1), λmax 437 nm (ε = 0.50 × 10
5
 M
-1
·cm
-1
), λmax 643 nm (ε = 0.16 × 
10
5
 M
-1
·cm
-1), λmax 700 nm (ε = 0.17 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3063 (w, CHaryl), 1533 
(s, C=O), 1262 (s, CF3), 689 (w, Pd(acac)2). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.58 (d, 
12 H, Hpyr), 8.36 (d, 12 H, H’pyr), 7.28 (s, 12 H, Hq), 5.73 (d, 12 H, Hcym), 5.53 (d, 12 H, 
Hcym), 3.40 (m, 2 H, CHacac), 2.85 (sept, 6 H, CH(CH3)2), 2.10 (d, 18 H, CH3), 1.32 (d, 36 H, 
CH(CH3)2), 0.02 (m, 12 H, CH3acac). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 171.8 
(CO), 170.7 (Ctpt), 154.3 (CHpyr), 145.2 (Ctpt), 138.4 (CHq), 125.0 (CH’pyr), 112.5 (Cq), 104.9 
(Ccym), 102.0 (CHacac), 100.5 (Ccym), 85.2 (CHcym), 84.2 (CHcym), 31.5 (CH(CH3)2), 23.1 
(CH(CH3)2), 22.3 (CH(CH3)2), 17.3 (CH3), 15.6 (CH3acac). Anal. calc. for 
C142H134F18N12O34PdRu6S6 (3799.8): C 44.88, H 3.45, N 4.42; Found: C 44.99, H 3.42, N 
4.55. 
[pyrene-XP2][CF3SO3]6: Yield 149 mg (83 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax = 308 
nm (ε = 3.88 × 105 M-1·cm-1), 377 nm (ε = 0.47× 105 M-1·cm-1), 563 nm (ε = 0.24 × 105 M-
1
·cm
-1), 613 nm (ε = 0.17 × 105 M-1·cm-1). IR (KBr, cm-1): 3060 (w, CHaryl), 1536 (s, C=O), 
1500 (m, C=C), 1260 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.40 (d, 12 H, Hα), 
7.78 (m, 12 H, Hβ), 7.47 (s, 12 H, Hq), 7.25 (m, 1 H, Hpyr), 7.08 (m, 1 H, Hpyr), 6.12 (m, 1 H, 
Hpyr), 5.82 (m, 1 H, Hpyr), 8.75 (m, 1 H, Hpyr), 5.69 (d, 12 H, Hcym), 5.44 (d, 12 H, Hcym), 5.22 
(m, 1 H, Hpyr), 4.92 (m, 1 H, Hpyr), 4.81 (m, 1 H, Hpyr), 4.75 (m, 1 H, Hpyr), 2.80 (sept, 6 H, 
CH(CH3)2), 2.07 (s, 18 H, CH3), 1.32 (d, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, 
CD3CN): δ = 171.2 (CO), 170.5 (Ctpt), 155.1 (CHα), 144.3 (Ctpt), 139.9 (CHq), 130.8 (Cpyr), 
128.6 (CHpyr), 127.8 (CHpyr), 126.6 (Cpyr), 126.2 (CHβ), 115.5 (Cq), 104.8 (Ccym), 100.4 
(Ccym), 85.1 (CHcym), 84.6 (CHcym), 31.4 (CH(CH3)2), 23.0 (CH(CH3)2), 22.1 (CH(CH3)2), 
17.3 (CH3) ppm. Anal. calc. for C151H129Cl2F18N15O30Ru6S6 (3845.4): C 47.16, H 3.38, N 
5.46; Found: C 47.08, H 3.46, N 5.42. 
[pyrene-G0P2][CF3SO3]6: Yield 116 mg (85 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax = 272 
nm (ε = 1.27 × 105 M-1·cm-1), 329 nm (ε = 0.39 × 105 M-1·cm-1), 345 nm (ε = 0.91 × 105 M-
1
·cm
-1), 444 nm (ε = 0.43 × 105 M-1·cm-1), 638 nm (ε = 0.11 × 105 M-1·cm-1), 696 nm (ε = 
0.12 × 10
5
 M
-1
·cm
-1
). IR (KBr): ν = 3060 (w, CHaryl), 2228 (s, CN), 1730 (s, C=O), 1536 (s, 
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C=O), 1500 (m, C=C), 1260 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD2Cl2): δ = 8.40 (d, 12 H, 
Hα), 8.13 (d, 2 H, Harom), 7.78 (m, 12 H, Hβ), 7.76 (d, 2 H, Harom), 7.72 (d, 2 H, Harom), 7.67 (d, 
2 H, Harom), 7.47 (s, 12 H, Hq), 7.33 (d, 2 H, Harom), 7.25 (m, 1 H, Hpyr), 7.08 (m, 1 H, Hpyr), 
6.99 (d, 2 H, Harom), 6.12 (m, 1 H, Hpyr), 5.82 (m, 1 H, Hpyr), 5.75 (m, 1 H, Hpyr), 5.71 (d, 12 
H, Hcym), 5.44 (d, 12 H, Hcym), 5.22 (m, 1 H, Hpyr), 4.92 (m, 1 H, Hpyr), 4.81 (m, 1 H, Hpyr), 
4.75 (m, 1 H, Hpyr), 4.22 (t, 2 H, CO2CH2), 4.08 (t, 2 H, CH2O), 3.03 (m, 2 H, CpyrCH2), 2.93 
(sept, 6 H, CH(CH3)2), 2.52 (t, 2 H, CH2CO2), 2.07 (s, 18 H, CH3), 1.90 (m, 2 H, 
CpyrCH2CH2), 1.90 (m, 2 H, CH2CH2O), 1.71 (m, 2 H, CO2CH2CH2), 1.44 (m, 2 H, 
CH2CH2CH2O), 1.32 (d, 36 H, CH(CH3)2), 1.30 (m, 10 H, Haliph) ppm. 
13
C(
1
H) NMR (100 
MHz, CD2Cl2): δ = 173.7 (CH2CO2CH2), 171.2 (CO), 170.5 (Ctpt), 165.2 (CO2Carom), 164.1 
(OCarom), 155.1 (CHα), 152.3 (CO2Carom), 145.0 (CaromCarom), 144.3 (Ctpt), 139.9 (CHq), 137.2 
(CaromCarom), 136.2 (CpyrCH2), 133.1 (CH), 132.5 (CH), 131.8 (Cpyr), 131.3 (Cpyr), 130.8 (Cpyr), 
130.3 (Cpyr), 129.1 (Cpyr), 128.7 (CH), 128.6 (CHpyr), 128.0 (CH), 127.8 (CHpyr and CHpyr), 
127.6 (CHpyr), 127.5 (CHpyr), 127.4 (CHpyr), 126.6 (Cpyr), 126.2 (CHβ), 126.1 (CHpyr), 125.2 
(Cpyr), 125.0 (Cpyr, CHpyr, and CHpyr), 124.9 (CHpyr), 123.7 (CHpyr), 122.6 (CH), 121.6 
(CaromCO2), 119.1 (CN), 115.5 (Cq), 114.6 (CH), 111.4 (CaromCN), 104.8 (Ccym), 100.4 (Ccym), 
85.1 (CHcym), 84.6 (CHcym), 68.9 (CH2O), 64.5 (CO2CH2), 34.2 (CH2CO2), 33.0 (CpyrCH2), 
31.4 (CH(CH3)2), 29.7 (CH2), 29.6 (CH2 and CH2), 29.4 (CH2), 29.1 (CH2CH2O), 27.2 
(CpyrCH2CH2), 26.3 (CH2CH2CH2O and CO2CH2CH2CH2), 23.0 (CH(CH3)2), 22.1 
(CH(CH3)2), 17.3 (CH3) ppm. Anal. calc. for C182H167F18N13O35Ru6S6 (4237.1): C 51.59, H 
3.97, N 4.30; Found: C 50.84, H 3.93, N 4.22.  
[pyrene-G1P2][CF3SO3]6: Yield 134 mg (81 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax = 270 
nm (ε = 1.29 × 105 M-1·cm-1), 330 nm (ε = 0.40 × 105 M-1·cm-1), 343 nm (ε = 0.88 × 105 M-
1
·cm
-1), 445 nm (ε = 0.45 × 105 M-1·cm-1), 640 nm (ε = 0.12 × 105 M-1·cm-1), 696 nm (ε = 
0.12 × 10
5
 M
-1
·cm
-1
). IR (KBr): ν = 3060 (w, CHaryl), 2229 (s, CN), 1733 (s, C=O), 1536 (s, 
C=O), 1500 (m, C=C), 1260 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD2Cl2): δ = 8.50 (t, 1 H, 
Harom), 8.38 (m, 12 H, Hα), 8.11 (d, 4 H, Harom), 7.91 (d, 2 H, Harom), 7.79 (m, 12 H, Hβ), 7.76 
(d, 4 H, Harom), 7.71 (d, 4 H, Harom), 7.60 (m, 4 H, Harom), 7.45 (br, 12 H, Hq), 7.32 (m, 4 H, 
Harom), 7.30 (m, 1 H, Hpyr), 7.12 (m, 1 H, Hpyr), 6.98 (d, 4 H, Harom), 6.15 (m, 1 H, Hpyr), 5.80 
(m, 1 H, Hpyr), 5.73 (d, 12 H, Hcym), 5.72 (m, 1 H, Hpyr), 5.48 (d, 12 H, Hcym), 5.20 (m, 1 H, 
Hpyr), 4.87 (m, 1 H, Hpyr), 4.82 (m, 1 H, Hpyr), 4.75 (m, 1 H, Hpyr), 4.04 (m, 4 H, CO2CH2), 
4.00 (m, 4 H, CH2O), 3.05 (m, 2 H, CpyrCH2), 2.81 (m, 6 H, CH(CH3)2), 2.53 (m, 2 H, 
CH2CO2), 2.28 (m, 2 H, CpyrCH2CH2), 2.05 (s, 18 H, CH3), 1.69 (m, 8 H, CO2CH2CH2 and 
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CH2CH2O), 1.45 (m, 8 H, CO2CH2CH2CH2 and CH2CH2CH2O), 1.32 (m, 16 H, Haliph), 1.28 
(m, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD2Cl2): δ = 171.9 (CaromCO2CH2), 
170.6 (CO), 170.4 (Ctpt), 165.1 (CH2CO2Carom), 165.0 (CaromCO2Carom), 163.8 (OCarom), 155.1 
(CHα), 151.0 (CaromCO2Carom and CH2CO2Carom), 145.0 (CaromCarom), 144.2 (Ctpt), 139.9 (CHq), 
137.1 (CaromCarom), 132.8 (CH), 132.7 (CaromCO2CH2), 132.6 (CH), 131.5 (Cpyr), 131.4 (Cpyr), 
130.7 (Cpyr), 130.4 (Cpyr), 129.8 (Cpyr), 128.5 (CHpyr and CH), 128.1 (CH), 128.0 (CH), 127.8 
(CHpyr, CHpyr, CHpyr, and CHpyr), 127.7 (CH), 127.2 (CHpyr), 126.6 (Cpyr), 126.5 (CHpyr), 
126.4 (CHpyr), 126.1 (CHβ), 125.3 (CHpyr), 124.8 (CHpyr), 123.2 (CHpyr), 122.6 (CH), 121.0 
(CaromCO2Carom), 119.1 (CN), 115.5 (Cq), 114.8 (CH), 111.5 (CaromCN), 104.6 (Ccym), 100.2 
(Ccym), 84.5 (CHcym), 84.4 (CHcym), 68.9 (CH2O), 66.2 (CO2CH2), 34.2 (CH2CO2), 31.4 
(CH(CH3)2), 30.2 (CpyrCH2), 27.2 (CH2), 26.8 (CH2), 26.7 (CH2), 26.6 (CH2), 26.5 (CH2), 
26.1 (CH2CH2O), 25.8 (CpyrCH2CH2), 25.2 (CH2CH2CH2O), 25.0 (CO2CH2CH2CH2), 23.0 
(CH(CH3)2), 19.8 (CH(CH3)2), 17.1 (CH3) ppm. Anal. calc. for C220H202F18N14O42Ru6S6 
(4854.8): C 54.43, H 4.19, N 4.04; Found: C 53.74, H 4.12, N 3.96.  
[pyrene-G2P2][CF3SO3]6: Yield 182 mg (77 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax = 270 
nm (ε = 1.25 × 105 M-1·cm-1), 330 nm (ε = 0.42 × 105 M-1·cm-1), 343 nm (ε = 0.88 × 105 M-
1
·cm
-1), 442 nm (ε = 0.45 × 105 M-1·cm-1), 640 nm (ε = 0.11 × 105 M-1·cm-1), 696 nm (ε = 
0.12 × 10
5
 M
-1
·cm
-1
). IR (KBr): ν = 3060 (w, CHaryl), 2225 (s, CN), 1732 (s, C=O), 1536 (s, 
C=O), 1500 (m, C=C), 1260 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD2Cl2): δ = 8.91 (m, 1 H, 
Harom), 8.59 (t, 2 H, Harom), 8.37 (d, 2 H, Harom), 8.36 (m, 12 H, Hα), 8.12 (d, 10 H, Harom), 8.11 
(d, 4 H, Harom), 7.79 (m, 12 H, Hβ), 7.75 (d, 8 H, Harom), 7.69 (d, 8 H, Harom), 7.66 (d, 8 H, 
Harom), 7.45 (s, 12 H, Hq), 7.29 (d, 8 H, Harom), 7.14 (m, 1 H, Hpyr), 7.05 (m, 1 H, Hpyr), 6.97 
(d, 10 H, Harom), 6.11 (m, 1 H, Hpyr), 5.81 (m, 1 H, Hpyr), 5.74 (m, 1 H, Hpyr), 5.68 (d, 12 H, 
Hcym), 5.41 (d, 12 H, Hcym), 5.20 (m, 1 H, Hpyr), 4.91 (m, 1 H, Hpyr), 4.75 (m, 1 H, Hpyr), 4.72 
(m, 1 H, Hpyr), 4.05 (m, 8 H, CO2CH2), 4.02 (m, 2 H, CO2CH2), 3.92 (m, 8 H, CH2O), 3.88 
(m, 2 H, CH2O), 3.12 (m, 2 H, CpyrCH2), 2.81 (m, 6 H, CH(CH3)2), 2.09 (s, 18 H, CH3), 2.05 
(m, 2 H, CH2CO2CH2), 1.99 (m, 2H, CpyrCH2CH2), 1.74 (m, 18 H, CH2CH2O and 
CO2CH2CH2), 1.59 (m, 2 H, CO2CH2CH2), 1.45 (m, 18 H, CH2CH2CH2O and 
CO2CH2CH2CH2), 1.30 (m, 42 H, CO2CH2CH2CH2 and Haliph),
 
1.29 (m, 36 H, CH(CH3)2) 
ppm. 
13
C(
1
H) NMR (100 MHz, CD2Cl2): δ = 173.0 (CH2CO2CH2), 171.3 (CO), 170.4 (Ctpt), 
165.1 (CaromCO2CH2), 165.0 (CaromCO2Carom), 164.7 (CaromCO2Carom), 164.5 (OCarom), 164.1 
(OCarom), 163.2 (CaromCO2Carom), 155.0 (CHα), 152.1 (CO2Carom), 152.0 (CO2Carom), 151.0 
(CO2Carom), 144.3 (Ctpt), 139.9 (CHq), 134.1 (CpyrCH2), 132.9 (CH), 132.1 (CH), 131.5(CH), 
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131.2 (CaromCO2), 130.6 (Cpyr), 129.3 (CH), 128.7 (CH), 128.6 (Cpyr), 128.5 (CH), 128.1 
(CH), 127.8 (Cpyr), 127.6 (CH), 126.8 (Cpyr), 126.6 (Cpyr), 126.4 (CHpyr), 126.3 (CHpyr), 126.2 
(CHβ), 125.8 (CHpyr), 125.3 (Cpyr), 124.9 (Cpyr), 124.3 (Cpyr), 124.2 (CHpyr), 124.1 (CHpyr), 
123.2 (CHpyr), 122.3 (CH), 121.6 (CaromCO2), 120.5 (CaromCO2), 119.2 (CN), 114.8 (Cq), 
114.6 (CH), 114.5 (CH), 111.1 (CaromCN), 104.8 (Ccym), 100.1 (Ccym), 85.1 (CHcym), 84.8 
(CHcym), 68.7 (CH2O and CH2O), 66.3 (CaromCO2CH2), 64.5 (CH2CO2CH2), 34.2 
(CpyrCH2CH2CH2), 31.4 (CH(CH3)2), 30.2 (CpyrCH2), 29.2 (CH2), 28.9 (CH2), 28.5 (CH2), 
28.4 (CH2), 28.2 (CH2), 27.7 (CH2), 27.5 (CH2 and CH2), 27.1 (CH2CH2O), 26.8 (CH2CH2O), 
26.4 (CpyrCH2CH2), 26.2 (CH2CH2CH2O), 25.3 (CH2CH2CH2O and CO2CH2CH2CH2), 23.0 
(CH(CH3)2), 22.1 (CH(CH3)2), 17.3 (CH3) ppm. Anal. calc. for C313H296F18N16O59Ru6S6 
(6366.5): C 59.05, H 4.69, N 3.52; Found: C 58.47, H 4.64, N 3.47. 
[phenanthreneP3][CF3SO3]6: Yield 68 mg (84%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 
373 nm (ε = 4.01 × 105 M-1.cm-1), λmax 399 nm (ε = 3.83 × 10
5
 M
-1
·cm
-1), λmax 554 nm (ε = 
0.13 × 10
5
 M
-1
·cm
-1), λmax 601 nm (ε = 0.18 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3068 (w, 
CHaryl), 1539 (s, C=O), 1262 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.74 (m, 3 H, 
Hbq), 8.70 (m, 3 H, Hbq), 8.56 (dd,
 
6 H, Hα), 8.53 (dd, 6 H, Hα), 8.19 (m, 12 H, Hβ), 8.02 (m, 6 
H, Hcq), 7.41 (m, 2 H, Hphenanthrene), 7.33 (d,
 
3 H, Haq), 7.29 (d, 3 H, Haq), 6.91 (d,
 
2 H, 
Hphenanthrene), 5.81 (m, 6 H, Hcym), 5.75 (m, 6 H, Hcym), 5.63 (m, 2 H, Hphenanthrene), 5.57 (m, 12 
H, Hcym), 5.20 (m, 2 H, Hphenanthrene), 4.50 (dd, 2 H, Hphenanthrene), 2.89 (sept, 6 H, CH(CH3)2), 
2.11 (m, 18 H, CH3), 1.32 (m, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 
171.5 (CO), 170.6 (CO), 170.3 (Ctpt), 154.0 (CHα), 153.9 (CHα), 145.0 (Ctpt), 138.8 (CHaq), 
134.5 (CHcq), 134.1 (Cq), 128.4 (CHbq), 124.8 (CHβ), 110.6 (Cq), 104.8 (Ccym), 100.7 (Ccym), 
85.3 (CHcym), 85.0 (CHcym), 83.9 (CHcym), 83.8 (CHcym), 31.5 (CH(CH3)2), 22.5 (CH(CH3)2), 
22.3 (CH(CH3)2), 17.6 (CH3) ppm. Anal. calc. for C158H136F18N12O30Ru6S6 (3823.7): C 49.63, 
H 3.59, N 4.40; Found C 49.77, H 3.72, N 4.45. 
[pyreneP3][CF3SO3]6: Yield: 68 mg (83%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): max = 321 
(7.1  104 M-1·cm-1), 337 (6.9  104 M-1·cm-1), 374 (4.3  104 M-1·cm-1), 402 (4.1  104 M-
1
·cm
-1
), 649 (2.3  104 M-1·cm-1) nm. IR (KBr, cm-1): 3064 (w, CHaryl), 1539 (s, C=O), 1260 
(s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.79 (m, 6 H, Hbq), 8.48 (m, 12 H, Hα), 8.10 
(m, 6 H, Hcq), 7.95 (m, 12 H, H), 7.42 (m, 6 H, Haq), 6.16 (m, 4 H, Hpyrene), 5.81 (m, 6 H, 
Hcym), 5.75 (m, 6 H, Hcym), 5.65 (br, 2 H, Hpyrene), 5.56 (m, 12H, Hcym), 5.00 (m, 4 H, Hpyrene), 
2.89 (sept, 6 H, CH(CH3)2), 2.09 (m, 18 H, CH3), 1.32 (m, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) 
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NMR (100 MHz, CD3CN): δ = 171.5 (CO), 170.7 (CO), 169.9 (Ctpt), 153.7 (CHα), 144.3 
(Ctpt), 139.0 (CHaq), 134.7 (CHcq), 134.2 (Cq), 129.9 (CHpyrene), 128.4 (CHbq), 127.1 (CHpyrene), 
125.1 (CHpyrene), 124.5 (CHβ), 110.7 (Cq), 104.8 (Ccym), 100.7 (Ccym), 85.2 (CHcym), 83.8 
(CHcym), 31.4 (CH(CH3)2), 22.4 (CH(CH3)2), 17.6 (CH3) ppm. Anal. calc. for 
C160H136F18N12O30Ru6S6 (3847.7): C 49.95, H 3.56, N 4.37; Found C 49.98, H 3.74, N 4.42. 
[triphenyleneP3][CF3SO3]6: Yield: 72 mg (84%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): max = 
380 nm (3.8  104 M-1·cm-1), 415 nm (4.0  104 M-1·cm-1), 550 nm (0.9  104 M-1·cm-1), 612 
nm (1.5  104 M-1·cm-1), 659 nm (1.9  104 M-1·cm-1). IR (KBr, cm-1): 3060 (w, CHaryl), 1539 
(s, C=O), 1260 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.82 (m, 6 H, Hbq), 8.38 (dd,
 
6 H, Hα), 8.29 (dd, 6 H, Hα), 8.28 (m, 6 H, Hcq), 7.71 (s, 3 H, Haq), 7.69 (d,
 
3 H, Haq), 6.92 (dd,
 
6 H, Hβ), 6.79 (dd, 6 H, Hβ), 6.58 (m, 6 H, Htriphenylene), 5.78 (m, 6 H, Hcym), 5.74 (m, 6 H, 
Hcym), 5.63 (m, 12 H, Hcym), 4.44 (m, 6 H, Htriphenylene), 2.88 (sept, 6 H, CH(CH3)2), 2.04 (m, 
18 H, CH3), 1.29 (m, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 171.3 
(CO), 171.1 (CO), 166.0 (Ctpt), 152.0 (CHα), 142.4 (Ctpt), 138.5 (CHaq), 134.6 (CHcq), 132.2 
(Cq), 128.4 (Ctriphenylene), 128.1 (CHbq), 127.1 (CHtriphenylene), 122.4 (CHtriphenylene), 120.2 (CHβ), 
108.9 (Cq), 103.2 (Ccym), 100.1 (Ccym), 86.4 (CHcym), 86.1 (CHcym), 83.0 (CHcym), 82.9 
(CHcym), 30.4 (CH(CH3)2), 21.6 (CH(CH3)2), 21.4 (CH(CH3)2), 16.9 (CH3) ppm. Anal. calc. 
for C162H138F18N12O30Ru6S6 (3873.8): C 50.23, H 3.59, N 4.34; found C 50.45, H 3.73, N 
4.43. 
[coroneneP3][CF3SO3]6: Yield: 72 mg (86%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): max = 385 
nm (3.9  104 M-1·cm-1), 409 nm (3.9  104 M-1·cm-1), 555 nm (0.8  104 M-1·cm-1), 609 nm 
(1.5  104 M-1·cm-1), 654 nm (1.8  104 M-1·cm-1). IR (KBr, cm-1): 3062 (w, CHaryl), 1539 (s, 
C=O), 1261 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.95 (m, 6 H, Hbq), 8.35 (dd,
 
6 
H, Hα), 8.30 (dd, 6 H, Hα), 8.29 (m, 6 H, Hcq), 7.70 (s, 3 H, Haq), 7.67 (d,
 
3 H, Haq), 6.86 (dd,
 
6 
H, Hβ), 6.77 (dd, 6 H, Hβ), 6.59 (s, 12 H, Hcoronene), 5.80 (m, 6 H, Hcym), 5.71 (m, 6 H, Hcym), 
5.53 (m, 12 H, Hcym), 2.88 (sept, 6 H, CH(CH3)2), 2.05 (m, 18 H, CH3), 1.31 (m, 36 H, 
CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 170.2 (CO), 170.1 (CO), 166.1 
(Ctpt), 152.2 (CHα), 142.0 (Ctpt), 138.4 (CHaq), 134.1 (CHcq), 133.3 (Cq), 127.8 (CHbq), 127.2 
(Ccoronene), 125.2 (CHcoronene), 122.6 (CHβ), 120.4 (Ccoronene), 109.7 (Cq), 103.9 (Ccym), 99.8 
(Ccym), 84.5 (CHcym), 84.1 (CHcym), 83.0 (CHcym), 82.9 (CHcym), 30.6 (CH(CH3)2), 21.6 
(CH(CH3)2), 21.4 (CH(CH3)2), 16.7 (CH3) ppm. Anal. calc. for C168H138F18N12O30Ru6S6 
(3945.8): C 51.09, H 3.62, N 4.25; Found C 51.14, H 3.53, N 4.26. 
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[Pd(acac)2P3][CF3SO3]6: Yield 147 mg (80 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax = 308 
nm (ε = 3.95 × 105 M-1·cm-1), 371 nm (ε = 0.66 × 105 M-1·cm-1), 447 nm (ε = 0.50 × 105 M-
1
·cm
-1), 648 nm (ε = 0.22 × 105 M-1·cm-1). IR (KBr, cm-1): 3060 (w, CHaryl), 1536 (s, C=O), 
1260 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.81 (m, 6 H, Hq), 8.64 (m, 12 H, Hα), 
8.15 (m, 6 H, Hq), 8.05 (m, 12 H, Hβ), 7.42 (m, 6 H, Hq), 5.81 (d, 12 H, Hcym), 5.63 (d, 12 H, 
Hcym), 3.49 (m, 2 H, CHacac), 2.81 (sept, 6 H, CH(CH3)2), 2.11 (s, 18 H, CH3), 1.30 (d, 36 H, 
CH(CH3)2), 0.02 (m, 12 H, CH3acac) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 171.5 (CO), 
170.5 (CO), 169.9 (Ctpt), 157.9 (CHα), 144.8 (Ctpt), 139.8 (CHq), 134.7 (CHq), 129.6 (CHq), 
124.9 (CHβ), 110.7 (Cq), 103.8 (Ccym), 102.0 (CHacac), 101.2 (Ccym), 89.7 (CHcym), 88.6 
(CHcym), 85.2 (CHcym), 84.7 (CHcym), 31.4 (CH(CH3)2), 22.5 (CH(CH3)2), 22.1 (CH(CH3)2), 
17.6 (CH3), 15.5 (CH3acac) ppm. Anal. calc. for C154H140F18N12O34PdRu6S6 (3950.0): C 46.83, 
H 3.57, N 4.26; found: C 46.31, H 3.54, N 4.15. 
[pyrene-XP3][CF3SO3]6: Yield 146 mg (78 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax = 308 
nm (ε = 3.79 × 105 M-1·cm-1), 442 nm (ε = 0.36 × 105 M-1·cm-1), 659 nm (ε = 0.18 × 105 M-
1
·cm
-1
). IR (KBr, cm
-1
): ν = 3060 (w, CHaryl), 1536 (s, C=O), 1500 (m, C=C), 1260 (s, CF3) 
cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.78 (m, 6 H, Hq), 8.60 (m, 12 H, Hα), 8.09 (m, 6 H, 
Hq), 8.01 (m, 12 H, Hβ), 7.96 (m, 1 H, Hpyr), 7.71 (m, 1 H, Hpyr), 7.40 (m, 6 H, Hq), 7.21 (m, 1 
H, Hpyr), 7.01 (m, 1 H, Hpyr), 5.98 (m, 1 H, Hpyr), 5.81 (d, 12 H, Hcym), 5.62 (d, 12 H, Hcym), 
5.52 (m, 1 H, Hpyr), 5.09 (m, 1 H, Hpyr), 4.96 (m, 1 H, Hpyr), 4.75 (m, 1 H, Hpyr), 2.80 (sept, 6 
H, CH(CH3)2), 2.10 (s, 18 H, CH3), 1.29 (d, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, 
CD3CN): δ = 170.5 (CO), 170.2 (CO), 169.8 (Ctpt), 156.7 (CHα), 142.4 (Ctpt), 141.0 (CHq), 
135.6 (CHq), 130.2 (CHq), 129.7 (Cpyr), 128.2 (CHpyr), 126.8 (CHpyr), 126.2 (Cpyr), 125.9 
(CHβ), 109.1 (Cq), 104.9 (Ccym), 101.1 (Ccym), 88.6 (CHcym), 87.8 (CHcym), 86.1 (CHcym), 85.9 
(CHcym), 32.2 (CH(CH3)2), 22.9 (CH(CH3)2), 22.7 (CH(CH3)2), 17.0 (CH3) ppm. Anal. calc. 
for C163H135Cl2F18N15O30Ru6S6 (3995.6): C 49.00, H 3.41, N 5.26; Found: C 48.91, H 3.48, N 
5.22. 
[phenanthreneP4][CF3SO3]6: Yield 70 mg (83%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): max = 
354 nm (6.3  104 M-1·cm-1), 368 nm (6.2  104 M-1·cm-1), 523 nm (1.7  104 M-1·cm-1), 563 
nm (2.7  104 M-1·cm-1), 607 nm (3.4  104 M-1·cm-1). IR (KBr, cm-1): 3070 (w, CHaryl), 1544 
(s, C=O), 1259 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.78 (dd, 12 H, Hbq), 8.54 (d, 
12 H, Hα), 8.01 (m, 24 H, Hβ and Hcq), 6.73 (br, 2 H, Hphenanthrene), 5.87 (d, 12 H, Hcym), 5.75 
(br, 2 H, Hphenanthrene), 5.63 (d, 12 H, Hcym), 5.56 (br, 2 H, Hphenanthrene), 5.16 (br, 2 H, 
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Hphenanthrene), 4.63 (br, 2 H, Hphenanthrene), 2.93 (sept, 6 H, CH(CH3)2), 2.11 (s, 18 H, CH3), 1.30 
(d, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 168.7 (CO), 152.5 (CHα), 
133.3 (Cq), 132.9 (CHcq), 127.0 (CHbq), 123.4 (CHβ), 106.7 (Cq), 103.5 (Ccym), 99.4 (Ccym), 
83.9 (CHcym), 82.3 (CHcym), 30.1 (CH(CH3)2), 21.2 (CH(CH3)2), 16.5 (CH3) ppm. Anal. calc. 
for C170H142F18N12O30Ru6S6 (3973.8): C 51.33, H 3.70, N 4.22; Found C 51.38, H 3.60, N 
4.23. 
[pyreneP4][CF3SO3]6: Yield 75 mg (84%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): max = 350 nm 
(6.1  104 M-1·cm-1), 362 nm (6.2  104 M-1·cm-1), 522 nm (1.6  104 M-1·cm-1), 565 nm (2.6 
 104 M-1·cm-1), 609 nm (3.6  104 M-1·cm-1). IR (KBr, cm-1): 3070 (w, CHaryl), 1540 (s, 
C=O), 1260 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.80 (dd, 12H, Hbq), 8.50 (d, 
12H, Hα), 8.01 (m, 24H, Hβ and Hcq), 6.14 (m, 4H, Hpyrene), 5.90 (d, 12H, Hcym), 5.70 (br, 2H, 
Hpyrene), 5.60 (d, 12H, Hcym), 5.05 (m, 4H, Hpyrene), 2.94 (sept, 6H, CH(CH3)2), 2.10 (s, 18H, 
CH3), 1.29 (d, 36H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 170.1 (CO), 
152.4 (CHα), 133.1 (Cq), 132.6 (CHcq), 129.7 (CHpyrene), 127.4 (CHpyrene), 127.0 (CHbq), 125.3 
(CHpyrene), 123.0 (CHβ), 106.8 (Cq), 103.4 (Ccym), 99.2 (Ccym), 83.6 (CHcym), 82.1 (CHcym), 
29.9 (CH(CH3)2), 19.2 (H(CH3)2) 16.8 (CH3) ppm. Anal. calc. for C172H142F18N12O30Ru6S6 
(3997.8): C 51.67, H 3.68, N 4.20; Found C 51.96, H 3.90, N 4.28. 
[triphenyleneP4][CF3SO3]6: Yield 75 mg (87%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): max = 
351 nm (6.3  104 M-1·cm-1), 368 nm (6.1  104 M-1·cm-1), 526 nm (1.5  104 M-1·cm-1), 564 
nm (2.5  104 M-1·cm-1), 608 nm (3.3  104 M-1·cm-1). IR (KBr, cm-1): 3069 (w, CHaryl), 1543 
(s, C=O), 1259 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.86 (m, 12 H, Hbq), 8.42 (d,
 
12 H, Hα), 8.12 (m, 12 H, Hcq), 7.58 (d, 12 H, Hβ), 6.58 (m, 6 H, Htriphenylene), 5.87 (d, 12 H, 
Hcym), 5.61 (d, 12 H, Hcym), 4.41 (m, 6 H, Htriphenylene), 2.92 (sept, 6 H, CH(CH3)2), 2.06 (s, 18 
H, CH3), 1.29 (d, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 170.2 (CO), 
168.6 (Ctpt), 153.0 (CHα), 143.9 (Ctpt), 134.6 (CHcq), 134.4 (Cq), 128.5 (Ctriphenylene), 128.5 
(CHbq), 126.4 (CHtriphenylene), 124.4 (CHβ), 122.9 (CHtriphenylene), 107.8 (Cq), 104.8 (Ccym), 100.8 
(Ccym), 85.3 (CHcym), 83.5 (CHcym), 31.5 (CH(CH3)2), 22.5 (CH(CH3)2), 17.8 (CH3) ppm. 
Anal. calc. for C174H144F18N12O30Ru6S6 (4023.9): C 51.94, H 3.61, N 4.23; Found C 51.92, H 
3.71, N 4.18. 
[coroneneP4][CF3SO3]6: Yield 71 mg (81%). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): max = 305 
nm (17.2  104 M-1·cm-1), 343 nm (8.7  104 M-1·cm-1), 372 nm (5.8  104 M-1·cm-1), 568 nm 
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(2.3  104 M-1·cm-1), 611 nm (3.0  104 M-1·cm-1). IR (KBr, cm-1): 3064 (w, CHaryl), 1544 (s, 
C=O), 1261 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.99 (dd, 12 H, Hbq), 8.36 (d,
 
12 
H, Hα), 8.27 (dd, 12 H, Hcq), 6.71 (d, 12 H, Hβ), 6.23 (s, 12 H, Hcoronene), 5.86 (d, 12 H, Hcym), 
5.60 (d, 12 H, Hcym), 2.93 (sept, 6 H, CH(CH3)2), 2.05 (s, 18 H, CH3), 1.31 (d, 36 H, 
CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 169.9 (CO), 166.0 (Ctpt), 152.1 
(CHα), 141.8 (Ctpt), 133.9 (Cq), 133.8 (CHcq), 127.7 (CHbq), 127.0 (Ccoronene), 124.9 
(CHcoronene), 122.5 (CHβ), 120.2 (Ccoronene), 107.1 (Cq), 104.0 (Ccym), 99.8 (Ccym), 84.2 (CHcym), 
82.7 (CHcym), 30.6 (CH(CH3)2), 21.6 (CH(CH3)2), 16.9 (CH3) ppm. Anal. calc. for 
C180H144F18N12O30Ru6S6 (4095.9): C 52.78, H 3.54, N 4.10; Found C 52.91, H 3.72, N 4.12. 
[Pd(acac)2P4][CF3SO3]6: Yield 157 mg (82 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax = 308 
nm (ε = 3.90 × 105 M-1·cm-1), 380 nm (ε = 0.56 × 105 M-1·cm-1), 607 nm (ε = 0.20 × 105 M-
1
·cm
-1), 655 nm (ε = 0.22 × 105 M-1·cm-1). IR (KBr, cm-1): 3060 (w, CHaryl), 1536 (s, C=O), 
1260 (s, CF3) cm
-1
. 
1
H NMR (400 MHz, CD3CN): δ = 8.80 (dd, 12 H, Hq), 8.51 (d, 12 H, Hα), 
8.02 (m, 24 H, Hq + Hβ), 5.90 (d, 12 H, Hcym), 5.60 (d, 12 H, Hcym), 3.51 (m, 2 H, CHacac), 
2.79 (sept, 6 H, CH(CH3)2), 2.10 (s, 18 H, CH3), 1.30 (d, 36 H, CH(CH3)2), 0.02 (m, 12 H, 
CH3acac) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 170.0 (CO), 165.7 (Ctpt), 152.2 (CHα), 
141.3 (Ctpt), 133.1 (Cq), 132.6 (CHq), 127.0 (CHq), 123.2 (CHβ), 106.5 (Cq), 103.4 (Ccym), 
102.2 (CHacac), 101.1 (Ccym), 85.2 (CHcym), 85.1 (CHcym), 84.8 (CHcym), 84.6 (CHcym), 31.2 
(CH(CH3)2), 22.1 (CH(CH3)2), 22.0 (CH(CH3)2), 17.9 (CH3), 15.8 (CH3acac) ppm. Anal. calc. 
for C166H146F18N12O34PdRu6S6 (4100.2): C 48.63, H 3.59, N 4.10; Found: C 47.92, H 3.57, N 
4.02. 
[pyrene-XP4][CF3SO3]6: Yield 155 mg (80 %). UV-vis (1.0 × 10
-5
 M, CH2Cl2): λmax = 308 
nm (ε = 3.60 × 105 M-1·cm-1), 390 nm (ε = 0.23 × 105 M-1·cm-1), 607 nm (ε = 0.14 × 105 M-
1
·cm
-1), 658 nm (ε = 0.13 × 105 M-1·cm-1). IR (KBr, cm-1): 3060 (w, CHaryl), 1536 (s, C=O), 
1500 (m, C=C), 1260 (s, CF3) cm
-1
.
 1
H NMR (400 MHz, CD3CN): δ = 8.90 (m, 12 H, Hα), 
8.84 (m, 12 H, Hβ), 8.11 (m, 12 H, Hq), 7.90 (m, 1 H, Hpyr), 7.75 (m, 1 H, Hpyr), 7.22 (m, 12 
H, Hq), 7.18 (m, 1 H, Hpyr), 7.09 (m, 1 H, Hpyr), 6.31 (m, 1 H, Hpyr), 5.88 (d, 12 H, Hcym), 5.61 
(d, 12 H, Hcym), 5.35 (m, 1 H, Hpyr), 5.18 (m, 1 H, Hpyr), 4.88 (m, 1 H, Hpyr), 4.71 (m, 1 H, 
Hpyr), 2.80 (sept, 6 H, CH(CH3)2), 2.09 (s, 18 H, CH3), 1.32 (d, 36 H, CH(CH3)2) ppm. 
13
C(
1
H) NMR (100 MHz, CD3CN): δ = 171.1 (CO), 166.9 (Ctpt), 151.3 (CHα), 140.2 (Ctpt), 
133.1 (Cq), 132.8 (CHq), 131.2 (Cpyr), 128.9 (CHpyr), 128.2 (CHpyr), 127.4 (Cpyr), 126.9 (CHq), 
124.3 (CHβ), 105.5 (Cq), 104.8 (Ccym), 100.9 (Ccym), 85.4 (CHcym), 85.3 (CHcym), 85.1 
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(CHcym), 84.9 (CHcym), 31.0 (CH(CH3)2), 22.2 (CH(CH3)2), 20.9 (CH(CH3)2), 18.1 (CH3) 
ppm. Anal. calc. for C175H141Cl2F18N15O30Ru6S6 (4145.8): C 50.70, H 3.43, N 5.07; Found: C 
49.97, H 3.41, N 4.97. 
6.2.5 Arene Ruthenium Metalla-Cubes Q2  Q14  
General procedure for [Q2  Q10][CF3SO3]8: A mixture of Ag(CF3SO3) (165 mg, 0.64 mmol) 
and [Ru2(arene)2(OO∩OO)2Cl2] (0.32 mmol; Q2 and Q3: p-cym, ox, 201 mg; Q4  Q6: p-cym, 
dobq, 218 mg; Q7: indane, dobq, 207 mg; Q8: nonylbenzene, dobq, 262 mg; Q9 and Q10: 
toluene, dobq, 185 mg) in methanol (30 mL) is stirred at room temperature for 3 h, then 
filtered. To the red filtrate, the corresponding porphyrin (0.16 mmol; Q4, Q7, Q8, and Q9: tpp-
2H, 99 mg; Q2 and Q5: tpp-Ni, 108 mg; Q3, Q10 and Q6: tpp-Zn, 106 mg) is added. The 
solution is refluxed for 48 h, and the solvent removed under vacuum. The residue is dissolved 
in acetonitrile (3 mL), and diethyl ether is added to precipitate the purple or black solid. 
Q2: Yield 305 mg (79 %). UV-vis (1.0 × 10
-5
 M, (CH2Cl2)): λmax 416 nm (ε = 4.09 × 10
5
 M
-
1
·cm
-1), λmax 542 nm (ε = 0.47 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3069 (w, CHaryl), 1521 (s, 
C=O), 1258 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 9.25 (d, 8 H, Hpyr), 9.18 (d, 8 
H, H’α), 8.92 (d, 8 H, Hβ), 8.17 (d, 8 H, Hα), 8.10 (d, 8 H, H’pyr), 7.91 (d, 8 H, H’β), 6.15 (m, 
16 H, Hcym), 5.97 (m, 16 H, Hcym), 3.05 (sept, 6 H, CH(CH3)2), 2.45 (s, 12 H, CH3), 1.49 (d, 
24 H, CH(CH3)2).
 13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 172.3 (CO), 153.7 (CH’α), 
151.2 (CHα), 149.4 (Cpyridyl), 140.1 (Cpyr), 139.9 (Cpyr), 133.5 (CH’β), 133.1 (CHβ), 130.0 
(CH’pyr), 129.6 (CH’pyr), 104.2 (Ccym), 101.3 (Ccym), 84.2 (CHcym), 83.8 (CHcym), 83.0 
(CHcym), 82.6 (CHcym), 32.0 (CH(CH3)2), 21.8 (CH(CH3)2), 21.2 (CH(CH3)2), 17.5 (CH3). 
ESI-MS: m/z 1045.0 [Q2 + (CF3SO3)4]
4+
. Anal. calc. for C176H160F24N16Ni2O40Ru8S8 (4777.7): 
C 44.24, H 3.37, N 4.69; Found: C 44.01, H 3.29, N 4.34. 
Q3: Yield: 298 mg (78 %). UV-vis (1.0 × 10
-5
 M, (CH2Cl2)): λmax 416 nm (ε = 4.12 × 10
5
 M
-
1
·cm
-1), λmax 510 nm (ε = 0.53 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3072 (w, CHaryl), 1520 (s, 
C=O), 1257 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ(ppm) = 9.28 (d, 8 H, Hpyr), 9.22 (d, 8 
H, H’α), 8.97 (m, 16 H, Hα), 8.15 (d, 8 H, Hβ), 8.10 (d, 8 H, H’pyr), 7.97 (d, 8 H, H’β), 6.15 (m, 
24 H, Hcym), 5.96 (m, 8 H, Hcym), 3.13 (sept, 8 H, CH(CH3)2), 2.36 (s, 24 H, CH3), 1.60 (m, 48 
H, CH(CH3)2). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ(ppm) = 171.2 (CO), 153.7 (CH’α), 153.1 
(CHα), 147.2 (CH’β), 147.0 (CHβ), 133.0 (Cpyr), 132.9 (Cpyr), 114.6 (CCH(CH3)2), 101.8 
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(CHq), 97.6 (CCH3), 83.9 (CHcym), 82.7 (CHcym), 81.8 (CHcym), 31.3 (CH(CH3)2), 21.9 
(CH(CH3)2), 21.4 (CH(CH3)2), 17.6 (CH3). ESI-MS: m/z 1048.7 [Q3 + (CF3SO3)4]
4+
 and 
1448.0 [Q3 + (CF3SO3)5]
3+
. Anal. calc. for C176H160F24N16O40Ru8S8Zn2 (4791): C 44.12, H 
3.37, N 4.68; Found C 43.82, H 3.19, N 4.68. 
Q4: Yield 287 mg (74 %). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 257 nm (ε = 4.32 × 10
5
 M
-
1
·cm
-1), λmax 312 nm (ε = 0.43 × 10
5
 M
-1
·cm
-1), λmax 411 nm (ε = 0.41 × 10
5
 M
-1
·cm
-1), λmax 
514 nm (ε = 0.08 × 105 M-1·cm-1), λmax 654 nm (ε = 0.01 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 
3450 (m, NH), 3070 (w, CHaryl), 1520 (s, C=O), 1260 (s, CF3). 
1
H NMR (400 MHz, CD3CN): 
δ (ppm) = 8.89 (d, 8 H, Hpyr), 8.81 (d, 8 H, H′α), 8.59 (m, 16 H, Hα + Hβ), 8.30 (d, 8 H, H′pyr), 
7.45 (d, 8 H, H′β), 6.20 (m, 16 H, Hcym), 6.17 (s, 8 H, Hq), 6.03 (m, 16 H, Hcym), 3.13 (sept, 8 
H, CH(CH3)2), 2.43 (s, 24 H, CH3), 1.54 (m, 48 H, CH(CH3)2), -6.96 (s, 4 H, NH). 
13
C(
1
H) 
NMR (100 MHz, CD3CN): δ (ppm) = 184.1 (CO), 183.6 (CO), 152.4 (CH’α), 151.2 (CHα), 
133.0 (CH’β), 131.5 (CHβ), 122.8 (Cpyr), 119.6 (Cpyr), 101.9 (CHq), 104.1 (CCH(CH3)2), 98.8 
(CCH3), 83.8 (CHcym), 83.3 (CHcym), 82.3 (CHcym), 82.2 (CHcym), 31.3 (CH(CH3)2), 21.5 
(CH(CH3)2), 21.9 (CH(CH3)2), 17.5 (CH3). ESI-MS: m/z 1067.3 [Q4 + (CF3SO3)4]
4+
; 1472.5 
[Q4 + (CF3SO3)5]
3+
. Anal. calc. for C192H172F24N16O40Ru8S8 (4864.5): C 47.41, H 3.56, N 
4.61; Found: C 46.87, H 3.11, N 4.43.  
Q5: Yield 311 mg (78 %). UV-vis (1.0 × 10
-5
 M, (CH2Cl2)): λmax 409 nm (ε = 3.45 × 10
5
 M
-
1
·cm
-1), λmax 533 nm (ε = 0.58 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3068 (m, CHaryl), 1520 (s, 
C=O), 1258 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.80 (d, 8 H, Hpyr), 8.77 (d, 8 
H, H’α), 8.44 (d, 8 H, Hβ), 8.32 (d, 8 H, Hα), 8.14 (d, 8 H, H’pyr), 7.39 (d, 8 H, H’β), 6.19 (d, 8 
H, Hcym), 6.15 (d, 8 H, Hcym), 6.11 (s, 8 H, Hq), 6.01 (d, 8 H, Hcym), 5.98 (d, 8 H, Hcym), 3.10 
(sept, 8 H, CH(CH3)2), 2.42 (m, 48 H, CH(CH3)2), 1.52 (s, 24 H, CH3). 
13
C(
1
H) NMR (100 
MHz, CD3CN): δ (ppm) = 184.1 (CO), 183.6 (CO), 152.5 (CH’α), 150.6 (CHα), 150.5 
(Cpyridyl), 141.1 (Cpyr), 140.8 (Cpyr), 132.5 (CH’β), 132.0 (CHβ), 131.2 (CH’pyr), 130.6 (CH’pyr), 
104.0 (Ccym), 101.9 (Ccym), 98.6 (CHq), 83.8 (CHcym), 83.2 (CHcym), 82.5 (CHcym), 82.3 
(CHcym), 31.4 (CH(CH3)2), 21.9 (CH(CH3)2), 21.4 (CH(CH3)2), 17.5 (CH3). ESI-MS: m/z 
1095.5 [Q5 + (CF3SO3)4]
4+
, 1510.3 [Q5 + (CF3SO3)5]
3+
. Anal. calc. for 
C192H168F24N16Ni2O40Ru8S8 (4977.9): C 46.33, H 3.40, N 4.50; Found: C 46.08, H 3.28, N 
4.41. 
Q6: Yield 301 mg (76 %). UV-vis (1.0 × 10
-5
 M, (CH2Cl2)): λmax 418 nm (ε = 4.28 × 10
5
 M
-
1
·cm
-1), λmax 506 nm (ε = 0.44 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3068 (w, CHaryl), 1521 (s, 
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C=O), 1257 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.83 (d, 8 H, Hpyr), 8.75 (d, 8 
H, H’α), 8.63 (d, 8 H, Hβ), 8.51 (d, 8 H, Hα), 8.20 (d, 8 H, H’pyr), 7.41 (d, 8 H, H’β), 6.20 (m, 
16 H, Hcym), 6.18 (s, 8 H, Hq), 6.04 (d, 8 H, Hcym), 5.97 (d, 8 H, Hcym), 3.12 (sept, 8 H, 
CH(CH3)2), 2.42 (m, 48 H, CH(CH3)2), 1.54 (s, 24 H, CH3). 
13
C(
1
H) NMR (100 MHz, 
CD3CN): δ (ppm) = 185.2 (CO) and 184.8 (CO), 154.0 (CH’α), 152.8 (CHα), 150.9 (Cpyridyl), 
148.2 and 147.7 (Cpyrrole), 134.6 (CH’β), 133.0 (CHβ), 132.8 (CH’pyr), 132.5 (CHpyr), 105.0 and 
99.9 (Ccym), 102.9 (CHq), 84.9, 84.5, 83.4 and 82.9 (CHcym), 32.4 (CH(CH3)2), 22.9 and 22.5 
(CH(CH3)2), 18.6 (CH3). ESI-MS: m/z 1099.3 [Q6 + (CF3SO3)4]
4+
 and 1515.4 [Q6 + 
(CF3SO3)5]
3+
. Anal. calc. for C192H168F24N16O40Ru8S8Zn2 (4993.3): C 46.18, H 3.43, N 4.49; 
found: C 46.08, H 3.42, N 4.47. 
Q7: Yield 315 mg (83 %). UV-vis (1.0 × 10
-5
 M, (CH2Cl2)): λmax 413 nm (ε = 3.49 × 10
5
 M
-
1
·cm
-1), λmax 519 nm (ε = 0.54 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3450 (m, NH), 3070 (w, 
CHaryl), 1528 (s, C=O), 1260 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.99 (m, 8 H, 
Hpyr), 8.90 (d, 8 H, H’α), 8.82 (m, 16 H, Hβ + Hα), 8.29 (m, 8 H, H’pyr), 7.43 (d, 8 H, H’β), 6.33 
(d, 8 H, Hindane), 6.25 (d, 8 H, Hindane), 6.15 (s, 8 H, Hq), 6.08 (t, 8 H, Hindane), 6.02 (t, 8 H, 
Hindane), 3.06 (m, 16 H, CH2indane), 2.95 (m, 8 H, CH2indane), -6.96 (s, 4 H, NH). 
13
C(
1
H) NMR 
(100 MHz, CD3CN): δ (ppm) = 184.9 (CO), 184.8 (CO), 153.5 (CH’α), 152.2 (CHα), 151.7 
(Cpyridyl), 133.7 (Cpyr), 133.5 (Cpyr), 132.5 (CH’β), 132.0 (CHβ), 127.0 (CH’pyr), 126.9 (CH’pyr), 
105.1 (Cindane), 104.8 (Cindane), 102.9 (CHq), 83.2 (CHindane), 83.0 (CHindane), 82.8 (CHindane), 
82.7 (CHindane), 30.7 (CH2indane), 23.5 (CH2indane). ESI-MS: m/z 1035.5 [Q7 + (CF3SO3)4]
4+
. 
Anal. calc. for C184H140F24N16O40Ru8S8 (4736.2): C 46.66, H 2.98, N 4.73; Found: C 46.44, H 
2.92, N, 4.58. 
Q8: Yield 337 mg (78 %). UV-vis (1.0 × 10
-5
 M, (CH2Cl2)): λmax 412 nm (ε = 4.05 × 10
5
 M
-
1
·cm
-1), λmax 522 nm (ε = 0.69 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3450 (m, NH), 3070 (w, 
CHaryl), 1528 (s, C=O), 1260 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.90 (d, 8 H, 
Hpyr), 8.84 (d, 8 H, H’α), 8.63 (m, 16 H, Hβ + Hα), 8.30 (d, 8 H, H’pyr), 7.42 (d, 8 H, H’β), 6.33 
(dd, 16 H, Hphenyl), 6.25 (s, 8 H, Hq), 6.15 (t, 8 H, Hphenyl), 6.09 (dd, 8 H, Hphenyl), 6.02 (d, 8 H, 
Hphenyl), 2.77 (t, 16 H, CH2), 1.52 (m, 16 H, CH2), 1.33 (m, 96 H, CH2), 0.89 (m, 24 H, CH3), -
6.96 (s, 4 H, NH). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 185.2 (CO), 184.8 (CO), 
153.5 (CH’α), 152.5 (CHα), 152.2 (Cpyridyl), 132.9 (Cpyr), 132.7 (Cpyr), 132.6 (CH’β), 129.3 
(CHβ), 129.2 (CH’pyr), 123.8 (CH’pyr), 108.5 (Cq), 102.8 (CHq), 90.1 (Cphenyl), 89.8 (Cphenyl), 
80.4 (CHphenyl), 79.9 (CHphenyl), 78.4 (CHphenyl), 33.8 (CH2), 32.6 (CH2), 30.2 (CH2), 30.0 
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(CH2), 29.9 (CH2), 23.4 (CH2), 14.4 (CH3). ESI-MS: m/z 1207.8 [Q8 + (CF3SO3)4]
4+
. Anal. 
calc. for C232H252F24N16O40Ru8S8 (5425.6): C 51.36, H 4.68, N 4.13; Found: C 51.10, H 4.61, 
N 4.02. 
Q9: Yield: 300 mg (83 %). UV-vis (1.0 × 10
-5
 M, (CH3)2CO): λmax 257 nm (ε = 3.90 × 10
5
 M
-
1
·cm
-1), λmax 314 nm (ε = 0.43 × 10
5
 M
-1
·cm
-1), λmax 410 nm (ε = 0.42 × 10
5
 M
-1
·cm
-1), λmax 
515 nm (ε = 0.08 × 105 M-1·cm-1), λmax 655 nm (ε = 0.01 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 
3470 (m, NH), 3075 (w, CHaryl), 1520 (s, C=O), 1260 (s, CF3). 
1
H NMR (400 MHz, CD3CN): 
δ (ppm) = 8.87 (m, 16 H, Hpyr + H′α), 8.69 (m, 16 H, Hα + Hβ), 8.32 (m, 8 H, H′pyr), 7.45 (d, 8 
H, H′β), 6.35 (m, 16 H, Hq + Htol), 6.14 (m, 16 H, Htol), 5.97 (m, 16 H, Htol), 2.48 (s, 24 H, 
CH3), -6.94 (s, 4 H, NH). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 184.3 (CO), 183.9 
(CO), 152.6 (CH’α), 151.1 (CHα), 132.6 (CH’β), 131.5 (CHβ), 123.0 (Cpyr), 120.1 (Cpyr), 101.8 
(CHq), 89.4 (CCH3), 79.7 (CHtol), 79.1 (CHtol), 76.7 (CHtol), 18.2 (CH3). ESI-MS: m/z 983.0 
[Q9 + (CF3SO3)4]
4+
; 1359.3 [Q9 + (CF3SO3)5]
3+
. Anal. calc. for C168H124F24Ru8N16O40S8 
(4527.9): C 44.52, H 2.74, N 4.95; Found: C 43.98, H 2.33, N 4.65. 
 Q10: Yield 219 mg (86 %). UV-vis (1.0 × 10
-5
 M, (CH2Cl2)): λmax 420 nm (ε = 4.02 × 10
5
 M
-
1
·cm
-1), λmax 515 nm (ε = 0.35 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3070 (w, CHaryl), 1518 (s, 
C=O), 1258 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = 8.85 (d, 8 H, Hpyr), 8.72 (d, 8 
H, H’α), 8.64 (d, 8 H, Hβ), 8.48 (d, 8 H, Hα), 8.17 (d, 8 H, H’pyr), 7.42 (d, 8 H, H’β), 6.22 (m, 
16 H, Htol), 6.18 (s, 8 H, Hq), 6.09 (d, 8 H, Htol), 5.99 (d, 8 H, Htol), 2.47 (s, 24 H, CH3). 
13
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 184.5 (CO), 184.0 (CO), 153.0 (CH’α), 152.0 
(CHα), 150.6 (Cpyridyl), 147.2 (Cpyrrole), 146.9 (Cpyrrole), 133.3 (CH’β), 131.9 (CHβ), 131.7 
(CHpyr), 131.6 (CH’pyr), 104.4 (Ctol), 89.6 (CCH3), 89.5, 79.8 and 79.3 (CHtol), 76.9 (CHq), 
18.8 (CH3). ESI-MS: m/z 1014.7 [Q10 + (CF3SO3)4]
4+
 and 1402.6 [Q10 + (CF3SO3)5]
3+
. Anal. 
calc. for C168H120F24Ru8N16O40S8Zn2 (4654.7): C 43.31, H 2.56, N 4.81; Found: C 42.48, H 
2.53, N 4.72. 
General procedure for Q11  Q14: A mixture of arene ruthenium dinuclear complexes C0 (Q11: 
57 mg, 0.09 mmol; Q13: 85 mg, 0.13 mmol) or C1 (Q12: 61 mg, 0.09 mmol; Q14: 92 mg, 0.13 
mmol), AgCF3SO3 (Q11, Q12: 46 mg, 0.18 mmol; Q13, Q14: 69 mg, 0.27 mmol) and the 
corresponding porphyrin panels 5,15-bis(4-pyridyl)-10,20-diphenylporphyrin (Q11, Q12: 55 
mg, 0.09 mmol) or 5,10,15-tris(4-pyridyl)-20-phenylporphyrin (Q13, Q14: 56 mg, 0.09 mmol) 
is stirred at 60°C for 24 hours and then the solution is filtered to remove silver chloride. The 
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solvent is removed under vacuum and the residue is taken up in dichloromethane (3 mL) and 
diethyl ether added to precipitate the products as red solids. 
Q11: Yield 75 mg (85%). UV-vis (1.0 × 10
-5
 M, ((CH3)2CO)): λmax 411 nm (ε = 3.27 × 10
5
 M
-
1
·cm
-1
), 515 nm (ε = 0.47 × 105 M-1·cm-1), 550 nm (ε = 0.30 × 105 M-1·cm-1), 589 nm (ε = 
0.16 × 10
5
 M
-1
·cm
-1
), 649 nm (ε = 0.12 × 105 M-1·cm-1). IR (KBr, cm-1): 3436 (m, NH), 3070 
(w, CHaryl), 1523 (s, C=O), 1258 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = - 4.25 (br, 
4 H, NH), 1.58 (d, 24 H, CH(CH3)2), 2.40 (s, 12 H, CH3), 3.13 (sept, 4 H, CH(CH3)2), 6.04 
(m, 8 H, Hcym), 6.18 (m, 8 H, Hcym), 7.25 (br, 7 H, Hphenyl), 8.17 (m, 4 H, Hpyr), 8.35 (m, 3 H, 
Hphenyl), 8.48 (m, 4 H, Hpyr), 8.55 (d, 4 H, Hβ), 8.90 (d, 4 H, Hα). 
13
C(
1
H) NMR (100 MHz, 
CD3CN): δ (ppm) = 18.4 (CH3), 22.7 (CH(CH3)2), 32.2 (CH(CH3)2), 83.1 (CHcym), 84.9 
(CHcym), 98.5 (CCH3), 103.6 (CCH(CH3)2), 115.5 (Cpyr), 132.1 (CHphenyl), 132.4 (CHphenyl), 
133.0 (CHβ), 133.4 (CHβ), 142.7 (Cphenyl), 142.8 (Cphenyl), 151.1 (CHα), 153.3 (CHα), 171.9 
(CO). ESI-MS: m/z 833.5 [Q11 + CF3SO3]
3+
, 587.9 [Q11]
4+
. Anal. calc. for 
C132H112N12F12O20S4Ru4 (2946.9): C 53.73, H 3.80, N 5.70; Found C 54.07, H 3.95, N 5.98. 
Q12: Yield 79 mg (86%). UV-vis (1.0 × 10
-5
 M, ((CH3)2CO)): λmax 413 nm (ε = 2.3 × 10
5
 M
-
1
·cm
-1
), 521 nm (ε = 0.23 × 105 M-1·cm-1), 560 nm (ε = 0.16 × 105 M-1·cm-1), 599 nm (ε = 
0.11 × 10
5
 M
-1
·cm
-1
), 654 nm (ε = 0.11 × 105 M-1·cm-1). IR (KBr, cm-1): 3446 (m, NH), 3066 
(w, CHaryl), 1631 (s, C=O), 1259 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = - 3.50 (br, 
4 H, NH), 1.55 (d, 24 H, CH(CH3)2), 2.39 (s, 12 H, CH3), 3.07 (sept, 4 H, CH(CH3)2), 5.92 (d, 
8 H, Hcym), 6.10 (s, 4 H, Hq), 6.13 (d, 8 H, Hcym), 7.25 (br, 7 H, Hphenyl), 8.10 (m, 4 H, Hpyr), 
8.35 (m, 3 H, Hphenyl), 8.42 (m, 4 H, Hpyr), 8.58 (d, 4 H, Hβ), 8.75 (d, 4 H, Hα). 
13
C(
1
H) NMR 
(100 MHz, CD3CN): δ (ppm) = 18.5 (CH3), 22.6 (CH(CH3)2), 32.3 (CH(CH3)2), 83.2 (CHcym), 
84.8 (CHcym), 98.4 (CCH3), 103.7 (CCH(CH3)2), 115.6 (Cpyr), 125.7 (CHphenyl), 132.8 
(CHphenyl), 132.9 (CHphenyl), 133.0 (CHβ), 133.1 (CHβ), 141.3 (Cphenyl), 141.4 (Cphenyl), 151.0 
(CHα), 153.3 (CHα), 171.8 (CO). ESI-MS: m/z 866.8 [Q12 + CF3SO3]
3+
, 612.8 [Q12]
4+
. Anal. 
calc. for C140H116N12F12O20S4Ru4 (3047.0): C 55.12, H 3.80, N 5.51; Found: C 55.38, H 3.63, 
N 4.92. 
Q13: Yield 97 mg (85%). UV-vis (1.0 × 10
-5
 M, ((CH3)2CO)): λmax 410 nm (ε = 3.4 × 10
5
 M
-
1
·cm
-1
), 522 nm (ε = 0.23 × 105 M-1·cm-1), 565 nm (ε = 0.16 × 105 M-1·cm-1), 602 nm (ε = 
0.12 × 10
5
 M
-1
·cm
-1
), 656 nm (ε = 0.10 × 105 M-1·cm-1). IR (KBr, cm-1): 3467 (m, NH), 3069 
(w, CHaryl), 1631 (s, C=O), 1258 (s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = - 6.94 (s, 
4 H, NH), 1.54 (m, 36 H, CH(CH3)2), 2.42 (s, 18 H, CH3), 3.14 (m, 6 H, CH(CH3)2), 6.22 to 
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6.26 (m, 12 H, Hcym), 6.36 to 6.42 (m, 12 H, Hcym), 7.32 (m, 1 H, Hβ), 7.39 (m, 2 H, Hphenyl), 
7.65 (m, 2 H, Hphenyl), 7.90 (m, 3 H, Hpyr), 7.99 (m, 4 H, Hphenyl), 8.10 (m, 2 H, Hpyr), 8.26 (m, 
1 H, Hα), 8. 30 (m, 1 H, Hphenyl), 8.38 (d, 1 H, Hβ), 8.40 (m, 1 H, Hα), 8.55 (m, 1 H, Hα), 8.78 
(m, 1 H, Hα), 8.86 (m, 3 H, Hpyr), 8.95 (m, 1 H, Hpyr), 9.20 (m, 1 H, Hpyr), 9.42 (d, 1 H, Hα), 
7.60 to 9.40 (br, 6 H, Hpyr, 1 H, Hphenyl, 7 H, Hα, 10 H, Hβ). 
13
C(
1
H) NMR (100 MHz, 
CD3CN): δ (ppm) = 19.1 (CH3), 19.2 (CH3), 19.2 (CH3), 22.1 (CH(CH3)2), 22.5 (CH(CH3)2), 
22.6 (CH(CH3)2), 32.0 (CH(CH3)2), 32.2 (CH(CH3)2), 32.2 (CH(CH3)2), 85.5 (CHcym), 88.3 
(CHcym), 99.6 (CCH3), 121.0 (Cpyr), 125.1 (CHphenyl), 125.2 (CHphenyl), 127.1 (CHβ), 128.5 
(CHphenyl), 128.7 (CHphenyl), 128.9 (CHphenyl), 129.7 (CHphenyl), 142.2 (Cphenyl), 153.2 (CHα), 
153.3 (CHα), 184.4 (CO), 184.5 (CO). ESI-MS: m/z 1119.8 [Q13 + CF3SO3]
3+
, 802.3 [Q13 + 
(CF3SO3)2]
4+
. Anal. calc. for C154H136N14F18O30S6Ru6 (3803.6): C 48.63, H 3.60, N 5.15; 
Found: C 48.27, H 3.29, N 5.02. 
Q14: Yield 98 mg (82%). UV-vis (1.0 × 10
-5
 M, ((CH3)2CO)): λmax 409 nm (ε = 3.6 × 10
5
 M
-
1
·cm
-1
), 517 nm (ε = 0.60 × 105 M-1·cm-1), 560 nm (ε = 0.14 × 105 M-1·cm-1), 654 nm (ε = 
0.15 × 10
5
 M
-1
·cm
-1
). IR (KBr, cm
-1
): 3434 (m, NH), 3059 (w, CHaryl), 1522 (s, C=O), 1258 
(s, CF3). 
1
H NMR (400 MHz, CD3CN): δ (ppm) = - 6.96 (s, 2 H, NH), - 6.76 (m, 2 H, NH), 
1.52 (m, 36 H, CH(CH3)2), 2.45 (m, 18 H, CH3), 3.15 (m, 6 H, CH(CH3)2), 5.80 to 6.30 (m, 
24 H, Hcym), 6.13 (s, 1 H, Hq), 6.14 (s, 1 H, Hq), 6.15 (s, 1 H, Hq), 6.16 (s, 1 H, Hq), 6.17 (s, 1 
H, Hq), 6.18 (s, 1 H, Hq), 6.75 (m, 1 H, Hpyr), 7.12 (m, 1 H, Hpyr), 7.18 (m, 1 H, Hβ), 7.32 (m, 
1 H, Hβ), 7.35 (m, 2 H, Hphenyl), 7.50 (m, 6 H, Hβ), 7.65 (m, 2 H, Hphenyl), 7.78 (m, 4 H, Hβ), 
7.85 (m, 3 H, Hpyr), 7.98 (m, 4 H, Hphenyl), 8.05 (m, 1 H, Hphenyl), 8.10 (m, 2 H, Hpyr), 8.18 (m, 
5 H, Hpyr), 8.22 (m, 1 H, Hα), 8.26 (m, 1 H, Hα), 8. 30 (m, 1 H, Hphenyl), 8.35 (m, 1 H, Hα), 
8.42 (m, 1 H, Hα), 8.58 (m, 1 H, Hα), 8.60 (m, 1 H, Hα), 8.62 (m, 1 H, Hα), 8.70 (m, 1 H, Hα), 
8.76 (m, 1 H, Hα), 8.77 (m, 1 H, Hα), 8.82 (m, 1 H, Hα), 8.85 (m, 3 H, Hpyr), 8.95 (m, 1 H, Hα), 
9.00 (m, 1 H, Hpyr). 
3
C(
1
H) NMR (100 MHz, CD3CN): δ (ppm) = 18.5 (CH3), 18.5 (CH3), 
18.5 (CH3), 18.6 (CH3), 18.6 (CH3), 18.7 (CH3), 22.2 (CH(CH3)2), 22.5 (CH(CH3)2), 22.5 
(CH(CH3)2), 22.5 (CH(CH3)2), 22.6 (CH(CH3)2), 22.6 (CH(CH3)2), 22.7 (CH(CH3)2), 22.8 
(CH(CH3)2), 22.8 (CH(CH3)2), 22.9 (CH(CH3)2), 22.9 (CH(CH3)2), 22.9 (CH(CH3)2), 32.4 
(CH(CH3)2), 32.4 (CH(CH3)2), 32.4 (CH(CH3)2), 32.4 (CH(CH3)2), 32.5 (CH(CH3)2), 32.5 
(CH(CH3)2), 82.8 (CHcym), 82.9 (CHcym), 82.9 (CHcym), 83.1 (CHcym), 83.2 (CHcym), 83.3 
(CHcym), 83.5 (CHcym), 83.8 (CHcym), 83.9 (CHcym), 83.9 (CHcym), 84.0 (CHp-cym), 84.0 (CHp-
cym), 84.2 (CHcym), 84.3 (CHcym), 84.3 (CHcym), 84.4 (CHcym), 84.4 (CHcym), 84.8 (CHcym), 
84.9 (CHcym), 85.0 (CHcym), 85.1 (CHcym), 85.1 (CHcym), 85.1 (CHcym), 85.1 (CHcym), 99.6 
Chapter 6: Experimental 
 
 
152    
 
 
(CCH3), 99.6 (CCH3), 99.7 (CCH3), 99.8 (CCH3), 99.8 (CCH3), 99.8 (CCH3), 102.6 (CHq), 
102.8 (CHq), 102.9 (CHq), 103.0 (CHq), 103.0 (CHq), 103.1 (CHq), 104.6 (CCH(CH3)2), 104.7 
(CCH(CH3)2), 104.7 (CCH(CH3)2), 105.0 (CCH(CH3)2), 105.1 (CCH(CH3)2), 105.2 
(CCH(CH3)2), (CCH(CH3)2), 122.1 (Cpyr), 122.4 (Cpyr), 122.6 (Cpyr), 122.9 (Cpyr), 125.4 
(CHphenyl), 125.5 (CHphenyl), 127.0 (CHβ), 127.2 (CHβ), 127.9 (CHβ), 128.3 (CHβ), 128.6 
(CHphenyl), 128.6 (CHphenyl), 128.6 (CHphenyl), 128.7 (CHphenyl), 129.4 (CHβ), 129.7 (CHphenyl), 
129.8 (CHphenyl), 129.9 (CHβ), 131.9 (CHβ), 132.0 (CHβ), 132.4 (CHphenyl), 132.4 (CHphenyl), 
132.5 (CHβ), 133.4 (CHβ), 135.5 (CHβ), 136.0 (CHβ), 141.3 (Cphenyl), 141.8 (Cphenyl), 150.2 
(CHα), 150.7 (CHα), 150.9 (CHα), 151.4 (CHα), 151.6 (CHα), 151.8 (CHα), 152.1 (CHα), 152.4 
(CHα), 152.8 (CHα), 152.9 (CHα), 153.3 (CHα), 153.5 (CHα), 184.4 (CO), 184.5 (CO), 184.6 
(CO), 184.6 (CO), 184.7 (CO), 184.7 (CO). ESI-MS: m/z 1169.5 [Q14 + CF3SO3]
3+
, 839.9 
[Q14 + CF3SO3]
3+
. Anal. calc. for C166H142N14F18O30S6Ru6 (3953.8): C 50.42, H 3.62, N 4.96; 
Found: C 50.27, H 3.23, N 4.52. 
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Food and Drug Administration: FDA 
imidazolium-trans-dimethylsulfoxide-imidazole-tetrachlororuthenate: NAMI-A 
imidazolium-trans-bis(1H-indazole)-tetrachlororuthenate: KP1019 
1,3,5-triaza-7-phosphaadamantane: pta 
ethane-1,2-diamine: en  
enhanced permeability and retention: EPR 
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6,11-dihydroxy-5,12-naphthacenedione: dhtq-H2 
5,8-dioxydo-1,4-naphthoquinonato: donq 
5,8-dioxydo-1,4-anthraquinonato: doaq  
6,11-dioxydo-5,12-naphthacenedionato: dotq 
oxamide: oxa 
oxonico: oxo 
1,2-bis(4-pyridyl)ethane: bpa 
metal-to-ligand charge transfer: MLCT 
intra-ligand charge transfer: ILCT 
tris(tetrachlorobenzenediolato)-phosphate(V): trisphat 
inductively coupled plasma mass spectroscopy: ICP-MS 
N,N’-dicyclohexylcarbodiimide: dcc  
4-(dimethylamino)pyrimidium para-toluenesulfonate: dpts 
standard deviation: SD 
5,10,15,20-tetra(4-pyridyl)porphyrin-M(II): (M = Ni (tpp-Ni), Zn (tpp-Zn)) 
electrospray mass spectrometry: ESI-MS 
fluorescence intercalation displacement: FID 
thiazole orange: TO 
5,15-bis(4-pyridyl)-10,20-diphenylporphyrin: bpp 
5,10,15-tris(4-pyridyl)-20-phenylporphyrin: tpp 
Resistance Factor: RF 
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Since the development of supramolecular chemistry in the 1980s 
more and more discrete molecular objects have been synthesised. In this 
research area metals play a key role. Indeed, the coordination-driven self-
assembly allows a directional-bonding approach that organises the 
different building blocks into supramolecular objects according to the 
coordination modes of the transition metal. Therefore, the versatility of 
metalla-cages and their application potential raised an increasing interest 
for this chemistry. 
 
On the other hand, ever since the clinical success of cisplatin as an 
antitumour drug, transition metals have raised considerable expectations 
for the treatment of cancer. So far, mononuclear arene ruthenium 
complexes are of central interest due to established cytotoxicity towards 
cancer cells and low general toxicity. 
 
The aim of this thesis was to combine the assembling properties of 
arene ruthenium complexes in supramolecular chemistry with their 
antiproliferative activity. Thus, different metalla-cages were synthesised, 
the permanent or reversible hosting ability of which was studied by 
various spectroscopic methods with different guest molecules. The 
antiproliferative behaviour of the resulting systems was established in 
vitro towards different cancer cell lines.  
 
 
  
 
 
 
